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SUMMARY
Coronary heart disease (CHD) is the leading cause of death worldwide. Its 
prevalence is determined by increasing age, gender (male > female), heredity and 
lifestyle factors. The latter include diet, which may lead to elevated blood lipids 
including cholesterol, triacylglycerol, non-esterified fatty acids, and to reduced 
insulin sensitivity. All of these have been implicated as contributing to the metabolic 
environment that predisposes to CHD. Two enzymes, hormone sensitive lipase 
(HSL) and lipoprotein lipase (LPL) are responsible for the mobilisation and 
clearance of fatty acids respectively.
A sensitive reverse transcriptase-polymerase chain reaction technique was developed 
previously in our lab for the measurement of LPL-mRNA, but in this thesis further 
development of this method is presented. To enable the assessment of the regulation 
of HSL and LPL enzymes in human adipose tissue in different nutritional or disease 
states, the development of a new reverse transcriptase-polymerase chain reaction 
procedure for measurement of HSL-mRNA was developed.
The acute regulation of both lipase activity and gene expression in the fasting and fed 
state, using adipose tissue biopsies from eight male subjects with type 2 -diabetes 
mellitus (2-DM) were compared with matched control male subjects. The findings 
indicated that type 2-DM subjects had significantly lower LPL-mRNA levels than 
control subjects in both fasting (61% of control values; /KO.002), and post-prandial 
(43% of control values; /?<0.002) states. In addition, HSL-mRNA levels were 
significantly lower in type 2-DM subjects compared with control subjects (p<0.01) 
in both fasting (34% of control values) and post-prandial (32% of control values) 
states. However, HSL-mRNA levels were significantly higher in the post-prandial 
compared with the fasting state (/K0.01) for both diabetic (fasting was 21 % of post­
prandial) and control subjects (fasting was 19 % of post-prandial). These findings 
suggest LPL-mRNA accumulates in the fasting state and is utilised in the fed state. 
On the other hand, HSL-mRNA accumulates in the fed and is utilised in the fasted 
state.
Epidemiological studies suggest that regional body fat distribution may be a better 
predictor of cardiovascular disease than the actual degree of adiposity. Many studies 
and reviews have shown an association between upper-body obesity (omental 
obesity) and insulin resistance, and the risk of developing type 2-DM and CHD. 
However, although widely postulated the causative link between insulin resistance 
and central adiposity lacks evidence from mechanistic studies. This thesis describes a 
study comparing subcutaneous and omental adipose tissue obtained from 10  non- 
obese premenopausal women. There were no differences in HSL or LPL activity or 
LPL-mRNA levels but omental cells were 61% smaller than those from the 
subcutaneous depot {P= 0.007). The similar levels of lipase activities in different 
regions found in the present study may have resulted from the subjects being young, 
non-obese and female.
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Chapter 1 
Introduction
1. Introduction
Lipoproteins provide a means for fat transport between different organs and tissues. 
Their main clinical importance is related to their role in the development of 
atherosclerosis. The risk of atherosclerosis is increased in non-insulin dependent 
diabetes or type 2  diabetes mellitus which is known to be associated with raised 
plasma lipids. The control of two enzymes, Hormone Sensitive Lipase (EC 3.1.1.3; 
HSL) and Lipoprotein Lipase (EC 3.1.1.34; LPL) during fasting and feeding is 
thought to be important for the maintenance of low plasma triacylglycerol (TAG) 
and fatty acid levels which reduce the risk of heart disease. HSL is the intracellular 
enzyme responsible for the hydrolysis of stored TAG during the process of lipid 
mobilisation from adipose tissue. LPL controls lipid hydrolysis for the clearance of 
TAG from circulating lipoprotein particles in the plasma.
This chapter examines the physiology and pathophysiology of both HSL and LPL, 
which are the focus of this research project, and investigates the factors that regulate 
LPL and HSL lipase activity and gene expression in omental and subcutaneous 
adipose tissue depots from young pre-menopausal women.
1.1. Lipoprotein Metabolism
The lipoprotein system evolved to solve the problem of transporting fats around the 
body in the aqueous environment of the plasma. A lipoprotein is a complex spherical 
structure which has a hydrophobic core covered by a hydrophilic coating. The core 
contains TAG and cholesteryl esters, while the surface contains phospholipid, free 
cholesterol and proteins. The proteins associated with lipoproteins are referred to as 
apolipoproteins or apoproteins. Some of their properties are given in Table 1.1. 
Cholesterol is an essential component of all cell membranes and is the precursor for 
steroid hormone and bile acid biosynthesis. Several different classes of lipoproteins 
exist whose structure and functions are closely related.
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Table 1.1 Properties of human Apolipoproteins, (Gaw et al, 1999)
Apolipoprotein Molecular
Weight
(kDa)
Site of synthesis Function
A-I 28 Intestine, Liver Activates LCAT*
A-II 17 Intestine, Liver -
B-100 549 Liver TAG and cholesterol transport 
Binds to LDL receptor
B-48 264 Intestine TAG transport
C-I 6 .6 Liver Activates LCAT*
C-II 8.85 Liver Activates LPL
C-III 8 .8 Liver Inhibits LPL
E 34 Liver, Intestine, 
Macrophage
Binds to LDL receptor and probably also 
to another specific liver receptor
*  LCAT  =  Lecithin cholesterol acyl transferase
They can be classified according to their hydrated density into Chylomicrons (CM), 
Very Low Density Lipoproteins (VLDL), intermediate Density Lipoproteins (IDL), 
Low Density Lipoproteins (LDL) and High Density Lipoproteins (HDL). With 
decreasing TAG content, the density of the lipoprotein particle increases and the size 
decreases, from CM through VLDL, IDL, LDL, to HDL, which are the smallest. 
Lipoproteins can also be classified by their electrophoretic mobility, where 
cc-lipoproteins (HDL) migrate furthest, followed by pre-P-lipoproteins (VLDL) and 
(3-lipoproteins (LDL). CM remain at the origin of the electrophoretic strip as cited by 
Dominiczak (1999). The metabolism of lipoproteins can be divided into two 
pathways, depending on whether the lipid is of exogenous or endogenous origin.
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1.1.1. Exogenous pathway
In the exogenous pathway, illustrated in figure 1.1 a, CM represent the major means of 
dietaiy lipid transport (Gurr, 1988). Dietary TAG are first hydrolysed by intestinal 
pancreatic lipase and are absorbed as monoacylglycerol, non-esterified fatty acid 
(NEFAs) and glycerol as cited by Dominiczak (1999). In the enterocytes, TAG is 
synthesised and, together with phospholipids and cholesterol, is combined with 
apolipoprotein (apo) B-48 to form CM. CM are secreted into the lymph, via the 
thoracic duct, and reach the plasma where they obtain apo E and apo C-I, C-II and C- 
III from HDL particles. CM normally appear in plasma after fat-containing meals. In 
the peripheral tissues, such as muscle and adipose tissue, CM are acted upon by LPL, 
which hydrolyses their TAG component. As a consequence the particles become 
smaller and are now called chylomicron remnants. The remnants are rapidly removed 
from the circulation by hepatic receptors that are internalised in the liver by Apo E 
receptor-mediated endocytosis and degraded in lysosomes, thus delivering dietary 
TAG and cholesterol to the liver (Sethi et a l, 1993). The half-life of CM in plasma, 
has been estimated to be 5 minutes (Grundy & Mok, 1976)
1.1.2. Endogenous pathway
I.I.2.I. VLDL metabolism
VLDL particles are synthesised and secreted by the liver and contain endogenously 
synthesised TAG and cholesterol (see figure 1.1b). Apo B-100 is an essential 
component. Apo C and E are incorporated into VLDL after secretion by transfer 
from HDL particles. As the particles circulate in the plasma they are delipidated by 
the action of LPL in the same way as CM. The depleted particles, called intermediate 
density lipoprotein (IDL) particles, may bind to the hepatocytes through apoprotein E 
receptors or have further TAG removed producing LDL particles (Dietschy et al,
1993). By this stage all the apoproteins, except for apo B-100, have been transferred
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from the particles to HDL. IDL or LDL particles can bind to receptors on 
hepatocytes where hepatic lipase (HL) causes further hydrolysis of TAG which may 
be necessary prior to their uptake.
1.1.2.2. LDL metabolism
LDL particles are cholesteryl ester-enriched and their function is to deliver 
cholesterol to cells (Fielding et a l,  1992). They are formed from VLDL via IDL. 
LDL can pass through the junctions between capillary endothelial cells and attach to 
LDL receptors on cell membranes that recognise apo B-100 (Marshall, 1995). 
Macrophages internalise LDL in endocytotic vesicles, which are passed onto 
lysosomes where the cholesterol esters are degraded by an acid hydrolase. This 
liberates free cholesterol which leaves the lysosome and is either excreted, 
transferred to HDL, or is re-esterifred in the cytoplasm by acyl-cholesterol 
acyltransferase (ACAT) (Small et a l, 1989). Stored cholesterol ester can be 
hydrolysed subsequently by a cytoplasmic neutral cholesterol ester hydrolase and 
passed to HDL or, in the absence of HDL, the free cholesterol is retained in the cell 
and re-esterifred by AC AT. About 50% of the stored cholesterol esters are 
hydrolysed and resterified each day via this cycle (Brown et a l,  1980). The release 
of free cholesterol is responsible for three regulatory responses that assist in 
cholesterol homeostasis: cholesterol synthesis is decreased primarily by suppression 
of the rate-limiting enzyme of cholesterol synthesis, HMG-CoA reductase; secondly 
intracellular cholesterol storage is increased by activation of ACAT activity to 
esterify excess cholesterol; modulation of the number of LDL receptors on the 
plasma membrane to prevent the over-accumulation of intracellular cholesterol 
through the receptor pathway (Tietz,1995).
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Figure 1.1 Major pathway of lipoprotein metabolism (a) Shows the exogenous 
pathway, (b) shows the endogenous pathway. The dashed lines show that 
particles may pass through several cycles of hydrolysis by LPL in capillary beds 
(after Frayn, 1996).
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1.1.2.3. HDL metabolism
HDL metabolism is involved in cholesterol transport from the tissues to the liver for 
export from the body. HDL are synthesised primarily in the liver and, to lesser 
extent, in small intestinal cells as disc-shaped precursor particles (nascent HDL) 
(Marshall, 1995). A major function of HDL is to act as a receptacle for excess 
phospholipid and cholesterol derived from cells or as by-products of lipolysis. The 
lipolysis of CM and VLDL by LPL results in a net transfer of phospholipid into 
HDL. Free cholesterol diffuses into HDL from other lipoprotein particles, 
erythrocytes, and endothelial cells. The HDL-associated enzyme lecithin cholesterol 
acyltransferase (LCAT) uses phospholipid and cholesterol to generate cholesteryl 
esters and lysophospholipid, thus driving the influx of further phospholipid and 
cholesterol into spherical HDL (Tall, 1990). The spherical HDL are relatively large 
cholesteryl ester-enriched particles known as HDLz. Their cholesteryl ester content 
can be transferred to remnant particles in exchange for TAG, this process being 
mediated by cholesteryl ester transfer protein (CETP), a 74 kDa protein which is 
synthesised in the liver (Tall, 1993). Some of the cholesteryl ester from HDL? 
particles is also transferred to the TAG-rich lipoproteins. The resulting smaller HDL 
particles are known as HDL3 and are ready to accept further cholesterol from 
peripheral tissues. Thus cholesterol is transferred from peripheral tissues to the liver, 
from where it can be excreted as cholesterol and as bile salts in the bile. This process 
of removal of cholesterol from the tissues, to the liver and ultimate excretion from 
the body is known as reverse cholesterol transport (Frayn, 1996).
1.2. Lipoprotein metabolism and atherosclerosis
Coronary heart disease (CHD) is the commonest cause of death in the UK (Kumar 
and Clark, 1995). The key event in early atherosclerosis is damage to the 
endothelium, which is initially only functional. The endothelium becomes more 
permeable to lipoproteins and allows migration of cells to the underlying layer, the 
intima. The LDL particles penetrate the vascular wall and are deposited in the intima.
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where they may undergo oxidation. Oxidised LDL stimulates endothelial expression 
of adhesion molecules, such as vascular cell-adhesion molecules and monocyte 
chemotactic proteins. These attract monocytes, which are the precursors of 
phagocyctic macrophages, to the arterial wall. Monocytes enter the wall and are 
transformed into macrophages under the influence of macrophage monocyte-colony- 
stimulating factor. Oxidised LDL facilitates this process by inhibiting the mobility of 
the macrophages, thus immobilising them in the sub-endothelial space. Oxidised 
LDL are ingested by macrophages through their scavenger receptors. Since the 
scavenger receptor are not regulated, the cells become overloaded with lipid to form 
foam cells. Conglomerates of foam cells form fatty streaks. Dying foam cells release 
lipid that forms pools within the arterial wall (Dominiczak, 1999). Further damage 
occurs through smooth muscle and endothelial cells which start to secrete cytokines, 
a range of small peptides regulating cell growth, as well as growth factors (Havel,
1994). These include platelet-derived growth factor, interleukin and tumour necrosis 
factor, which stimulate smooth-muscle cells to proliferate and to migrate towards the 
luminal side of the arterial wall. At that time smooth-muscle cells start synthesising 
extracellular matrix, in particular collagen. The relocation of smooth-muscle cells 
and accumulation of new matrix results in the formation of a cap that covers the lipid 
pool and consists of collagen-rich fibrous tissue, smooth muscle cells, macrophages 
(Mead et a l, 1999) and T-lymphocytes (Dominiczak, 1999). Eventually the final 
lesion is termed a mature atherosclerotic plaque. The presence of an atherosclerotic 
plaque in the artery causes increased rigidity in the vessels as well as a narrowing of 
the lumen. The consequences of atherosclerosis primarily result from impaired 
blood supply leading to ischaemic heart disease (IHD). The effects of IHD range in 
severity from short-lasting chest pain of varying severity (angina pectoris) to more 
severe and more prolonged pains of myocardial infarction (MI). Angina results from 
ischaemia, which is due to the imbalance between the heart's demands for oxygen 
and the poor blood supply. Such imbalance is accentuated by physical exertion such 
as exercise.
MI, on the other hand, is due to the lack of blood supply, which leads to anoxic- 
necrosis of part(s) of the myocardium. In MI a non-functional, non-contractile
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fibrous tissue made of collagen fibrils replaces the normal contractile myocardium. 
The presence of this ectopic fibrous tissue can cause disruption of the normal heart's 
conductive system which can lead to various, and sometimes life-threatening, 
arrhythmias such as ventricular fibrillation which is probably responsible for the 
majority of deaths within the first few hours of the infarct.
A further consequence of atherosclerosis is thrombus formation. This event may be 
intiated by macrophages, residing at the edges of the plaque secreting 
metalloproteinsases, which are enzymes that degrade the extracellular matrix. In 
addition, T-cells produce y-interferon, which inhibits collagen synthesis in the 
smooth-muscle cells. These processes weaken the plaque cap and may result in its 
breakage. The breakage exposes collagen and lipids to the blood stream. This leads 
to adherence and aggregation of platelets and initiates the formation of a blood clot 
or "thrombus" (Dominiczak, 1999). Thrombus formation in the coronary arteries can 
produce thromboembolic effects on the cardiovascular system leading to blockage of 
various vessels such as the cerebral arteries causing the cerebrovascular disease 
"stroke" as well as the myocardium causing coronary artery disease.
In addition to the above effects, which relate to atherosclerosis of the coronary 
arteries, atherosclerosis of other arteries can result in severe pathological symptoms. 
Atherosclerosis of peripheral arteries e.g. femoral arteries in the limbs can lead to 
peripheral vascular disease. Peripheral vascular disease is characterised by ischaemia 
to the lower limbs resulting in various symptoms such as difficulty in walking long 
distances without pain, and in severe cases, gangrene from ischaemic necrosis 
(Kumar & Clark, 1995). It can be deduced from the above account that the effects of 
atherosclerosis are severe. However the effects can be prevented to some extent by a 
reduction of blood cholesterol and TAG levels (Havel, 1994). One way in which this 
can be achieved is by changes in diet. In addition atherosclerosis can be reduced by a 
reduction in smoking and hypertension or by an increase in exercise. One proposed 
mechanism by which changes in diet and exercise can reduce cholesterol and TAG 
levels is by regulation of LPL activity. Decreased LPL activity can result in high 
blôôd lipids (Reaven & Chen, 1988; Fisher et a l, 1997). So patients with decreased
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LPL activity are more prone to raised blood lipids and atherosclerosis (Goldberg,
1996).
1.3. Introduction  to L ipases
Lipases play a central role in lipoprotein metabolism by hydrolysing TAG molecules 
that are too large for direct transport across cell membranes (Doolittle & Reue,
1999).
LPL and HSL are enzymes that hydrolyse glycerol esters of long chain fatty acids, 
the products of the reaction are two moles of fatty acids and one mole of 2- 
acylglycerol (P-monoacylglycerol) per molecule of TAG (Eckel, 1989). The latter is 
resistant to hydrolysis, due to steric hindrance, but it can spontaneously isomerise to 
the a  form (3-acylglycerol). This isomerization permits the third fatty acid to be split 
off, but at a much slower rate (Bensadoun et al., 1991). Another enzyme, a 
monoacylglycerol lipase (MAG lipase) (EC 3.1.1.23), present in high activity, is 
responsible for removal of the third fatty acid (scheme 1.1). Thus three fatty acids 
and one glycerol molecules are produced from each molecule of TAG (Belfrage et 
a/,1985).
Scheme 1.1 Action of HSL and MAG lipase in the main reaction sequence of 
adipose tissue lipolysis (after Belfrage et a i, 1985).
MAG lipase
HSL
Adipocyte TAG 1,2-diacyIglycerol 2-monoacylglycerol glycerol
FFA FFA FFA
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Different lipases are found in a variety of extracellular and intracellular locations. 
For example, lingual lipase, gastric lipase, pancreatic lipase, and bile salt-activated 
lipase are present in the gastrointestinal tract. LPL and HL are bound to the capillary 
endothelium and hydrolyse TAG in circulating lipoproteins. LPL and bile salt- 
activated lipase are also present in milk. In contrast, lysosomal lipase and HSL are 
intracellular enzymes (Doolittle & Reue, 1999).
HSL and LPL are the main subjects of this thesis. They are the key enzymes 
responsible for fat mobilisation and deposition, respectively, in white adipose tissue 
(Figure 1.2), (Frayn et a l, 1995). Both enzymes are hormone responsive. Like other 
lipases, HSL catalyses the breakdown of TAG and plays a pivotal role in the 
mobilisation of non esterified fatty acid (NEFA) from adipose tissue by controlling 
the rate of lipolysis of stored TAG (Ikezu et ai, 1999). LPL can be shown to be 
essential for fat storage, as CM and VLDL are too big to be taken up directly into the 
adipocyte by passage through the endothelium. Hydrolysis of TAG contained in 
these particles by LPL produces smaller moieties, fatty acids, which can diffuse 
directly through the interstitium and into the respective organ.
VLDL
CM Fatty-acid
3-glycerol phosphate
LPL --jgr
TAG
I
Fatty-acid
I
-► Fatty-acid
V
Glvcerol
Y
Fat storage
Jv
Glvcerol
J
Y
Fat mobilisation
Figure 1.2 Outline of the major pathways of fat storage and fat mobilisation 
in white adipose tissue, showing the roles of LPL and HSL (after Frayn,
1995).
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1.3.1. Hormone sensitive lipase (HSL)
1.3.1.1. Properties and function of HSL
HSL is a multifunctional enzyme that plays a key role in energy mobilisation as the 
rate limiting enzyme in the hydrolysis of TAG and diacylglycerol in adipose tissue 
(Talmud et al., 1998). HSL has been studied extensively since it was initially 
identified over 30 years ago (Rizack,1961) but it is only relatively recently that 
details of the structure of the enzyme molecule have started to become available, and 
as yet very little is known about the molecular mechanism whereby HSL is activated 
by phosphorylation (Smith et al., 1996). For each molecule of stored TAG, three 
fatty acids and one glycerol molecule are produced (Langfort et ah, 1999). The fatty 
acids for the most part leave the adipocyte cells and bind to the carrier protein 
albumin to form NEFA in the plasma (Large et al., 1998). The glycerol moiety also 
leaves the cell as it cannot be utilised for re-esterification of fatty acids since adipose 
tissue lacks glycerol kinase, an enzyme required for fatty acid estérification to form 
TAG (Frayn, 1998). In addition, HSL has cholesterol hydrolase activity and 
generates free cholesterol for steroid synthesis (Talmud et al., 1998). Recently 
experiments were carried out by Osterlund et al (1996) to study the properties of 
HSL. Rat HSL-cDNA, in the eukaryotic expression vector, was subjected to site- 
directed mutagenesis at codons for conserved aspartic acid and histidine residues. 
The results clearly showed that Asp-703 and His-733, together with the previously 
identified Serine-432, are essential for lipase activity of HSL. In 1999, Syu & Satiel 
identified a novel binding protein for HSL, called lipotransin, that fulfils a number of 
criteria for an HSL docking protein, they detected HSL and lipotransin in an 
overlapping but not identical adipocyte cellular fraction. In addition, in response to 
lipolytic agents, HSL translocated to a fraction that was highly enriched in 
lipotransin. Additionally, the lipotransin and HSL genes exhibited a similar pattern of 
expression in both human and mouse tissue. From their data they suggested a 
molecular model for the hormonal regulation of lipolysis. Upon phosphorylation, 
HSL interacts directly with lipotransin, which serves to dock the protein at the outer 
surface of the lipid droplet. Once bound, lipotransin can then undergo a cycle of ATP
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hydrolysis due to ATPase activity, thus permitting the dissociation of HSL and its 
direct association with the fat droplet.
1.3.1.2. Regulation of HSL
HSL is tightly regulated postranslationally by the physiological catecholamines 
through cAMP-dependent phosphorylation (Raclot et al., 1998; Morimoto et al., 
2000; Clifford et al., 2000). Insulin, in contrast, prevents this phosphorylation and 
inactivates HSL by lowering cAMP levels (Raynolds et al., 1990). The primary 
regulators of adipose tissue lipolysis occur when catecholamines bind to adrenergic 
receptors: p i, p2, P3 and a2. The a2 receptor couples with Gi-proteins to inhibit 
cAMP formation and lipolysis, while the p receptor couples with Gs-protein and 
stimulates cAMP formation and lipolysis. The pi receptor may mediate low level 
catecholamine stimulation, while the P3 receptor, which is activated by higher levels 
of catecholamines, may deliver a more sustained signal. The second stage of HSL 
activation involves the regulation of cAMP, the intracellular messenger that activates 
protein kinase A (Carey, 1998). Adenyl cyclase is activated, and ATP is converted to 
c-AMP, which activates protein kinase A. Protein kinase A consists of two catalytic 
subunits and two regulatory (R) subunits, when c-AMP is present it binds to the two 
regulatory units and liberates the two active catalytic subunits. These active 
monomers of protein kinase A play a role in stimulating HSL promoting fat 
mobilisation from adipose tissue (Strâlfors & Belfrage, 1983), (see figure 1.3), 
(Salway, 1999). Equally important is the inactivation of HSL by insulin, which 
prevents the phosphorylation and activation protein kinase A by lowering c-AMP 
levels by activating phosphodiesterase. The latter is a very potent effect. These 
pathways respond very rapidly to relatively low concentrations ( 20-30 pM) of 
insulin (Belfrage et al., 1985).
With regard to the molecular details behind the translocation process, it is not clear 
whether the phosphorylation-induced changes in the HSL molecules expose a 
hydrophobic lipid-binding region, which allows HSL to bind to the lipid droplet, or if
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conformational changes allow the expression of a region that interacts with one or 
several other proteins, which aid HSL in translocating and binding to the lipid 
droplet (Boyer, 1983). Some studies give support to the hypothesis that regulation at 
the transcriptional level does exist Raclot et al. (1998) have shown that treatment of 
3T3 cells with glucose alters HSL gene expression, suggesting pretranslational 
control, while Large et al, (1998) in their studies of human subabdominal 
subcutaneous adipocytes, with high and low lipolytic activity, postulate that the 
levels of HSL protein could be explained, in part, by control at the transcriptional 
level.
Extensive work since 1970, primarily by Steinberg & collaborators, led to the 
formulation of the model of the lipolytic activation cascade, to describe the 
mechanism by which lipolytic hormones activate HSL in adipose tissue and thus, 
enhance the adipose tissue lipolysis rate. Slavin et al (1994) examined the hormonal 
regulation of HSL during primaiy cultures of rat adipocytes. The hormones tested 
included adrenaline, glucagon, growth hormone and dexamethasone (a synthetic 
glucocorticoid). HSL activity was measured along with HSL-mRNA levels. Each of 
these hormones resulted in increases in HSL activity but only dexamethasone 
resulted in an increase in HSL-mRNA. Therefore, the conclusions of this study were 
that the major regulatory pathway of HSL is likely to be reversible 
phosphorylation/dephosphorylation although some regulation at the mRNA level was 
possible in response to dexamethasone. Another study, by Sztalryd & Kraemer 
1994a, examined the regulation of HSL during fasting. They examined rats fasted for 
periods of up to 5 days. HSL activity was measured in both extracts of intact 
epididymal fat pads and in extracts from unstimulated adipose tissue cells from 
epididymal fat pads from control animals. Fasting was associated with an increase in 
HSL activity. Although no statistically significant changes in HSL activity were 
detected during the first 2  days of fasting, an increase of 60-100% was detected after 
3-5 days of fasting. In addition, fasting caused an increase in the expression of 
immunoreactive HSL protein in extracts in both of the tissues examined. HSL- 
mRNA level were increased two-fold after 3-5 days of fasting in intact epididymal 
fat pads and similar changes were observed in the isolated adipose tissue but were
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only significantly elevated after 5 days of fasting. Not surprisingly, food deprivation 
resulted in a significant reduction, within one day of fasting, in total body weight and 
the wet weight of epididymal fat pads. In addition, an approximate two-fold increase 
in circulating NEFA occurred within one day of fasting, which remained at the same 
level throughout the fasting period. Sztalryd & Kraemer (1994a) concluded from 
their study that HSL activity appears to be regulated by pre-translational mechanisms 
during prolonged fasting. However, increases in NEFA flux during short-term fasting 
appeared to involve either posftranslational control of HSL or the regulation of other 
enzymes.
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Figure 1.3 Regulation of HSL and mobilisation of fat in adipose tissue (after 
Salway, 1999).
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1.3.1.3. HSL tissue distribution
The tissue distribution of HSL is relatively broad and the enzyme has been 
implicated in a variety of metabolic processes. In 1981 Cook et al., published the 
first direct evidence for the presence of HSL in various tissues other than adipose 
tissue. They demonstrated that the presence of neutral cholesterol ester hydrolase 
activity in rat adrenal cortex was due to a protein with an apparent molecular mass of 
84 kDa, identical to HSL from rat adipose tissue. Cholesteryl ester hydrolase activity 
had been found in a number of tissues, including adrenal cortex, which demonstrates 
that one of the enzymes main functions is to release cholesterol to be used for the 
synthesis of steroids (Yeaman, 1990). HSL is also expressed in corpus luteum, 
another steroid producing tissue (Kraemer et al., 1993a). In addition. Small et al
(1989) strongly suggested that HSL is responsible for the cholesteryl ester hydrolase 
activity in macrophages. They incubated both purified bovine HSL and macrophage 
homogenates with the catalytic subunits of cAMP-dependent protein kinase in the 
presence of [y-32P] ATP-Mg and showed a large number of polypeptides became 
phophosphorylated. The further treatment of the phosphorylated extracts with anti- 
HSL immunoglobulins led to immunoprécipitation of a single phosphorylated 
polypeptide of approximately 84 kDa, the same size as bovine HSL. Khoo et al 
(1993) supported the conclusion that HSL is responsible for the neutral cholesterol 
ester hydrolase activity in macrophages. Their studies indicated that HSL-mRNA 
was expressed in mouse adipose tissue, peritoneal macrophages and the murine 
P388Di macrophage cell line. The HSL activity in macrophages has been suggested 
to be important in the development of atherosclerosis, as the accumulation of 
cholesterol esters is a central step in foam cell formation (Harte et al., 2000).
Other studies indicated the presence of HSL in a variety of rat tissues, including, 
heart, skeletal muscle, lung, young testes and brown adipose tissue (Kraemer et al., 
1993; Rashid, 1996; Langfort et a l, 1999; Osuga et a l, 2000).
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I.3.I.4. Molecular biology of HSL
The human HSL gene has been mapped to chromosome 19ql3.1-13.2 ( Holm et ah, 
1988; Egan et al., 1992). It contains a 786-amino acid sequence (Kanaya et al., 
1998). A multi-domain structure was identified with each functional domain encoded 
by a different exon, the catalytically inactive form of HSL in exon 6  (Large et ah,
1998), phosphorylation sites in exon 8 and the lipid binding domain encoded by exon 
9 (Talmud et al., 1998). Two isoforms of human HSL have been characterised. 
Human adipocytes express a 2.8 kb mRNA that encodes for a 88  kDa protein (Blaise 
et al., 1999) with the full-length gene containing 3250 nucleotides (nt). Human testes 
express a 120 kDa HSL protein which is encoded by a 3.9 kb mRNA (Grober et al.,
1997). Large et al. (1998) found a smaller 84 kDa protein band in addition to the 
main 88  kDa protein in human adipose tissue. They suggested that the 84 kDa band 
and 88  kDa proteins shared common epitopes and were structurally related.
The first evidence of a human HSL promoter was published by Grober et al. (1997), 
they established that the human HSL transcripts expressed in adipose tissue 
contained a single 5' UTR (5' untranslated region) of 74 n t . The first 54 nt of this 5'- 
UTR were found in the genomic sequence, in exon B and located 1.5 kb upstream of 
the first coding region (exon 1), and the other of 150 bp (exon A) that is 13 kb 
upstream of the testis-specific exon (exon T). Thus the 1.5 kb between exon B and 
exon 1 was termed intron B, and between exon A and B as intron A (figure 1.4) 
(Talmud et ah, 1998).
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Figure 1.4: Genomic structure of HSL after Talmud et a l, (1998). Showing 
relative position of the testicular HSL specific exon (T) and the adipocyte HSL 
first exon (1), with intervening, noncoding exons A and B. UTR indicates 
untranslated regions.
1.3.1.5. Measurement of HSL
1.3.L5.1. HSL activity and HSL mass
The activity of HSL has been assessed in previous studies of lipolysis, indirectly by 
measuring the release of glycerol using a radioisotope-labelled monoether analogue 
of dioleoylglycerol: 3H-monoacylmonoalkylglycerol (3H-MOME) substrate
(Tornqvist et al., 1978) with either quiescent or stimulated fat cells. The method of 
using this radioisotope-labelled substrate was first described by Fredrikson et al. 
(1981). This substrate has the advantage of high sensitivity and specificity although 
both phosphorylated and de-phosphorylated forms of HSL have the same activity 
towards this substrate and so the total amount of activatable enzyme in the sample is 
measured (Reynisdottir et al., 1997a). Other lipid substrates have been used to 
measure HSL activity including dioleoylglycerol, trioleoylglycerol, cholesteryl 
esters, and monooleoylglycerol (Robin, 1997). Dioleoylglycerol is as sensitive as 
MOME but is less specific since a substrate for monoacylglycerol lipase is formed 
after hydrolysis of the first ester bond. Since emulsified monooleoylglycerol can only 
be used for measuring HSL activity in preparations not containing monoacylglycerol 
lipase, it is not useful for assays of adipose tissue or infranatant fractions. Cholesteryl 
esters and trioleoylglycerol are the only substrates that can be used to monitor the
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activation of HSL in crude preparations. Because of the substrate specificity of HSL, 
with high preference for diacylglycerols (Fredrikson et ah, 1983), the assay methods 
based on trioleoylglycerol and cholesteryl esters are less sensitive than assay 
methods using diacylglycerol as the substrate (Boyer, 1983). Osterlund et al (1996), 
described two substrates that can be used in water soluble conditions, /?-nitrophenyl 
butyrate and tributyrin, and described their use with crude enzyme preparations. 
However, as they can be hydrolysed by a wide range of hydrolytic enzymes, the 
assay method based on these substrates is non-specific (Robin, 1997).
Determination of HSL mass using Western blot analysis of infranatant samples was 
recommended by Robin (1997). This method used a specific anti-HSL antibody 
(Morimoto et ah, 2000; Clifford et ah, 2000), which was raised against recombinant 
rat HSL and cross-reacted well with human HSL. This technique has been used to get 
an accurate determination of the total amount of HSL in adipose tissue preparations.
1.3.1.5.2. Northern blot analysis
This technique in brief is as follows, the total cellular RNA, which can be routinely 
extracted from adipose tissue using the acid guanidinium thiocyanate-phenol- 
chloroform method (Chomczynski and Sacchi, 1987), is separated by size on an 
agarose gel. The RNA molecules in the gel are transferred to a nitro-cellulose or 
nylon membrane, and hybridised to a specific cDNA probe and visualised by 
autoradiography (Watson et ah, 1992). This assay has many disadvantages including: 
it requires a large amount of total RNA, it is time consuming (which is not suitable 
for large clinical studies) and it is only semi-quantitative.
1.3.1.5.3. Polymerase chain reaction
The Polymerase chain reaction (PCR) is a highly sensitive and specific methodology 
for the detection of minute amounts of DNA. With the addition of a reverse 
transcription (RT) step, RT-PCR is an extremely useful tool for the detection of 
extremely low levels of RNA. RT-PCR has been used by investigators to measure
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HSL-mRNA (Laville et al., 1996; Laurell et al., 1997; Montague et a l, 1998; Harte 
et a l, 2000). The development of new techniques for the quantitative measurement 
of HSL-mRNA in this laboratory is one aspect of this thesis and is discussed in detail 
in Chapter 3.
1.3.2. Lipoprotein lipase
LPL is the key hydrolytic enzyme in human lipoprotein metabolism responsible for 
the rate-limiting clearance of TAG-rich CM and VLDL from the circulation (Eckel et 
a l, 1995). It plays a role in the regulation of NEFA levels and in the distribution of 
cholesterol to both LDL and HDL. The enzyme is located on the luminal surface of 
the capillary endothelium of extra-hepatic tissues, including cardiac and skeletal 
muscle (Seip et a l,  1995), adipose tissue, lactating mammary gland and 
macrophages (Olivercrona et a l, 1995; Sartippour et al., 2000). LPL activity has also 
been observed associated with a variety of other tissues including kidney, lung, 
ovaries and the brain (Braun & Severson 1992). LPL is activated by apo C-II which 
is present on the surface of CM, VLDL and HDL (Wang et a l, 1992). Apo C-II, 
which is produced in the liver, is a protein with a molecular weight of 8.9 kDa with 
78 amino acids and activates LPL (Olivecrona et a l, 1991). In contrast, apo C-IH 
acts as an inhibitor of LPL activity (Eckel, 1989).
1.3.2.1. Synthesis and function of LPL
LPL is a glycoprotein which is synthesised in the membrane-bound ribosomes 
attached to the rough endoplasmic reticulum of parenchymal cells. However, it 
functions at the luminal surface of the vascular endothelium (Hide et a l,  1992). 
Since LPL must act in the capillaries, it is exported to the endothelial cells lining the 
capillaries where it is attached non-covalently to the endothelial cells by highly 
negatively charged glycosaminoglycan chains, primarily heparan sulphate. 
Attachment of the enzyme molecule occurs by charge-charge interaction (Frayn, 
1996). The LPL attached to the endothelial cells is termed functional LPL and this 
can be demonstrated by the resultant decrease in function (e.g. degradation of
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lipoproteins) by displacement of the enzyme by perfusion with heparin (Braun and 
Severson, 1992) or inhibition of LPL activity by antibodies to LPL (Olivecrona et 
a l,  1984). The location of LPL on the capillary endothelium provides an optimal 
position for performing its function. As lipoprotein particles pass through the 
capillaries, hydrolysis by LPL occurs. LPL hydrolyses the two end fatty acids on the 
1 and 3 positions of the TAG molecules contained in T AG-rich lipoprotein particles. 
The result of the enzyme action is the production of two fatty acid molecules and one 
molecule of 2-monoacylglycerol (Eckel, 1989). The resulting fatty acids can then be 
taken up for estérification, in the case of adipose tissue. The way in which the cells 
absorb fatty acids after diffusion through the interstitial space is possibly by a carrier 
mechanism, research into the mechanism is currently underway. After production by 
LPL there are three possible fates for the fatty acids; in the first instance they can be 
taken up and esterified, this is the case in adipose tissue, or alternatively oxidation 
can occur, this occurs in muscle and brown adipose tissue and finally NEFA can be 
released into the plasma to be taken up by other tissues (Giralt et a l, 1990; Frayn
1996). Only the fate of fatty acids taken up by adipose tissue will be considered here. 
Figure 1.2 shows the pathway taken by NEFA into the adipocyte. For storage the 
fatty acid produced by LPL must be esterified to TAG. The estérification pathway 
takes place in the adipocytes and involves converting the fatty acids to CoA 
derivatives, then combination with glycerol-3-phosphate by the phosphatidic 
pathway to ultimately form TAG. Glycerol-3 -phosphate is formed during glycolysis 
from glucose that enters the adipocyte by the GLUT 4 transporter (Frayn 1996).
1.3.2.2. Regulation of LPL
The regulation of LPL is influenced by various factors, including the fasting and fed 
states, hormones such as insulin and catecholamines, and disease states such as 
obesity and diabetes mellitus. Furthermore, in many instances, the effects of 
regulatory factors on LPL activity appear to be tissue-specific. For example, insulin 
has been shown to have divergent effects on adipose tissue LPL and skeletal muscle 
LPL (Doolittle et a l, 1990; Raynolds et a l,  1990).
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During short-term fasting LPL activity in adipose tissue is down regulated without 
corresponding changes in mRNA levels, synthesis rate or mass. Thus, regulation 
during short-term fasting occurs primarily at the post-transcriptional level and causes 
a decrease in specific activity, which is restored within 4 hours by re-feeding (Bergô 
etal., 1997).
Studies carried out comparing the fed to the fasting state either find no change in 
LPL-mRNA, LPL protein synthesis and LPL mass (Ong & Kern 1989), an increase 
in LPL-mRNA (Enerback et al., 1988), or a decrease in LPL-mRNA and protein 
synthesis with no change in enzyme mass (Doolittle et al., 1990). The majority of the 
studies indicate that LPL-mRNA, synthetic rates and enzyme mass do not account 
for the changes in enzyme activity, suggesting that regulation of LPL must be post- 
translational. Doolittle et al. (1990) observed predominantly high mannose LPL 
(endoplasmic reticulum bound) in the fasting state and high complex-carbohydrate 
LPL (Golgi bound) in the fed state. They proposed that newly synthesised LPL was 
redistributed into either a secretory pathway (during feeding) or an intracellular 
degradative pathway (during fasting) which would account for the constant enzyme 
mass observed in the fasted state. More recently it has been demonstrated that during 
fasting, adipose tissue LPL is present in an inactive form that is converted into an 
enzymatically active state during feeding (Bergô etal.,1996).
Hormonal regulation shows that LPL activity is positively correlated to the plasma 
insulin level (Bergô et al., 1997). On the other hand, catecholamines appear to 
inactivate or reduce the activity of the enzyme prior to its secretion, possibly by 
accelerating the degradation of the enzyme (Boyer, 1983). Insulin causes increased 
LPL-mRNA levels in adipocytes as well as increased rates of LPL synthesis and LPL 
activity. Activation of LPL by insulin involves transcription, altered enzyme 
processing and increased export to endothelial cells, the process takes 3-4 hours 
(Reaven & Chen, 1988). Assays of LPL gene transcription with insulin showed that 
insulin did not increase gene transcription rates (Raynolds et a l,  1990; Simosolo et 
al., 1992). So the resulting increase in mRNA levels was due to changes in mRNA 
stability, i.e. the mechanism is posttranscriptional. By increasing the stability of
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mRNA more mRNA is available for the synthesis of LPL. Other studies using 
cultured rat adipocytes have demonstrated that cells respond to insulin with an 
increase in LPL activity, protein synthesis and mRNA (Ong et al., 1998). In contrast, 
Semenokovich et a. I (1989) found an increase in LPL activity without an increase in 
mRNA. Other hormones that regulate LPL include glucocorticoids, thyroxine, 
glucagon, GIP and other hormones affecting intracellular cAMP.
In 1997 Zechner studied the tissue-specific regulation of LPL in adipose tissue and 
muscle during conditions of fasting and refeeding. LPL activity or mRNA were 
shown to be high in adipose tissue during feeding and postprandially but were down 
regulated during fasting. Thus the postprandial state provides a large amount of 
NEFA for fat deposition in adipose tissue. In contrast, no consistent effects of fasting 
and feeding have been seen on LPL expression in skeletal muscle or cardiac muscle.
I.3.2.3. Molecular Biology of LPL
The LPL gene has been mapped to the p22 (short arm) region of chromosome 8 
(Sparkes e ta l,  1987; Mattel e ta l,  1993). The human LPL gene spans approximately 
30 kb and contains ten exons and nine introns. The gene codes for a protein of 475 
amino acids, including a hydrophobic leader sequence of 27 amino acids and the 
mature protein comprised of 448 amino acids (Wion et a l,  1987). The amino acid 
sequence corresponds to various components of the enzyme. Each component can be 
listed, firstly the 27 amino acid signal peptide which is cleaved before the mature 
protein is formed, the catalytic site, the site for interaction with apoprotein C-II, the 
polycation site for binding with the glycosaminoglycans at the vascular endothelium, 
the interfacial binding site which binds lipids and a site for non-covalent interactions 
between subunits (Oka et a l, 1990). The 10 exons have been linked to the above 
functions of the enzyme (Edwards et a l, 1993). Exon 1 codes for the 5’ untranslated 
region as well as the signal peptide (the 5’ upstream region contains four 
transcription initiation sites, two promoter elements and several enhancer motifs). 
Exon 2 codes for the N-linked glycosylation site, exon 4 codes for the interfacial 
binding site and exon 5 codes for the active site. Exon 6  codes for the
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glycosaminoglycan binding site, exon 8 for an extra N-linked glycosylation site and 
finally exon 10 codes for the 3’ untranslated region. Several steps are involved in the 
production of LPL from transcription of the LPL gene in the nucleus to the 
positioning of LPL on the luminal surface of capillary endothelial cells. The steps 
involved are transcription, translation and glycosylation, processing and 
oligomerisation, vesicular transfer, translocation and binding to the luminal surface 
of capillary endothelial cells.
The first step is transcription, which takes place in the nucleus. Transcription of the 
LPL gene produces two different mRNA lengths of 3350 and 3750 base pairs 
depending on which of the 3’ terminal polyadenylation sites are used (Wion et a l, 
1987). These multiple mRNA lengths have been observed in all species excluding 
the rat (Hocquette el a l, 1996). Next translation and glycosylation of the mRNA 
occurs in the rough endoplasmic reticulum of the corresponding cell. From studies 
using radiolabelled amino acids and by SDS/polyacrylamide gel electrophoresis the 
highest rate of LPL synthesis has been shown to occur in adipocytes and cardiac 
muscle (Semb etal., 1986; Simsolo e ta l,  1992; Liu e ta l ,  1995).
The N-linked glycosylated sequence is modified whilst the LPL molecule is 
transported through various cell compartments which contain the enzymes required 
for modification. The first modification involves removing the three terminal glucose 
residues by glucosidases 1 and 2, this occurs in the endoplasmic reticulum. A high 
mannose structure is then formed by the removal of one mannose residue by an 
mannosidase, after which the structure is transferred to the Golgi complex by 
vesicular transfer (Hiraizumi et a l, 1993). In addition to translation and N-linked 
glycosylation, further processing and oligomerisation (Klausner et a l, 1990) occurs 
which primarily involves oligomerisation of LPL into a homodimer which is the 
functional form of the enzyme (Garfmkel et a l, 1983). By inhibiting various stages 
in N-linked glycosylation, various studies have concluded that catalytic activity of 
LPL is associated with glycosylation and processing in the endoplasmic reticulum 
(Masuno el ah, 1991), the processing of the glycosylated residues can induce 
dimérisation of LPL as well (Davis et a l,  1992). In addition, at this stage in the
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rough endoplasmic reticulum some LPL may be degraded (Semb and Olivecrona, 
1987). Vesicular transfer to the Golgi apparatus follows and the LPL molecule with 
the high mannose structure attached goes through the various parts of the Golgi 
system where further processing and folding occurs. The parts of the Golgi system 
can be divided into the cis Golgi network, Golgi stacks and trans Golgi network 
(Keenan, 1998). The cis Golgi network functions as a receiving centre for the vesicle 
containing the LPL homodimer and transfers the vesicle onto the Golgi stacks. The 
Golgi stacks have cis, medial and trans components. The cis Golgi in the Golgi 
stacks processes the enzyme further by removing three mannose residues by 
mannosidase 1. Next, further galactose and sialic acid residues are added in the 
medial Golgi component with the removal of two additional mannose residues by 
mannosidase 2 (Rothman & Orci, 1990). The trans Golgi component adds additional 
modifications. Here the structure, which leaves the medial Golgi network undergoes 
a series of transferase reactions, which by the addition of extra galactose and sialic 
acid residues, produces a complex variety of oligosaccharide chains (Rothman & 
Orci, 1990). Next the enzyme enters the trans Golgi network which functions as a 
sorting centre where LPL is incorporated into secretoiy vesicles for exocytosis 
(Olivecrona et a l, 1987) to the plasma membrane or degraded in the lysosomes 
(Vannier et a l, 1989). Vesicular transport of the secretory vesicles transports the 
LPL to the surface of the plasma membrane from the Golgi apparatus (Vannier et al, 
1989), here the enzyme is bound to heparan sulphate proteoglycans (Vannier et al, 
1989; Hoogeworf et a l, 1991). Attachment to the surface of the plasma membrane is 
glycosylphosphatidylinositol linked (Turner et a l, 1991) and release, which occurs 
before translocation, may occur by a physiological phosphatidylinositol specific 
phospholipase C (Chan et a l, 1988). Heparan sulphate proteoglycans comprise a 
glycosaminoglycan linked to a core protein by a trisaccharide link (Chan et al, 
1992). Glycosaminoglycans are abundant in the extracellular matrix and consist of 
long unbranched polysaccharide chains of repeating disaccharide units. 
Glycosaminoglycans are highly negatively charged (from sulphate and carboxyl 
groups on the sugar components) and so interact with LPL which is positively 
charged (Eckel et al, 1995). Heparin administration can separate LPL from its link 
to heparan sulphate and provides a useful experimental tool for separating functional
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LPL for subsequent measurement (Eckel, 1989). It is postulated that heparan 
sulphate is bound to LPL within the secretory vesicles before LPL reaches the 
plasma membrane and that the LPL bound to heparan sulphate is active on the 
adipocyte before export to the capillary (Eisenberg et ah, 1992). Next LPL combined 
with the glycosaminoglycan link is translocated in the interstitial space to the 
capillary endothelium. The movement is so far postulated to occur along bridges of 
heparan sulphate molecules or a transport mechanism may exist (Blanchette-Mackie 
et ah, 1989). The binding of LPL and glycosaminoglycans at the capillary 
endothelial surface occurs at functional heparan sulphate proteoglycan binding sites, 
which are 220 kDa proteoglycans (Klein et ah, 1992). Finally, LPL as mentioned 
earlier, requires apolipoprotein C-II for its full activity. This is transferred to the 
surface of the TAG-rich lipoprotein from HDL, to which it returns after TAG has 
been depleted by LPL action. The activation of LPL by apo C-II is thought to be 
through the binding between the two molecules. Apo C-II forms a bridge between 
the LPL molecules and the TAG-rich lipoprotein, thus enabling substrate hydrolysis 
(Gotto, 1987). The negatively charged -CO'2 terminal of apo C-II apparently reacts 
with the positively charged region of LPL whilst the positively charged -NKT  ^
terminal of apo C-II reacts with the lipid substrate (Gotto, 1987). The end point of 
LPL activity is probably determined by the loss of apo C-II from the surface of the 
TAG-rich particle back to HDL (Vance & Vance, 1985).
I.3.2.4. Measurement of LPL 
L3.2.4.1. LPL activity and protein mass
Post-heparin plasma lipase measurements are the most commonly used assessments 
of LPL activity. The method involves the administration of a bolus dose of heparin 
intravenously. Heparin then strips off potentially active lipase from the capillary 
endothelium into the circulation. Peak lipase activity occurs between 5 and 15 
minutes after the heparin injection. One disadvantage of this method is that it is not 
specific to LPL. Heparin releases both hepatic lipase (HL) and LPL and from both 
muscle and adipose tissue sites (Boyer et ah, 1983). The activity assay is based on an
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artificial radio-labelled triolein substrate which mimics the natural lipoprotein 
substrates. The substrate emulsion must present an oil-water interface for enzyme 
action to occur. This is accomplished by emulsifying the triolein substrate in the 
presence of phospholipid. The release of free radiolabeled oleate by LPL hydrolysis 
is determined after a simple one-step liquid-liquid partition system for the isolation 
of fatty acids free of unhydrolysed substrate (Belfrage & Vaughan, 1969).
This methodology utilises the physico-chemical properties of LPL, in that it is 
activated by the cofactor apo CII, and is inhibited by high ionic strength solutions, 
such as 1 M NaCl. Thus the LPL activity can be distinguished from total lipase 
activity (Doolittle & Reue, 1999).
Nilsson-Ehle et al (1972) described a method to assay LPL activity in acetone-ether 
preparations of adipose tissue using the same radio-labelled substrate as described 
above. They suggested that the measurement of LPL activity directly in adipose 
tissue specimens would avoid the problem of heterogeneity of TAG lipases that were 
observed in post-heparin plasma samples. The assay appears to be highly specific for 
LPL activity as it exhibits optimal activités at alkaline pH and the substrate is not 
hydrolysed by monoglyceride esterase activity. HSL in the adipose tissue samples is 
destroyed by acetone-ether treatment, and therefore its activity is absent from the 
enzyme preparation.
Other techniques are available for the examination of the LPL protein levels using 
specific antibodies. These include ELISA, immunocytochemistry, and 
immunoprécipitation (Doolittle & Reue, 1999). This latter technique is typically used 
in conjunction with SDS polyacrylamide gel electrophoresis, the specific LPL band 
is then visualised by autoradiography or Western blotting techniques (Doolittle & 
Reue, 1999).
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I.3.2.4.2. LPL gene expression
There are 3 methods available for measuring mRNA which provide information on 
the level of gene expression. Northern blotting and RNase protection assays involve 
using labelled cDNA probes to specific sequences within the target mRNA. RNase 
protection is approximately 10 times more sensitive than Northern blotting. RT-PCR 
techniques are more sensitive than RNase protection and are described as specific 
and sensitive for the rapid amplification of a selected region of DNA. It has been 
used by a number of investigators to measure LPL-mRNA and has been successfully 
performed in human muscle and adipose tissue (Laville et al., 1996; Murphy et al,
1999).
1.4. Insulin
1.4.1. Structure of insulin
Insulin is a small protein with a molecular weight of 5750 daltons. It consists of two 
polypeptide chains, the A-chain containing 21 amino acids and the B-chain 
containing 30 amino acids joined by two interchain disulphide bridges formed from 
cysteine residues. The molecule also contains one intrachain disulphide bridge. The 
insulin gene specifies the structure of a single-chain precursor of insulin, 
preproinsulin (Ashcroft & Ashcroft, 1992).
1.4.2. Synthesis and production of insulin
The precursor of insulin within the (3-cells is the single chain preproinsulin 
(Dominiczak, 1999). Production of preproinsulin commences with mRNA 
transcription from the gene for insulin synthesis. Next, preproinsulin is transported to 
the endoplasmic reticulum and is converted to proinsulin, this involves folding and 
processing. Folding and processing involves various stages, for example the removal 
of the signal peptide by a signal peptidase, the action of binding proteins (which aid
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folding by functioning as molecular chaperones as well as being slow ATPases) and 
the formation of disulphide bonds by the action of protein disulphide isomerase in a 
reaction which involves the reduction of glutathione. The resulting proinsulin is then 
converted to mature insulin and C-peptide (figure 1.5) (Dominiczak, 1999), this 
occurs primarily in the Golgi apparatus. The formation of insulin from proinsulin 
involves the action of two endopeptidases (endopeptidase 1 and endopeptidase 2) and 
carboxypeptidase H. The main aspect of the conversion is the removal of the C- 
peptide. Endopeptidase 1 cleaves proinsulin at two arginine residues at positions 31 
and 32 and endopeptidase 2 cleaves proinsulin at a lysine residue at position 64 and 
an arginine residue at position 65, the result is the formation of two split proinsulins. 
Carboxypeptidase H then acts on the resultant split proinsulins by removing the 
resultant exposed basic carboxyterminal amino acids to form two des proinsulins 
(Ashcroft & Ashcroft, 1992). A further round of proteolytic cleavage produces 
mature insulin. Mature insulin is packaged in secretory granules and is ready for 
secretion.
Insulin is secreted from the (3-cells of the islets of Langerhans. These cells are the 
most numerous type of islet cell and are positioned in the centre of the islet, 
surrounded by the glucagon-secreting a-cells. Somatostatin (D-cells) and pancreatic 
polypeptide (PP) secreting cells are also present.
C-peptide
Insulin
Preproinsulin Proinsulin + Signal peptide
Figure 1.5: Steps of insulin synthesis, C-peptide, Signal peptide. Intra-chain 
S-S, (after Dominiczak, 1999).
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1.4.3. Secretion of the insulin by the pancreas
Insulin secretion occurs by exocytosis of secretory vesicles via the plasma membrane 
of the pancreatic (3-cells (Poitout & Robertson, 1996; Prentki, 1997). The stimulus 
for secretion is circulating glucose which in turn enters the (3 cell by specific glucose 
transporters. Currently, there is a debate as to the true glucose transporter, which is 
probably GLUT 1 and/or 3 in humans (Halban, 1997). Phosphorylation of the 
glucose then occurs by the action of glucokinase (which is rate limiting) to form 
glucose 6 -phosphate which is then metabolised. Although (3-cells normally use fatty 
acid derived from TAG for their metabolic requirements, glucose entry shifts the 
metabolic pathways to glycolysis. The result is an increased ATP/ADP ratio. This 
inhibits K+ -ATP channels in the (3-cell which depolarise the (3-cell causing an influx 
of calcium ions inducing insulin release into the extracellular space (Ashcroft & 
Ashcroft, 1992).
Insulin exerts its effects by binding to specific insulin receptors contained in the 
plasma membrane of cells (Combettes-Souverain et a i, 1997). The insulin receptor 
is composed of a- and (3-subunits in the (3  ^configuration. The a-subunit is on the 
extracellular side of the membrane and contains the insulin-binding site. The (3- 
subunit stretches across the plasma membrane and has both an extracellular and 
intracellular part. The a- and (3-subunits are joined together by disulphide bonds and 
the extracellular portions of both the a- and (3-subunits are glycosylated. The insulin- 
binding site is a cysteine rich region on the a-subunit, the binding of insulin results 
in insulin being surrounded by its receptor and this binding induces conformational 
changes in the receptor. Two parts of the (3-subunit are important for the effects of 
insulin. The part of the (3-subunit next to the membrane contains a signal for 
endocytosis and the innermost part of the (3-subunit is a tyrosine kinase domain. This 
tyrosine kinase domain contains an ATP binding site which is unblocked when 
insulin binds and a proposed catalytic loop which is involved in catalytic activity. In 
addition the (3-subunit contains tyrosine residues which are autophosphoiylated. The 
conformational changes induced by insulin binding induce autophosphorylation
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which in turn activates the tyrosine kinase leading to changes within the cell 
contributing to the effects of insulin (see below). Following insulin binding the 
insulin-insulin receptor complex is rapidly moved to clathrin coated pits and 
endocytosis of the complex occurs, the complex then enters the endosomal system 
where dissociation occurs. The receptor is then recycled to the plasma membrane 
whilst insulin is fully degraded.
1.4.4. Regulation of insulin secretion
Insulin secretion varies according to the nutritional state of the individual (Ganong, 
1995; Rorsman et a l, 1997). Increased plasma glucose concentrations cause 
increased insulin secretion. Although glucose is by far the most important regulator 
of secretion, insulin secretion can also be stimulated by amino acids (some are more 
stimulatory than others) and possibly ketone bodies (Ashcroft & Ashcroft, 1992). 
Evidence for and against stimulation of insulin secretion by KEF A exists, although it 
is not likely to be of physiological importance. A typical diet rarely involves the 
consumption of fat alone, some carbohydrate is always present and will stimulate 
insulin secretion (Frayn, 1996). In addition, various hormones and neurotransmitters 
can directly stimulate or inhibit insulin secretion from the pancreatic (3-cell such as 
glucose dependent insulinotropic peptide (GIF), cholecystokinin, glucagon like 
peptide-1 (GLP-1) and vasoactive intestinal peptide (VIP), which are secreted 
following ingestion of foods and potentiate insulin secretion (Dominiczak, 1999).
1.4.5. Insulin function
Insulin acts on three main target tissues - the liver, muscle, and adipose tissue. Its 
actions are primarily concerned with metabolism and increased cell growth, so 
insulin can be considered to be anabolic (Dominiczak, 1999). Insulin causes 
increased glucose transport, glucose phosphorylation, glycolysis and glycogen 
synthesis as well as decreased gluconeogenesis and glycogen breakdown. In protein 
metabolism insulin causes increased amino acid uptake, protein synthesis and
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decreased protein breakdown. For fat metabolism insulin causes increased storage of 
fatty acids and TAG in adipose tissue. The activity of insulin on LPL results in 
increased fat storage.
Insulin increases LPL-mRNA levels in adipocytes as well as increased rates of LPL 
synthesis and LPL activity. Activation of LPL by insulin involves transcription, 
altered enzyme processing and increased export from endothelial cells, the process 
takes 3-4 hours (Reaven & Chen, 1988, Ong et a l, 1988). However, Raynolds et a l,
(1990) suggested that insulin did not increase gene transcription rates and the 
resulting increase in mRNA levels was due to changes in mRNA stability. By 
increasing the stability of mRNA more mRNA is available for the synthesis of LPL.
1.5. Glucose dependent insulinotropic polypeptide
Glucose dependent insulinotropic polypeptide (GEP) is one of the gastrointestinal 
hormones which is involved in stimulating insulin release from the pancreas as well 
as inhibiting gastric acid secretion in the stomach (Ranganath et al 1999; Yeung et 
al., 1999). GIP is a 42 amino acid containing protein, belonging to the VlP-secretin- 
glucagon family (Mazzocchi et al., 1999). It is synthesized in specific endocrine cells 
located in the mucosal layer of the duodenum and jejunum, and in the submandibular 
salivary gland (Yeung et al., 1999). The plasma levels range between 0.05-0.1 nM 
(Chapman, 1996) and levels rise in response to glucose (Tseng et al., 1999) or TAG 
(Murphy et al., 1995). The human GIP gene spans 10 kb and is located on the long 
arm of chromosome 17. It is derived from a 153 amino acid precursor protein that is 
encoded in exon 2, .3 and 4. Most of the sequence for mature GIP is in exon 3 
(Chapman, 1996).
A recent review demonstrated that the insulinotropic effect of GIP was selectively 
reduced in diabetic subjects, suggesting that abnormalities in GIP release and 
function may be involved in the pathogenesis of diabetes mellitus (Yip & Wolfe,
2000). Kubota et al. (1996) have recently identified miss-sense mutations in the GIP
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receptor gene: Gly198 to Cys and Glu354 to Gin. Both Gly198 and Glu354 are conserved 
among human, rats, and hamster GIP receptors. The substitution of a thiol containing 
Cys residue for Gly and that of an uncharged Gin residue for the acidic Glu were 
expected to affect protein structure and function. In fact, it was found that GIP 
stimulated cAMP formation was considerably impaired with the Gly198 to Cys198 
mutation whereas the change of Glu354 to Gin354 was not significantly different from 
that of the normal GIP receptor. However, because type 2-DM is polygenic, the 
possibility that these or other unidentified mutations of the GIP receptor may 
represent a risk factor in a small subset of individuals with type 2-diabetes mellitus 
(DM) cannot be excluded (Yip & Wolfe, 2000).
GIP has been shown to stimulate the synthesis and release of LPL in cultured mouse 
preadipocytes (Eckel et al., 1979). In animal studies, exogenous GIP infusion has 
been shown to promote the clearance of CM-TAG (Wasada et al., 1981) and to lower 
post-prandial circulating TAG levels (Ebert et al., 1991).
1.6. Diabetes mellitus
Diabetes mellitus is the commonest endocrine disorder encountered in clinical 
practice. It is defined as a syndrome characterised by hyperglycaemia due to an 
absolute or relative lack of insulin and/or insulin resistance (World Health 
Organization, 1999).
1.6.1. Classification of diabetes
Various types of diabetes exist and can be classified as primary or secondary 
(Williams, 1991). Primary diabetes mellitus consists of insulin dependent diabetes 
mellitus (IDDM), which is now known as type 1 diabetes mellitus. Non-insulin 
dependent diabetes mellitus, more commonly known as type 2 diabetes mellitus 
(type 2-DM) can be further subdivided into obese and non-obese type 2-DM. Other 
types of diabetes include gestational diabetes and maturity onset diabetes of the
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young (MODY). Secondaiy DM is diabetes secondary to other conditions, for 
example pancreatic disease and endocrine disorders. The pathogenesis of type 1-DM 
and type 2-DM are different.
Patients with type 1 are frequently young (aged 1-25) and are non-obese, whereas 
patients with type 2-DM are frequently older (over 40) and present with obesity. 
Also the diseases are treated differently. Type 1-DM requires treatment with 
exogenous insulin and a controlled diet, whereas type 2-DM can be treated by dietary 
means and/or oral hypoglycaemic agents e.g. sulphonylureas (Williams, 1991, 
Gerich et al.9 1989). However, in many cases exogenous insulin becomes necessary 
in the treatment of type 2-DM.
1.6.2. Pathogenesis of diabetes
The pathogenesis of type 1-DM involves the autoimmune destruction of pancreatic (3 
cells and a genetic linkage is believed to be associated with type 1-DM, patients with 
the HLA DR 3 and 4 genotypes being particularly susceptible (Williams, 1991). In 
contrast, the pathogenesis of type 2-DM involves a combination of insulin resistance 
and an insulin secretory defect, although it is an area of current debate as to which 
comes first. Frequently patients present with normal (3-cell function and resistance to 
the actions of insulin alone. However, the secretory defect is characterised by various 
(3-cell abnormalities such as the presence of islet cell amyloid, selective insensitivity 
to glucose (by down regulation of the GLUT 1 and/or 3 transporter and abnormality 
of the glucokinase gene), loss of the characteristic phasic pattern of insulin secretion 
and increased proinsulin secretion (McCarthy et a l, 1994; Olefsky et al., 1995).
1.6.3. Metabolic effect in diabetes
In type 1-DM the metabolic state is primarily catabolic, with a depletion of the fuel 
stores as well as the tissues (Frayn, 1996). For carbohydrate metabolism, lack of 
insulin leads to hyperglycaemia (which show fluctuating levels especially after
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meals) which results from increased hepatic glucose output following 
gluconeogenesis and decreased glycogen synthesis as well as glycogen mobilisation. 
In addition, glucose uptake by cells is impaired, especially via GLUT 4, found in 
heart, skeletal muscle and adipose tissue, is insulin sensitive. Up-regulation of this 
transporter by insulin is a major way of reducing hyperglycaemia after meal. 
Hyperglycaemia contributes to various complications of diabetes for example 
retinopathy from non-enzyme glycation of the basement membrane, neuropathy 
possibly from abnormalities of the sorbitol pathway and atherosclerosis due to 
impaired fat metabolism and in part by protein glycation. Defects in protein 
metabolism include increased protein breakdown providing amino acids for 
gluconeogenesis and decreased tissue uptake of amino acids.
Defects in lipid metabolism due to insulin deficiency or insulin resistance result in 
HSL not being switched off in the fed state. This will accelerate mobilisation of fat 
from adipose tissue and release free glycerol and NET A in to the bloodstream 
(Williams, 1991; Frayn, 1996). The free glycerol further contributes to 
gluconeogenesis and the increased availability of NEFA for oxidation causes glucose 
to be displaced as the main oxidative fuel (Luo et ah, 1998). Decreased activation of 
LPL in insulin resistance states results in prolonged circulation of VLDL and CM 
which are normally cleared through LPL action.
Alterations in lipid metabolism resulting from type 2-DM (especially if untreated or 
poorly controlled) can cause atherosclerosis. At least two theories have been 
proposed to explain the high TAG levels observed in type 2-DM. In adipose tissue, 
insulin prevents TAG metabolism by inhibiting HSL activity. In uncontrolled 
diabetes, therefore, increased lipolysis occurs, so that mobilization of fatty acids and 
glycerol is increased by up to 300% (Salway, 1999). In addition, the reduced activity 
of LPL to clear plasma TAG results in prolonged post-prandial lipaemia (Reaven & 
Chen, 1988).
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1.7. Quantitative polymerase chain reaction
Quantitation by PCR is used to determine the initial number of target molecules in 
sample or the relative levels of starting molecules between various samples. Several 
methods have been used to quantitate PCR product (Pannetier et al., 1993; Riedy et 
al., 1995; Zimmermann & Mannhalter, 1996). These include the measurement of 
incorporated labelled nucleotides or primers into the amplified DNA. In an attempt to 
correct for tube-to-tube variations in amplification efficiency, most investigators use 
internal amplification standards. This internal standard may include the use of an 
endogenous gene transcript that is normally present in the sample (Horikoshi et al., 
1992) such as 'housekeeping genes' like p-actin (Beier et al., 1997) or p2- 
microglobulin (Laville et al., 1996) or an exogenous nucleic acid fragment added to 
the amplification reaction (Wang et al., 1989). Alternatively an endogenous internal 
standard, such as the P-actin or Pa-microglobulin, which uses the same primer 
sequences as the target RNA but yields a different sized product may be used 
(Newton & Graham, 1997). The ratios of the amount of PCR products generated by 
target and endogenous standard sequences in different samples are then determined 
and compared.
However, there are several problems with this approach. Firstly, the product obtained 
from the amplification of the endogenous standard and the target sequence may not 
reach the plateau phase of PCR at the same time. In other words, the amplification 
process of the endogenous standard may increase exponentially and level off earlier 
than that for the target sequence. This means that the number of cycles to be used for 
the endogenous standard and the target sequence would have to be different. 
Secondly, the gene-specific target primers need to have the same or a very similar 
annealing temperature value as the mimic for efficient amplification of both genes in 
the same reaction tube. Furthermore, it is also uncertain whether the different primers 
used in a single reaction tube would interfere with one another. Thirdly, the level of 
expression of the endogenous standard must be the same in each sample to be 
compared and must not change during the experimental treatment since variations
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can introduce considerable error in the quantitation. Finally, the expression of 
housekeeping genes may be subjected to modulation by a number of factors or 
inducers under study.
As indicated above, exogenous sequences may also be used as internal PCR 
standards. The exogenous standard, can either be a synthetic RNA added during 
cDNA priming (Riedy et a l,  1995) or a DNA not normally present in the target 
sample added directly to the PCR reaction. A significant advantage of this approach 
is that the specific amount of starting material added is known and this makes 
comparison with the amplification of the target gene more accurate (Schneeberger & 
Zeillinger, 1996). Also, it is possible to construct such exogenous fragments so that 
they are amplified by the same primer set on the target sequence to be quantified.
RT-PCR is reportedly a thousand times more sensitive than the traditional RNA blot 
techniques (Byrne et al, 1988; Wang et al, 1989). However, quantitation of the data 
obtained following RT-PCR is difficult due to the fact that PCR is an exponential 
reaction whereby small variations in amplification efficiency can result in large 
changes in the amount of products. Hence, competitive PCR, which uses an 
exogenous template (PCR mimic) as an internal standard, was chosen as an approach 
for obtaining quantitative information about the mRNA levels of target genes. The 
amplification of target and standard sequences were conducted in the same PCR 
reaction tube using the set of HSL primers that had been designed using the HSL 
genome from gene bank with accession number (LI 1706). This resulted in a specific 
and reproducible assay that could be used to assess the levels of HSL-mRNA in the 
human adipose tissue biopsy samples.
1.8. Aims and scope of this research project
This literature survey stresses the importance of the metabolic roles of HSL and LPL. 
They may affect cardiovascular disease risk because HSL plays a pivotal role in 
hydrolysis of TAG, which is already stored in the fat cells, and therefore the release
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of NEFA into the circulating blood. LPL is the rate-limiting step in the clearance of 
TAG, from CM and VLDL. Therefore, precise control of HSL and LPL during 
feeding and fasting is thought to be important for the maintenance of low plasma 
TAG and NEFA level and subsequent risk of atherosclerosis. The effect of insulin on 
regulating HSL and LPL is very important, since it inhibits the action of HSL and 
activates LPL to clear TAG from the circulation.
Therefore the Aims o f  this research project were:
To compare the response of HSL and LPL activity and gene expression in the fed 
and fasted states in adipose tissue samples taken from subjects with type 2-DM and 
control subjects.
To investigate the effect of changes in insulin and GIP levels in the same subjects 
and to examine their relationship with both lipase activity and gene expression.
To investigate HSL and LPL activity and gene expression in different fat depots 
obtained from abdominal, omental and subcutaneous adipose tissue of non-obese 
pre-menopausal women.
In pursuing these aims, the following experimental work was performed:
The modification of a new assay to measure LPL activity in post-heparin sample 
using a fluorimetric assay.
The development of acetone-ether-extraction preparations using about 10 mg of 
human adipose tissue for LPL activity measurement.
The development of an assay to measure HSL activity in about 10 mg of human 
adipose tissue.
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To develop an RT-PCR for measuring HSL-mRNA in about 10 mg of human 
adipose tissue.
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Chapter 2 
Materials and Methods
2. Materials and Methods
2.1. Materials
All general laboratory chemicals were supplied by Fisons, Loughborough or BDH, 
Poole and were ÀR grade unless otherwise stated. Specific chemicals ordered 
include:
Radiochemicats Supplier
I23I-sodium iodide 
125I-Insulin
ICN, Thame, UK.
Amersham International pic., Amersham, UK.
Glycerol Tri (9,10(n)-3H) Oleate Amersham International pic., Amersham, UK.
Hormones
GIP (porcine) 
GIP (human) 
Insulin (porcine)
Sigma Chemical Company Ltd., Poole UK 
Peninsula Laboratories, St. Helens, UK. 
Sigma Chemical Company Ltd., Poole, UK
Cobas Mira Analysis kits
TAG Analysis Kit 
Cholesterol Kit 
Glucose Kit 
NEFA Kit
Direct HDL-Cholesterol
Roche Diagnostic Products Ltd., Welwyn 
Garden City, UK.
Roche Diagnostic Products Ltd., Welwyn 
Garden City, UK.
Roche Diagnostic Products Ltd., Welwyn 
Garden City, UK.
WAKO Chemicals (Alpha Laboratories, 
Eastleigh), UK.
Randox. Laboratories, USA.
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NEFA Kit
Direct HDL-Cholesterol
WAKO Chemicals (Alpha Laboratories, 
Eastleigh), UK.
Randox Laboratories, USA.
Fluorometric lipase test
Total Lipase Test Progen Biotechink GMBH
Heidelberg, Germany.
Hepatic Lipase Test Progen Biotechink GMBH
Heidelberg, Germany.
Molecular biolozv srade products
Ethidium bromide 
Agarose
Polaroid black / white 
print film 667
Sigma Chemicals Company Ltd., Poole, UK. 
Immunogen International Ltd., Sunderland, UK. 
Sigma Chemical Company Ltd., Poole, UK.
Polaroid positive and 
Negative Film 665 
Tris
Access RT-PCR system 
Total RNA Isolation system 
1 kb DNA ladder 
Orange G Dye 
Filter Tips
0.5 ml Thermocycler tubes 
Primers
Sigma Chemical Company Ltd., Poole, UK.
Boehringer Mannheim GmbH, Germany. 
Promega Coloration, Madison, USA. 
Promega Corporation, Madison, USA.
Gibco BRL (Life Technologies), Paisley, UK. 
Sigma Chemical Company Ltd., Poole, UK. 
Promega Corporation, Madison, USA.
Gibco BRL (Life Technologies), Paisley, UK. 
Gibco BRL (Life Technologies), Paisley, UK.
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Others
BSA (Fraction V, RIA Grade) 
BSA (essentially fatty-acid free) 
HS A Fraction V 
Triolein
L-cc-phosphatidylcholine 
Aprotinin (from bovine lung) 
Bacitracin
Affinity purification columns 
Trizma base
Heparin (porcine,soduim salt) 
Optiphase safe
Lignocaine hydrochloride 
injection BP (2%)
Straight iris scissors 
LP3 tubes
Cannulae (Y- CAN 19 g)
5 ml heparin tubes 
10 ml EDTA tubes 
5 ml Fluoride Oxalate tubes 
Polycarbonate centrifuge tubes
15 ml opaque centrifuge tubes
Sigma Chemical Company Ltd., Poole, UK 
Sigma Chemical Company Ltd., Poole, UK. 
Sigma Chemical Company Ltd., Poole, UK. 
Sigma Chemical Company Ltd., Poole, UK. 
Sigma Chemical Company Ltd., Poole, UK. 
Sigma Chemical Company Ltd., Poole, UK. 
Sigma Chemical Company Ltd., Poole, UK. 
Cliffinar Associates Ltd., Guildford, UK. 
Sigma Chemical Company Ltd., Poole, UK. 
Sigma Chemical Company Ltd., Poole, UK. 
Wallac UK, manufactured by Fisons 
Chemicals, Leicester, UK.
Antigen Pharmaceuticals Ltd., Ireland.
Downs Surgical Ltd., Mitcham, Surrey, UK. 
LIP Services, Shipley, UK.
H.G. Wallace Ltd., UK.
LIP Services, Shipley, UK.
LIP Services, Shipley, UK.
LIP Services, Shipley,UK.
Nalge-Sybron Corporation,
Rochester, USA.
Sarstedt Ltd., Leicester, UK.
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2.1.1 General procedures
2.1.1.1. Insulin phosphate buffer
0.04 M  phosphate buffer pH 7.4
NaH2P 0 4 23 g
Na2HP04.2H20  5.97 g
Make up to 5 litres and store at 4°C
2.1.1.2. Insulin assay buffer
BSA 0.5 g
(Bovine serum albumin)
0.04 M phosphate buffer 100 ml 
This buffer is stable for about 1 week at 4°C.
2.1.1.3. GIP phosphate buffer
0.4 M  phosphate buffer pH  6.5
0.4 M KH2P 0 4 A
0.4M N a2HPO4 B
1 litre of each solution is prepared and solution A is added drop wise to solution B to 
give the required pH.
2.1.1.4. GIP assay buffer
0.4 M phosphate buffer 20 ml
HSA 1 g
(human serum albumin)
Aprotinin 0.018 g
Reverse osmosis water (RO) 180 ml
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Aprotinin 0.018 g
Reverse osmosis water (RO) 180 ml
2.I.I.5. Tris acetate (TAE) buffer
Tris 48.4 g
0.5 M EDTA, pH 8.0 20 ml
Glacial acetic acid 11.42 ml
Made up to 10 litres with milli Q water, adjust to pH 8.3
2.1.1.6. Orange G loading dye
Orange G dye 0.02 g
Formamide 10 ml
0.5 M EDTA, pH 8.0 200 pi
2.11.7. Ready to load 1 Kilobase (kb) DNA ladder
1 kb DNA ladder ( 1 pg/ml) 10 pi 
Nuclease free water 90 pi
Orange G loading dye 30 pi
Mix and store at room temperature. Eight microlitres of this DNA marker were used 
for each marker lane for the gel electrophoresis.
2.1.1.8. Agarose gel preparation
Agarose 3 g
1 x TAE buffer 100 ml
Boil in a microwave for 2-5 minutes, the molten agarose was left to cool slightly 
before 4.5pl of ethidium bromide (10 mg/ml) was added and swirled to mix. The 
agarose was allowed to cool to a hand-hot temperature before being poured into the 
gel mould. The gel was left to set at room temperature, wrapped in cling film and 
kept at 4°C for 20 minutes, before using.
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2.1.1.9. Gel electrophoresis
The prepared gel cast was placed in a gel tank, and sufficient buffer (Ix TAE) to fill 
the electrode chambers and cover the gel by a depth of 1-2 mm, was added. Samples 
were loaded into the gel and all gels were run at 3-5 v/cm for 1.5-2.0 hours.
2.2. Methods
2.2.1. Collection of plasma samples
All blood samples were collected into EDTA tubes, except those for glucose 
analysis, which were collected into fluoride oxalate tubes, and those for lipoprotein 
lipase activity which were collected into lithium heparin tubes. The blood tubes were 
centrifuged at 533 g for 10 minutes in a bench-top centrifuge, the plasma was 
removed and stored in aliquots at -20°C.
2.2.2. Adipose tissue lipoprotein lipase assay
Lipoprotein lipase activity was measured by a modified method described by 
Nilsson-Ehle et al, (1976). The method uses the detection of dH-labelled free fatty 
acids from a labelled triolein substrate emulsion, according to the equation below;
Glycerol 3H -trioleate------------ ► 3 3H -oleic acid + glycerol
2.2.2.1. Preparation of 3H-glycerol emulsion
3H -triolein (50 pi), triolein (250 pi) and phosphatidyl choline (50 pi) were placed in 
a sonicating vial and blown down under nitrogen in the dark for 1 hour. Glycerol (5 
ml) was added and the emulsion mixed using a vortex mixer. The emulsion was kept
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on ice throughout this preparation stage. The emulsion was sonicated for 4 x 30 
seconds with the tip of the sonicator probe just under surface; energy output on 2. 
The emulsion was then stored at room temperature in brown glass tubes and was 
stable for up to 5 weeks. The linearity of each emulsion was checked by a dose 
response curve, using a milk standard prepared from fresh unpasteurised cow's milk 
that was stored at -80°C.
2.2.2.2. Preparation of milk standards
The milk was first decreamed by centrifuging at 463 g for 10 minutes to bring the 
cream to the surface. The cream layer was then scraped off and the remaining milk 
passed through glass wool three times to remove any other fat. The standards were 
either a 1 in 10 or a 1 in 4 dilution of the decreamed milk, diluted using 0.2 M NaCl- 
Tris buffer (pH 8.1).
2.2.2.3. Preparation of apo C-Il source
Heat inactivated serum was used in each assay to provide apo C-ll. Venous blood 
was taken from a group of volunteers and collected into tubes without anticoagulant. 
The blood was left to clot at room temperature for 2 hours and centrifuged at 553 g 
for 10 minutes in a benchtop centrifuge. The plasma was removed, pooled and 
incubated at 65°C for 15 minutes before being stored at -80°C in 500 pi aliquots.
2.2.2.4. Extraction of LPL enzyme from adipose tissue using acetone 
ether precipitation
The acetone ether extraction was performed by a modification of the method 
described by Nilsson-Ehle (1972). A 10 mg sample of human adipose tissue was 
placed in a 50 pi of medium A (1 part of serum + 3 parts of 0.0067 M Tris HC1, pH = 
7.4). The tissue was thoroughly homogenised, then 1 ml of cold acetone was added 
and re-homogenised until no fragments were visible, the homogenate was transferred 
to a 1.5 ml microfuge tube, and spun at 4°C for 2 minutes at 1500 g. The supernatant
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was discarded and this step was repeated 3 times. Then 1 ml of cold ether was added 
to the pellet and mixed using a vortex mixer, the mixture was re-spun at 4 °C as 
above. The supernatant was discarded and the pellet dried under reduced pressure for 
30 minutes. The acetone-ether product was kept in a container which contained silica 
gel to keep it dry and stored at -80°C. The precipitate was resuspended in 200 pi of 
0.05 M NH4OH-NH4CI buffer (pH = 8.1) immediately prior to use.
2.2.1.5. Preparation of substrate emulsion
The substrate emulsion was prepared fresh on the day of assay by adding 500 pi 3H- 
triolein-glycerol emulsion, 500 pi heat inactivated serum and 1000 pi 0.2 M NaCl- 
Tris buffer (pH 8.1). The substrate emulsion was sonicated for 2 x 30 seconds with 
the tip of the probe just under surface, energy output on 2. A 1000 pi aliquot of 6% 
(w/v) BSA (essentially fatty-acid free) was added to the emulsion, the emulsion was 
vortex mixed and incubated at 37°C for 10 minutes before being added to the 
reaction tubes.
2.2.1.6. Assay protocol for tissue LPL activity
The assay tubes were initially set up on ice, to prevent the enzymatic reaction 
occurring prematurely. One hundred microlitres of substrate emulsion (containing 
0.2 M NaCl-Tris buffer (pH 8.1) with BSA (3% w/v), JH-triolein-glycerol emulsion 
and heat-inactivated serum) was added to all of the tubes. Acetone ether extracts (40 
pi) were pipetted, in duplicate in to each of the sample tubes, with 60 pi of 0.2 M 
NaCl-Tris buffer (pH 8.1) at 4°C, and the tubes were mixed for 10 seconds. The 
enzymatic reaction was started by incubating the tubes at 37°C, in a shaking water 
bath, for 30 minutes. At the end of this period the tubes were placed back on ice and 
3.25 ml o f organic solvent (chloroform, heptane and methanol in the ratio 1.25: 1:
1.41 by volume) followed by 1.05 ml of 0.1 M K2CO3 (adjusted to pH 10.5 with 
saturated boric acid) were added to all tubes to stop the reaction and to extract the 
free fatty acids into the upper methanolic phase. The tubes were vigorously mixed to 
aid the extraction of the fatty acids and centrifuged at 1700 g for 10 minutes in a
49
Beckman J6 centrifuge. Part o f the aqueous layer (500 jil) was removed and added to 
a scintillation vial containing 4 ml Optiphase safe and 75 pi glacial acetic acid. The 
glacial acetic acid is a neutralising agent that reduces chemiluminescent light 
intensity. The vials were inverted several times and left for a minimum of 1 hour in 
the dark before being counted for radioactivity on a Wallac 1410 beta counter. Each 
tube was counted for 5 minutes using a present programme. The intra-assay 
coefficient o f variation (CV) was 4.9% at 70 pi and the inter-assay CV was 5.6% at 
70 pi (Milk standard).
The results from the blank incubations were subtracted from the acetone extract 
sample values and the enzyme activity was calculated using the following equation: -
Enzyme activity. A, (pmole oleate released per min) at 37°C was corrected for the 
weight of tissue, B (in mg).
A= (DPM-Blank) x 1 x ________ 1________________ x 3 x 4.9 x 1
t specific radioactivity of triolein 0.76
Where;
t = incubation time in minutes
Specific radioactivity of
triolein = 2170699.34 dpm/micromole(varies with 
batch)
3 = 3 fatty acids liberated from each 
triacylglycerol hydrolysed
4.9 = dilution factor (0.5 ml taken from 2.45 
ml aqueous methanolic phase)
0.76 = partition coefficient from oleate into the 
aqueous methanolic phase
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B=  mg tissue________
total |il of tissue homogenates
x\x\ homogenate used
Then specific activity = *g- X 1000 X 1000 nmol oleate released per minute 
per gram at 37°C.
mg tissue = the mg of tissue that were used in the 
acetone ether extraction
total pi of tissue = 200 pi
homogenate
pi homogenate used = 40 pi
1000 = to convert the mg into g
1000 = to convert to nmol oleate released per
minute at 37°C
2.2.3. Postheparin plasma lipoprotein lipase activity
Post-Heparin Plasma lipase activities (PHLA) were measured using a fluorometric 
technique based on two kits, one which measured total lipase and the other hepatic 
lipase. They were supplied, with the standard, by Progen Biotechnik GMBH. The 
tests used a specially prepared lipase substrate, l-trinitrophenyl-amino-dodecanoyl- 
2-pyrendecanoyl-3-0-hexadecyl-sn-glycerol This is a TAG in which the pyrene 
fluorescence is intra-molecularly quenched by the trinitrophenyl group. Upon 
addition of active lipase, the increase in pyrene fluorescence intensity is measured at 
342 nm Excitation (Ex) and 400 nm Emission (Em). Distinct assay conditions (pH, 
NaCl and Triton X 100 concentration) allow the selective determination of HE. The 
standard provided is the unquenched fluorescent derivative of the substrate.
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2.2.3.1. Adjustment of sensitivity and assay range: calibration of the
fluorimeter
The test requires a linear assay range. Dilution of the pyrene standard provided gave 
the following concentrations 20 pmol/1, 5 pmol/1, 1.25 pmol/1 and 0.3 pmol/1. 2ml of 
each diluted standard was placed into a cuvette and the fluorescence measured at Ex 
342 nm and the Em at 400 nm at room temperature. The sensitivity of the instrument 
was adjusted with the highest standards. The increasing concentrations of the 
unquenched standards gave a linear response over the whole range (see figure 2.1 )
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Figure 2.1: Typical calibration curve using the standards provided for both 
lipase assays.
The molar fluorescence of the pyrene group in Relative Fluorescence Unit 
(pmol.mf1) is needed to calculate the concentration of the unquenched pyrene 
groups which accumulate over time in the kinetic lipase assays. This value was 
obtained from the slope of the standard curve.
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2.2 3 .2. Assay protocol
Two millilitres of freshly reconstituted substrate were transferred to a cuvette and 
warmed up to 37°C. A 20 pi sample of 1:10 prediluted (using the assay buffer which 
was supplied with the kit) was added and mixed well. The progress of the reaction 
was followed for 2 minutes at 37°C, using the same fluorimeter settings as for the 
calibration using the standard.
2.2.3.3. Calculation of lipase activity
The activity of each lipase sample was calculated as the ratio of the change in 
fluorescence intensity with time (RFU/min) and the molar fluorescence. The intra­
assay CV was 3.4% for total lipase at 61 pmol oleate released per minute, ml"1 at 
37°C), (n=9) and 6.8% at 10 pmol oleate released per minute, ml*1 (n=9) for hepatic 
lipase.
2.2.4. Plasma insulin
Plasma insulin concentrations were measured using a radioimmunoassay technique 
based on a method described by Albano et al, (1972) and modified by Flatt & Bailey 
(1981). The assay uses an 125Iodine labelled insulin tracer, antiserum to insulin raised 
in guinea pigs and a polyethylene glycol (PEG)-accelerated double antibody 
separation step.
The assay was performed at 4°C and samples were assayed in duplicate. Plasma 
samples were defrosted at the time of the assay and centrifuged at 1700 g for 10 
minutes at 4°C to remove fibrin that would otherwise prevent accurate pipetting. 
Assay diluent, consisting of 0.04 M phosphate buffer (pH 7.4), human serum 
albumin (0.5% w/v) and aprotinin (50,000 KIU/100 ml), was placed in LP3 tubes 
(100 pi to the standard tubes; 200 pi to the zero standard and the sample tubes; 300 
pi to the tube used to determine non-specific binding (NSB) during the assay).
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Standards (100 fil) ranging from 1500 pmol to 23 pmol were added to the standard 
curve tubes. Standards were prepared by serial dilution from stock standards 
containing synthetic human insulin. Plasma samples (100 pi) were added to the 
sample tubes and one NSB tube was set up for each sample. Charcoal-stripped serum 
(CSS) (100 pi) was then added to the standard curve tubes. Anti-insulin antiserum 
(100 pi) was then diluted 1:100 in assay diluent and added to all tubes except those 
needed for the NSB determination. The tubes were then vortex mixed and left at 4°C 
overnight.
The 125I-insulin label was bought ready purified and was diluted 1:80 immediately 
prior to addition to the assay tubes. Label (100 pi) was added to all tubes and they 
were kept at 4°C for 48 hours. On day 4 of the assay, normal guinea pig serum was 
diluted 1:200 with assay buffer and donkey-anti-guinea pig serum was diluted 1:20 
with assay buffer, 100 pi of each and 4% (w/v) PEG 2000 (700 pi) was added to all 
tubes except the total tubes. The tubes were vortex mixed and held at 4°C for 2 hours 
before being centrifuged at 1700 g for 30 minutes in the Beckman J-6B. The liquid 
was aspirated off the tubes under vacuum and the pellet containing the bound insulin 
was counted on a gamma counter.
The intra-assay CV was 6.7% at 35 pmol/1 and inter-assay CV was 9 % at the same 
concentration
2.2.5. Plasma GIP
Plasma GIP was measured using a method described by Morgan et al, (1979). This 
technique is a four days radioimmunoassay using ^Iodine-labelled GIP. Separation 
of antibody bound and free antigen is achieved by a second antibody plus 
polyethylene glycol (PEG). The assay employs an antiserum raised in rabbit against 
purified natural porcine GIP, so on day 3, normal rabbit and donkey anti- rabbit 
serum were added. All procedures were performed at 4°C.
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The intra-assay CV was 3.4% at 297 pmol/1 and the inter-assay CV was 8% at 360 
pmol/1.
2.2.5.1. Affinity purification of radiolabelled GIP
A disposable plastic column consisting of a solid phase of rabbit anti-GIP antibodies 
chemically coupled to silica beads. The column was stored in 0.1 M bicarbonate 
buffer (pH 9.8), so the first step was to remove the caps and allow this to drain 
through. The column was then washed with 10 ml 0.3% (v/v) HC1 which was passed 
through under pressure from a syringe. The column was then washed with four 
successive aliquots of GIP assay diluent (5 ml) which were allowed to drain through 
and the column was stoppered before it went dry. The tracer sample was 
reconstituted with 3 ml assay diluent and layered onto the column with a disposable 
plastic pipette. The column was then capped and inserted into a boiling tube and 
roller mixed for 30 minutes. At the same time, a 5 ml glass vial was filled with assay 
diluent and also rolled for the same length of time. This vial was for collecting the 
eluted purified label and this process reduces the loss of label due to its sticking to 
the walls of the vial. After 30 minutes, the column was reclamped and allowed to 
resettle before the column was washed again with four X 5 ml aliquots of distilled 
water. The assay diluent was poured out of the vial and the purified label was eluted 
with 5 X 1 ml 0.3% (v/v) HC1. These fractions were collected into the 5 ml vial 
which was then capped and mixed by inversion. The purified label (100 pi) was 
counted and diluted to give a count of 5000 cpm/100 pi for addition to the assay 
tubes. The used column was washed with 10 ml bicarbonate buffer before being 
stored in bicarbonate buffer at 4°C.
2.2.5.2. Assay protocol
Samples are assayed for non-specific binding as well as a specific binding (one NSB 
tube/subject if mutiple samples taken from one subject) see table 2.1 for details.
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Table 2.1 Plasma GIP assay protocol
Reagents Tubes
Day 1 Totals NSB
Std
Zero
Std
Std NSB
QC
QC NSB
Unknown
Unknown
Assay
diluent
300 pi 200 pi 100 pi 300 pi 200 pi 300 id 200 id
GIP
Std
100 pi
CSS 100 pi 100 pi 100 pi
QC
plasma
100 pi 100 pi
sample 100 pi 100 pi
Anti-
serum
100 pi 100 pi 100 pi 100 pi
Vortex mix all tubes and incubate 24 lours at 4°C.
Day 2 
label
100 pi 100 pi 100 pi 100 pi 100 pi 100 pi 100 pi 100 pi
Vortex mix all tubes and incubate 48 lours at 4°C.
Day 4 
NRS
50 pi 50 pi 50 pi 50 pi 50 pi 50 pi 50 pi
DAR 50 pi 50 pi 50 pi 50 pi 50 pi 50 pi 50 pi
14% PEG 100 pi 100 pi 100 pi 100 pi 100 pi 100 pi 100 pi
Vortex mix all tubes and incu Date 4 hours at 4°C. Centrifuge at 1700 g f 
count the pellet.
or 20 minutes, aspirate and
Std: standard; NSB: non specific binding; NRS: normal rabbit serum; DAR: donkey anti-rabbit 
serum; PEG: polyethylene glycol; QC: quality control.
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2.2.6. Automated analysis on the Cobas Mira Plus
Prior to analysis, all plasma samples were defrosted, vortex mixed and centrifuged at 
1700 g for 10 minutes in a Beckman J-6B centrifuge, to precipate any fibrin, which 
interferes with accurate pipetting by the analyser.
2.2.6.1. Measurement of plasma TAG
Plasma TAG levels were measured by an automated, enzymatic, colorimetric 
technique on the Cobas Mira Plus analyser (Roche Products Ltd., UK). Roche 
diagnostic products Ltd., supplied the kit used, and Nycomed, Birmingham, UK 
supplied QC. The principle of this assay is described in the following equations and 
involves the use of enzymes TAG lipase, glycerol kinase, glycerol phosphate oxidase 
and peroxidase:-
Triacylglycerol ----------------------------► Glycerol+fatty acids
Glycerol + ATP  ► Glycerol-3-phosphate + ADP
Glycerol - 3 - phosphate + O2 ---------► Dihydroxyacetone phosphate
+  H 2 O 2
H2O2 + 4- chlorophenol  ► Quinoneimine derivative
+ 4- aminophenazone
The red-coloured quinoneimine derivative absorbs at 500 nm. The colour intensity 
measured is directly related to the TAG concentration in the sample. The intra-assay 
CV was 1.7% at 1.05 mmol/1 (n = 6).
2.2.6.2. Measurement of plasma glucose
Plasma glucose was measured on the Cobas Mira Plus analyser using a kit and QC 
supplied by Roche Products Ltd., UK. This is an enzymatic, photometric assay that is
read in the UV spectrum. The principle of the assay is described in the following
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equations and involves the enzymes hexokinase and bacterial glucose-6-phosphate 
dehydrogenase: -
The formation of NADH is directly related to the concentration of glucose in the 
sample and is measured at 340 nm. The intra-assay CV was 0.72% at 3.86 mmol/1
2.2.6.3. Measurement of plasma NEFA
Plasma NEFA was analysed on the Cobas Mira Plus analyser using a kit made by 
WAKO Chemical GmbH, Germany and supplied by Alpha Laboratories Ltd., 
Eastleigh UK. The assay employs an enzymatic, colorimetric method involving the 
enzymes acyl-CoA synthetase, acyl-CoA oxidase and peroxidase: -
NEFA +ATP + CoA  ► Acyl-Co A + AMP +PPi
Acyl-CoA +O2  ► 2,3-Trans-enoyl-CoA+H2O2
H2O2 +3 -methyl-N-(P-hydroxyethyl) —► Purple-coloured adduct 
aniline +4-amino-antipyrine
The purple-coloured adduct can be measured colorimetrically at 550 nm. The 
intensity of the colour formed is proportional to the NEFA concentration. The intra­
assay CV was 0.11% at 1.05 mmol/1 (n=6).
2.2.6.4. Measurement of plasma cholesterol
Plasma total cholesterol was measured on the Cobas Mira Plus analyser using a kit 
supplied by Roche Products Ltd., UK and a QC supplied by Nycomed, Birmingham,
D-glucose +ATP 
D-glucose-6-phosphate 
+ NAD+
>  D-glucose -6-phosphate + ADP
6-phospho-gluconate + 
NADH +H+
(n=6).
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UK. The total cholesterol assay is an enzymatic, colorimetric test involving the 
enzymes cholesterol esterase, cholesterol oxidase and peroxidase:-
Cholesterol ester + TfeO 
Cholesterol + O 2 
H2O2 + 4- chlorophenol >  Quinoneimine derivative
>  Cholesterol +fatty acids
Cholestenone + H2O2
+ 4- aminophenazone
In the presence of peroxidase the hydrogen peroxide catalyses the oxidative coupling 
of the phenol and 4-aminophenazone to form a red-coloured quinoneimine 
derivative. The colour intensity measured is directly proportional to the concentration 
of cholesterol in the sample. The intra-assay CV was 1.9% at 4.4 mmol/1 (n=6).
2.2.6.5. Measurement of HDL- and LDL-cholesterol
HDL-C analysis was carried out using direct measurement of HDL-C, without 
sample pre-treatment. The measurement was done using the Cobas Mira Plus 
analyser. The kit and the QC used were supplied by Randox. The assay consists of 2 
distinct reaction steps:
Elimination of cholesterol in chylomicrons, VLDL and LDL was done using 
cholesterol esterase, cholesterol oxidase and subsequently catalase.
Step 1
Cholesterol ester
cholesterol
esterase >  Cholesterol + fatty acid
Cholesterol + O2 cholesterol oxidase Cholestenone + H2O2
2H 2O 2
catalase
^  TEO + O2
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Step 2
Specific measurement of HDL-Cholesterol after release of HDL-C by detergents in 
reagent 2.
Cholesterol ester
Cholesterol + O2
2 H2O2 + 4-aminoantipyrine ^ erQx^ ase ^  Quinoneimine pigment + 4 H2O. 
+ 2-hydroxy-3-sulfopropyl-3,5-dimethoxyaniline
cholesterol
esterase
Cholesterol + fatty acid
cholesterol oxidase
_____________________ ^  Cholestenone + H2O2
The intensity of the quinoneimine dye produced is directly proportional to the 
cholesterol concentration when measured at 600 nm.
LDL-C was calculated from total and HDL-Cholesterol according to Friedewald's 
formula (cited by Mackness & Durrington, 1992);
LDL-C = Total serum Cholesterol
Total TAG
HDL-C +
2.2
The intra-assay CV for Direct HDL-Cholesterol was 1.8 % at 0.84 mmol/1 (n=6)
2.2.7. Adipose tissue biopsy
Approximately 100 mg of adipose tissue was taken from each subject. The biopsy 
was taken from the upper gluteal region using a standard procedure utilising a scalpel
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and forceps (figure 2.2); the procedure was done under the local anaesthetic, 
lignocaine. Following removal, the sample was immediately wrapped in aluminium 
foil and put into liquid nitrogen. A single stitch was made at the biopsy site. The 
sample was stored at -80°C.
h i
;
->:
Figure 2.2 View to illustrate the method used to obtain the adipose tissue 
sample.
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2.2.8. RNA extraction
2.2.8.1. RNA preparation
Adipose tissue, which was stored frozen, was initially pulverised in liquid nitrogen. 
The next step in the method was RNA preparation in which total RNA was extracted 
with organic solvent, phenol/chloroform that was provided with the kit. This and 
subsequent steps were performed on ice so as to reduce the rate of RNA degradation.
The first step in the RNA extraction involved disrupting the adipose tissue cells, 
denaturing nucleoprotein complexes (i.e. proteins which are bound to RNA at 
extraction), inactivating endogenous ribonuclease (RNase) activity (which is 
important as it is released from membrane bound organelles when the cells in the 
tissue are disrupted) and removing possible contaminants such as chromosomal DNA 
and proteins. This disruption of the tissue was performed manually by homogenising 
a weighed sample (about 10 mg) of sample in a 1 ml-glass homogeniser with 120 pi 
of denaturing solution which was provided with the kit. The denaturing solution 
contains guanidine thiocyanate and citrate/N-laurylsarcosine /p2 mercaptoethanol 
buffer (pH 4.0). Guanidine thiocyanate and p2 mercaptoethanol are strong inhibitors 
of RNase and in addition guanidine thiocyanate and N-lauryl sarcosine denature 
nucleoprotein complexes so that the RNA is not protein bound when it is extracted.
Next, 12 pi of sodium acetate (2 M, pH 4.0) was added and the tube mixed 
thoroughly by inversion, then 120 pi of phenol: chloroform: isoamyl alcohol in the 
ratio of (125:24:1) was added. The phenol: chloroform: isoamyl alcohol addition 
resulted in acid extraction of the RNA. This caused separation into an organic phase, 
an interface containing chromosomal DNA as well as proteins and an aqueous phase 
containing RNA (Chomczynski & Sacchi, 1987).
The next stage involved mixing the tube by inversion, chilling on ice for 15 minutes 
and centrifugation at 10,000 g for 20 minutes at 4°C using a micro-centrifuge. The
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resulting aqueous phase was then removed and precipitation of the RNA was 
performed by adding 120 jil of isopropanol at room temperature. The RNA was then 
pelleted by centrifugation (10,000 g for 20 minutes at 4°C) and washed with 1 ml of 
iced cold 75% (v/v) ethanol. Next, the pellet was broken up with an RNase free 
pipette tip, recentrifuged (using conditions identical to the two previous occasions), 
air dried for 5 minutes and dissolved in 200 pi nuclease free water and stored at 
-80°C.
Note: -
Contamination is a frequent problem with RNA extraction, this primarily involves 
ribonucleases. Ribonucleases, as already described, cause breakdown of RNA by 
their activity. In addition, the inactivation of ribonucleases is difficult. Contamination 
can occur from various sources and as a result sterile techniques must be used for 
RNA extraction. Various precautions were adopted in this procedure such as the use 
of gloves, handling the equipment in a sterile manner, baking glassware at 180°C 
overnight and autoclaving apparatus where appropriate.
The average yield of the total RNA obtained was determined spectrophotometrically 
at 260 nm where one absorbance unit is equal to 40 pg of RNA/ml. (Sambrook et al, 
1989). The purity of the RNA was also measured spectroscopically by comparing 
relative absorbances at 260 nm and 280 nm. Pure RNA produces a 260 nm to 280 nm 
ratio of 2.0. The range of acceptable values was 1.70 to 2.50. Variations exist due to 
variability in the starting materials and in performing the procedure. A lower ratio 
indicates carry over of DNA during the precipitation stages (Sambrook et al, 1989). 
A summary of the method of RNA extraction is shown in figure 2.3. The average 
yield of the total RNA was 71.0 pg/ml; the acceptable range was 5-125 pg/ml.
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Summary of the Protocol o f RNA Extraction,
Homogenise cells or tissue in denaturing solution (120 pil)
(5 minutes)
4
Add 2 M sodium acetate pH 4.0 (12 pi)
1
Add phenol: chloroform: isoamyl alcohol pH 4.7 (120 pi) 
Keep on ice for 15 minutes
V
Transfer to fresh centrifuge tube (20 minutes) 
(Centrifuge at 10,000 g for 20 minutes at 4°C.)
Remove aqueous phase containing RNA (other phase contains DNA and protein) 
Precipitate with 120 pi isopropanol (incubate overnight)
v
Centrifuge at 10,000 g for 20 minutes at 4 C.
Pellet RNA
V
Wash pellet by adding 1 ml iced-cold 75% (v/v) ethanol
V
Break up the pellet with an RNase free pipette tip 
Centrifuge (10,000 g for 10 minutes at 4^C.)
V
Air-dry for 5 minutes
V
Add 200 pi nuclease free water 
Store at -80%.
Figure 2.3 Summary of the Protocol of RNA Extraction.
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2.2.9. Quantitative competitive reverse transcription-polymerase 
chain reaction (RT-PCR)
Traditional methods used in the measurement and analysis of mRNA levels include 
procedures such as Northern blotting, RNA dot/slot blots and in situ hybridisation. 
The advent of the polymerase chain reaction (PCR) technique has provided a highly 
sensitive and rapid method for mRNA analysis (Wang et al, 1989; GiUiand et al, 
1990; Auboeuf & Vidal, 1997). PCR is an enzymatic process whereby the products 
of one reaction serve as templates for the next. Thus, the amount of product increases 
exponentially and not linearly following multiple cycles of the reaction. In the later 
cycles of PCR, the amplification rate becomes slower and eventually reaches a 
plateau. The number of cycles needed to reach the plateau phase varies, depending 
on the size of the sequence and the original amount of target molecule.
The PCR-based method for analysis of mRNA levels has been termed reverse 
transcription-PCR (RT-PCR) and its use in the present study is illustrated in figure 
2.4. RNA is first extracted from human adipose tissue samples as previously 
described, and used as a template for the synthesis of complementary DNA (c-DNA) 
by reverse transcription. The c-DNA in turn forms a template for PCR using primers 
designed to amplify selected types and regions of the c-DNA of interest. The 
amplified product is analysed by agarose gel electrophoresis, visualised by ethidium 
bromide staining (Gebhardt et al, 1994) and the size of this product is identified 
based on the predicted molecular size of the c-DNA nucleotide sequence.
2.2.9.1. A multi-specific internal standard
A multi-specific internal standard had been produced by Vidal's group in France 
(Laville et al, 1996). The standard was a 525 bp long synthetic gene, the sequence of 
which corresponded to the juxtaposition of the complementary sequences of 13 
specific sense-primer sequences, followed by the juxtaposition of the complementary 
12 specific anti-sense primers in the same order. A schematic diagram of this RNA 
multi-specific standard is shown in figure 2.5.
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Total-RNÀ 
extraction
Reverse
transcription step
c-DNA
i PCR with primers specific to c-DNA
i Forward primer
Amplified product
Reverse primer
—y
Agarose Gel Electrophoresis of PCR Product
Densitometry of DNA Bands
Figure 2.4 Schematic illustration of the RT-PCR method used.
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Figure 2.5: Organisation of the multi-specific internal standard adapted from 
Laville et a l  (1996). A 525 bp long synthetic gene, the sequence of which 
corresponded to the juxtaposition of 13 specific sense-primer sequences, 
followed by the juxtaposition of the complementary sequences of 12 specific 
anti-sense primers in the same order, r Indicates the primers used in this 
project.
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2.2.9.2. The primer’s design
The multi-specific internal standard that was produced by Vidal's group in France 
had included primer sequences for the LPL gene and for the housekeeping gene p2- 
microglobulinuin (p2-microglobulin). The sequence of both primers (sense and 
antisense) are shown below:
LPL sense primer 5'-ACACAGCTGAGGACACTTGC-3'
LPL antisense primer 5'-CACTGGGTAATGCTCCTGAG-3’
p2-microglobulin sense primer 5 '-CCAGCAGAGAATGGAAAGTC-31
p2Jnicroglobulin antisense primer 5'-GATGCTGCTTACATGTCTCG-3'
These primers produced the following PCR product sizes:
LPL mimic =267 bp LPL target =227 bp
p2 .microglobulin mimic =306 bp p2 -microglobulin target =269 bp
2.2.9.3. Optimisation of the RT-PCR using the LPL and p2- 
microglobulin primers
The earlier development of this method was described by another worker in this 
laboratory (Brooks, 1998). Further optimisation, which was carried out as part of this 
project, included alteration of the primer concentration, MgSCL concentration, 
annealing temperature, and cycle number. The Promega access RT-PCR system was 
used for the RT and PCR amplification of a specific target total RNA. The system 
uses AMY reverse transcriptase (AMV-RT) from Avian Myeloblastosis Virus for
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first strand DNA synthesis, and the thermostable Tfl DNA polymerase from Thermits 
Flavus for second strand cDNA synthesis and DNA amplification. Hence the optimal 
conditions were found for each primer, as summarised in table 2.2.
Table 2.2: Optimisation of RT-PCR conditions for amplification of LPL and 
Pa-microglobulin gene using Access RT-PCR system by Promega (1997b).
Parameters Ranges tested Optimum parameters chosen
LPL P2-microglobulin
Primer concentration 25-50 pmolar 50 pmolar 50 pmolar
MgSCU 0.5-2.5 mM 1 mM 1 mM
Tfl DNA polymerase 0.1 u/pl O.lu/pl 0.1 u/pl
AMV-RT 0.1 u/pl O.lu/pl 0.1 u/pl
Number of cycles 25-35 28 26
Annealing temperature (°C) 55-68 62 60
Denaturing temperature (°C) 94 94 94
Extension temperature (°C) 68 68 68
2.2.9.4. Amplification and competition
Competitive RT-PCR was carried out using gene-specific primers as shown in figure 
2.6. Competitive RT-PCR was set up for each sample using 2-fold dilutions of the 
RNA standard which is known as mimic (ranging from 100 to 0.195 picograms), 
with a constant amount of target c-DNA.(as shown in table 2.2). A negative control, 
containing kit reagents and primers only, was also set up each time. Examples of the
69
results of the competitive RT-PCR for the quantitation of LPL and ^-microglobulin 
are shown in figures 2.7 and 2.8.
The amplified products were resolved by agarose gel electrophoresis and quantitated 
by scanning laser densitometry. The principle of the quantitation is that when the 
molar ratio of PCR products generated from target and PCR mimic is equal to one, 
the amount of target in the reaction was equal to the amount of mimic. Since the 
amount of mimic is known, the amount of target can be determined.
Adipocyte RNA
Reverse transcription
Spike with dilution
 h l - Z  I  ! z  ÉÜ
c-DNA PCR mimic
PCR with 
Gene-specific
Primers (LPL or p2-niicoglobulin)
Agarose gel 
electrophoresis i PCR product
mimic
Target
When molar ratio is 1:1 
Target=mimic concentration
Figure 2.6: Schematic of the competitive RT-PCR technique.
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Figure 2.7: An example of the results of a competitive RT-PCR reaction using 
the LPL primers. The photograph shows a 2-fold serial dilution of competitor 
RNA. Lane 1-10 contain a 2-fold serial dilution of the LPL competitor ranging 
from 100- 0.195 pg. Lane 11 is the negative control. Lane 12 contains 1Kb DNA 
ladder marker. The approximate equivalence point is at 1.56 pg (lane 7). The 
267 bp on the right hand side indicates the position of the mimic and the target 
PCR fragments are at 227 bp.
Figure 2.8: An example of the results of a competitive RT-PCR reaction using 
the p2 microglobulin primers. The photograph shows a 2-fold serial dilution of 
competitor RNA. Lane 3-9 contain a 2-fold serial dilution of the p2 
microglobulin competitor ranging from 100-1.56 pg. Lane 2 & 11 are the 
negative control. Lane 1 & 12 contain 1Kb DNA ladder marker. The 
approximate equivalence point is around 12.5-6.25 pg (lane 6 & 7). The 306 bp 
on the right hand side indicates the position of the mimic and the target PCR 
fragments are at 269 bp.
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Table 2.3 The RT-PCR protocol using the Access RT-PCR kit.
Reagent Volume (pi)
Nuclease free water 30.0
AMV/T/75X buffer 10.0
dNTPs 1.0
MgS04 2.0
AMY reverse transcriptase 1.0
Tfl DNA polymerase 1.0
Primers (sense+antisense) 2.0
(LPL or (32-microglobulin)
Sample (total RNA) 2.0
Total volume 49.0
The mimic RNA was defrosted and Ifjl o f each dilution was added to an individual 
reaction tube, (for concentration see table 2.2).
2.2.9.S. Quantitation of RT-PCR product yields
The relative intensities of the bands corresponding to the target and mimic PCR 
products were quantitated by scanning densitometry of the Polaroid negative of the 
gel. The relative amounts of target and mimic products were calculated after 
correcting for the difference in their size (as discussed below in data processing 
section 22.9.6). The ratios of target to mimic were then plotted against the reciprocal 
of the amount of PCR mimic added to the PCR reaction (see figure 2.9 for 
explanation). Typically the R2 values obtained were 0.95 or greater. The 
concentration of the target c-DNA was calculated from this graph and was expressed 
as the number of molecules of LPL-mRNA per molecule of ^-microglohulin- 
mRNA. The intra-assay CV was 3.7% at 2.1xl05 molecules of pi-microglobulin- 
mRNA per total RNA, and 6.6% at 3.3x104 molecules of LPL mRNA per total RNA.
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Figure 2.9 Competitive RT-PCR graph for the calculation of target LPL-mRNA 
concentration.
A competitive RT-PCR graph of the ratio of target : mimic against the reciprocal of 
PCR mimic concentration allows the concentration of the target LPL-mRNA to be 
determined (Brooks, 1998). The intensities of target to mimic electrophoretic bands 
were determined by densitometry, calculated after correcting for the size difference 
between them. The equation of the graph, in this case, Y = 5 X l(f  x + 0.3733, was 
used to calculate the concentration of target c-DNA present during the competitive 
PCR. As illustrated in figure 2.7 and 2.8, at the ratio of 1, the concentration of target 
equals the concentration of mimic, that is, where y equals 1. Based on this, x (which is 
the concentration of target) was calculated taking into account the dilution factor used 
in each competitive PCR experiment. The graph was plotted using Microsoft Excel1X1 
which also calculates the equation of the line and R2 values.
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2.2.9.6. Data processing
Calculations which were performed on the results obtained from scanning 
densitometry were used to evaluate the concentration of LPL-mRNA and
p2-microglobulin-mRNA.
The nucleotide ratio of target : mimic was determined for each gene thus:
LPL-mRNA = 227 bp : 267 bp = 0.85
p2-microglobulin-mRNA = 269 bp : 306 bp = 0.88
The first stage in the calculation involved correcting for the different size (i.e. 
difference in nucleotide number) of the two products (target : mimic).
2- Next the sample densitometer results were divided by these corrected values to 
obtain the mimic results.
3- The results were expressed as the number of molecules of LPL-mRNA per P?- 
microglobulin-mRNA
In case of the LPL-mRNA mimic, the mimic was 267 base pairs long and the mean 
molecular weight for a base pair is 660, this is adjusted to 330 as the value of 660 
refers to double stranded molecules and single stranded RNA was used.
The molecular weight was calculated as 267 x 330 = 88110.
This was related to Avogadro’s number 6.023x1023 molecules/mole
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So 1 gram of mimic contains 6.023xl023 molecules/88110 molecular weight
i.e. 6.84x1018 molecules
4- Next a plot of 1/number of molecules on the x-axis (the reciprocal was used for 
ease of presentation on the x-axis) against sample to competitor ratio on the y-axis. 
This in turn produced values for the equation y = mx+c.
When y = 1
i.e. the required equal sample concentration or equivalence point, then the value x 
could be calculated (see figure 2.9).
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Chapter 3
Hormone sensitive lipase activity and gene expression
method development
77
3.1. Introduction
This chapter describes the development of two assays, one to measure HSL activity 
and the other, gene expression of HSL in human adipose tissue using a competitive 
reverse-transcription polymerase chain reaction (RT-PCR) technique.
Historically, HSL was identified before LPL due to its greater responsiveness to 
hormones. However, investigation of HSL was limited by the lack of suitable 
methodology (Frayn et al, 1993). The HSL activity method was adapted from an 
existing method (Frayn et al, 1993) that used human adipose tissue samples of 
approximately 100 mg in weight. This method was scaled down for use with adipose 
tissue biopsy samples of approximately 10 mg. It is based on the use of a specific 
monoacylmonoalkylglycerol (MOME) substrate (Tomqvist et a l, 1978).
In addition, this chapter describes the method developed for the measurment of HSL- 
mRNA using a competitive RT-PCR technique which provides a reliable and 
accurate method for measuring the mRNA levels in adipose tissue samples. The 
principle of the method is an initial reverse transcription, which converts the RNA to 
DNA, and this is followed by PCR on the DNA formed. Quantitation is achieved by 
use of a known amount of competitor of a similar size to the HSL primers used. The 
resulting strengths of the signals are compared and the amount of mRNA for HSL is 
determined.
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3.2. Materials and Methods
All general chemicals were supplied by Fisons, Loughborough, UK or BDH, Poole, 
UK and were Molecular Biology grade unless otherwise stated.
Materials Supplier.
Radiochemical
Synthesised and supplied by Dr 
H MOME Lennart Krabish,vThomandes Vag 2C
(3H-Monoacylmonoalkylglycerol). Lund SWEDEN.
Chemicals
MOME
(Monoacylmonoalkylglycerol) 
Phospholipid (PC:PI)
Synthesised and supplied by Dr Lennart 
Krabish,vThomandes Vag 2C Lund 
SWEDEN.
Antipain
Leupeptin
Pepstatin
Dithioerythritol
Molecular biolosv grade
Betaine
Formamide
DMSO
Sigma Chemical Company Ltd., Poole, UK. 
Sigma Chemical Company Ltd., Poole, UK. 
Sigma Chemical Company Ltd., Poole, UK. 
Sigma Chemical Company Ltd., Poole, UK.
Sigma Chemical Company Ltd., Poole, UK. 
Sigma Chemical Company Ltd., Poole, UK. 
Sigma Chemical Company Ltd., Poole, UK.
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Sybr-Green dye Gibco BRL (Life Technologies), Paisley, UK.
Primers
TOPO TA Cloning Kit 
Magic miniprep DNA 
Kanamycin 
EcoRI enzyme 
Agarose
1 kb Ladder DNA 
Polaroid black / white 
print film 667 
Polaroid positive and 
Negative Film 665 
Tris
Access RT-PCR system 
Total RNA Isolation system 
Filter Tips
0.5 ml Thermocycler tubes 
Agar
Petri dishes
Yeast
Tryptone
Others
BSA (essential fatty-acid free) 
Polycarbonate ultracentrifuge 
tubes
Thermocycler tube 
Filter tips
Gibco BRL (Life Technologies), Paisley 
UK.
Invitrogen Corporation, CANADA.
Promega Corporation, Madison, USA.
Sigma Chemical Company Ltd., Poole, UK 
Promega Corporation, Madison, USA 
Gibco BRL (Life Technologies), Paisley 
UK.
Promega Corporation, Madison, USA.
Sigma Chemical Company Ltd., Poole, UK.
Sigma Chemical Company Ltd., Poole, UK.
Boehringer Mannheim GmbH, Germany. 
Promega Corporation, Madison, USA. 
Promega Corporation, Madison, USA. 
Promega Corporation, Madison, USA.
Gibco BRL (Life Technologies), Paisley, UK. 
Unipath Ltd., Basingstoke, UK.
Gibco BRL (Life Technologies), Paisley, UK. 
Unipath Ltd., Basingstoke, UK.
Unipath Ltd., Basingstoke, UK.
Sigma Chemical Company Ltd., Poole, UK. 
Beckman Instruments Inc., Fullerton, CA 
USA.
Promega Corporation, Madison, USA. 
Promega Corporation, Madison, USA.
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1 ml Bounce tissue grinder Jencons Scientific Inc., USA
3.2.1. General procedures
3.21.1. SED-Buffer (0.25 M sucrose, 1 mM EDTA, 1 mM 
dithioerythritol)
Sucrose 8.55 g
EDTA 38 mg
dithioerythritol 15.4 mg
Distilled water 100 ml
Adjust the pH to 7.0 with 1 M HC1 and 1 M NaoH.
3.2.1.2. PED-Buffer (20 mM KH2PO4,1 mM EDTA pH 7.0,1 mM 
dithioerythritol)
2 0  mM KH2PO4 0 .6 8  g
1 mM EDTA 95 mg
1 mM. dithioerythritol 38 mg
Distilled water 250 ml
Adjust the pH to 7.0 with 1M HC1 and 1 M NaOH.
3.2.1.3. 0.02% (w/v) PED-BSA buffer
PED-buffer 100 ml
BSA (essential 2 0 mg
fatty-acid free)
3.2.1.4. Luria -Bertani (LB) medium
Tryptone
Yeast
10 g 
10 g
Made up to 1 litre with reverse osmosis (RO) water and autoclaved. Store at room 
temperature until use.
3.2.1.5. Kanamycin antibiotic stock
Kanamycin powder 
Nuclease free water
10 mg 
1 ml
Dissolve Kanamycin powder in RO water.and sterilise using a 0.2 pm filter. Store 
aliquots at -20°C.
3.2.1.6. LB-medium with antibiotic
A 500 ml bottle of sterile LB-medium was opened in a flow cabinet, and 2.5 ml of 
kanamycin antibiotic stock (10 mg/ml) was added. This provided a working 
antibiotic concentration of 50 pg/ml. The solution may be stored for up to 1 month at 
4°C in the dark.
3.2.1.7. Tris acetate (TAE) buffer
Tris
0.5 MEDTA, pH 8.0 
Glacial acetic acid
48.4 g 
2 0  ml 
11.42 ml
Made up to 10 litres with RO water, adjust to pH 8.3
3.2.1.8. Sybr green agarose gel preparation
Agarose 
TAE buffer
3 g
100  ml
Sybr-green dye 25 pi
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3.2.1.9. TOPO TA cloning kit contents
TOPO TA cloninz vector 
Kanamycin and ampicillin resistant
SOC medium (supplied with the kit)
Tryptone 2  % (w/v) Yeast extract 0.5 % (w/v)
NaCl 10 mM KC1 2.5 mM
MgCl2 10 mM MgS04 10 mM
Glucose 20 mM
6 X  TOPO clonim stop solution (supplied with the kit)
NaCl 0.3 M
MgCl2 0.06 M
Shot cell
This is a competent cell which is an E coli strain.
3.3. Methods
3.3.1. HSL activity assay
HSL activity was measured by a modification of the method described by (Frayn et 
al, 1993). The method used a labelled 3H-Monoacylmonoalkylglycerol substrate 
(3H-MOME) and frozen human adipose tissue that had been stored at -80°C.
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3.3.L1. Enzyme preparation
Frozen human adipose tissue biopsy specimens (10 mg) were immediately 
transferred to a 1 ml glass homogenizer and homogenised for 2 min at 4°C in 800 pi 
SED buffer (0.25 M sucrose,! mM EDTA, 1 mM dithioerythritol) containing the 
protease inhibitors 2  pi leupeptin (20  pg/ml), 2  pi antipain (20  pg/ml) and 10 pi 
pepstatin, (1 pg/ml). The homogenate was transferred to a polycarbonate 
ultracentrifuge tube and centrifuged at 100 000g for 45 minutes at 4°C in a Beckman 
TL-100 Ultracentrifuge. The fat layer was removed as completely as possible from 
the samples using a plastic loop, and the infranatant was transferred in 100  pi 
aliquots into microcentrifuge tubes and stored at -80°C.
3.3.I.2. Preparation of MOME substrate emulsion
3H-labelled MOME (75 pi), MOME (120 pi) at unspecific concentration supplied by 
Dr Lennart Krabish (Tomqvist et a l, 1978), and (30 pi) from (20mg/ml) 
phospholipid (Tomqvist et al., 1975) were placed in a 4 ml sonication vial and placed 
under a stream of nitrogen in the dark for 20 minutes. One ml of 0.1 M potassium 
phosphate buffer (pH 7) was added at room temperature. The emulsion was sonicated 
using a Soniprep 150 ultrasonic disintegrator (MSE Scientific Instruments) at 
amplitude setting 2 , with the tip of the probe just under the surface of the mixture for 
20 second until all the substrate was in suspension. The mixture was then re­
sonicated with the tip halfway immersed 4 times, each for 30 seconds, energy output 
on 2. Then 1.6 ml of 0.1 M potassium phosphate buffer (pH 7) was added, and the 
emulsion was sonicated with the probe tip 1 cm under the surface for 4 times for 30 
seconds. Phosphate buffer (400 pi) containing 20% (w/v) BSA (essential fatty-acid 
free; pH 7) was added, the emulsion was vortex mixed and stored at -20°C for up to 5 
weeks.
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3.3.1.3. HSL assay protocol
The setting up procedure was carried out on ice as the enzyme activity declines 
rapidly at room temperature.
One hundred microlitres of 0.02% (w/v) PED-BSA buffer was added to the blank 
tubes and 50 pi to the sample tubes. A 50 pi aliquot of the enzyme preparation was 
added to each sample tube. A 100 pi of the 3H-MOME substrates emulsion was 
added to all the tubes and mixed using a vortex mixer. The enzymatic reaction was 
started by incubating the tubes at 37°C, in a shaking water bath, for 30 minutes. At 
the end of this period the tubes were placed back on ice and 3.25 ml of organic 
solvent (chloroform, heptane and methanol in the ratio 1.25: 1: 1.41 by volume) 
followed by 1.05 ml of 0.1 M K2CO3 (adjusted to pH 10.5 with saturated boric acid) 
were added to all tubes to stop the reaction and to extract the free fatty acids into the 
upper methanolic phase. The tubes were vigorously vortex mixed to aid extraction of 
the fatty acids and centrifuged at 1700 g for 20 minutes in a Beckman J6  centrifuge. 
Part of the aqueous layer (500 pi) was removed and added to a scintillation vial 
containing 4 ml Optiphase safe and 75 pi glacial acetic acid. A test standard was run 
next to the samples in three of the scintillation vials containing 25 pi of 3H-MOME 
substrate added to 500 pi of the aqueous layer from each one of the blanks. The 
glacial acetic acid acts as a neutralising agent which reduces chemiluminescent light 
intensity. The vials were inverted several times and left for a minimum of 1 hour in 
the dark before being counted for radioactivity on a Wallac 1410 beta counter. Each 
tube was counted for 5 minutes using a preset programme.
The results from the blank incubations were subtracted from the sample values and 
the enzyme activity was calculated using the following equation: -
1 1
A= (Dpm-Blank) x X X 3 X 4 . 9 X
t specific radioactivity of MOME 0.76
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Where;
t = incubation time in minutes
Specific radioactivity of MOME
= 3.3 X 109Dpm/micromole
3 = 3 fatty acids liberated for each 
triacylglycerol hydrolysed
4.9 = dilution factor (0.5 ml taken from 2.45 ml 
aqueous methanolic phase)
0.76 = partition coefficient for oleate into the 
aqueous methanolic phase
mg tissue
total jil of tissue homogenate ^  ^  homogenate used
The activity = B X 1000 X 1000 nmol oleate released per minute per g at 
37°C.
Or
= - ê — X 1000 X 1000 x 1000 pmol oleate released per minute per g at
37°C.
Where,
mg tissue = the mg of tissue used in the HSL enzyme 
preparation
total pi of tissue homogenate = 800 pi
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jxl homogenate used = 50 (il
1000 = to convert the mg into g
1000 = to convert to nmol oleate released per minute 
at 37°C
1000 = to convert to pmol oleate released per minute 
at 37°C
The results were expressed in nmole of oleate released per minute at 37°C. Some of 
the samples had lower activities and were expressed by pmol of oleate released per 
minute per gram at 37°C.
3.3.1.4. Optimisation of the HSL activity assay
A series of experiments were performed using samples from a single sample of 
human adipose tissue. This was obtained from a young, pre-menopausal, non-obese 
female. After homogenisation, different volumes of homogenate were used to 
optimise the HSL activity assay. In addition, the substrate emulsion was blown down 
using different flow rates of nitrogen. The results shown in figure 3.1 to 3.3 illustrate 
the findings used to determine the optimal conditions which are summarised in (table 
3.1)
The intra-assay CV was 8.2% (n= 8) at 37 pmol oleate released per minute per gram 
at 37°C, and the inter-assay CV was 2.7% (n= 6) for the same activity.
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Table 3.1 HSL activity optimisation condition.
Parameters Range tested Optimum value of 
parameter chosen
Amount of adipose tissue 10 to 100 mg 10 mg
Amount of enzyme 5 to 100 pi 50 pi
homogenate
N2 gas flow * -£q  **** **
There was no flow meter - * indicates no gas blowing, ^-indicates gentle flow, ***- 
indicates a medium flow and ****- indicates strong gas flow.
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Figure 3.1 The relationship between the amount of adipose tissue and the HSL 
activity.
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Figure 3.2 The relationship between the amount of sample homogenate and 
the Dpm obtained.
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Figure 3.3 The relationship between nitrogen flow and the Dpm for the blanks. 
(The symbol * indicates no gas blowing, ^-indicates gentle flow, **^indicates a 
medium flow and ****- indicates strong gas flow )
3.3.1.5. Results
Results of experiments to optimise the assay are given in figures 3.1 to 3.3. Figure 
3.1 shows the enzyme activity using varying amounts of the starting adipose tissue 
(10 to 100 mg) and shows a narrow range of differences in the activity of the enzyme 
per weight of tissue (32.8 ± 3.2 pmol oleate release per min at 37°C). Figure 3.2, 
shows the effect of increasing the volume of enzyme homogenate prepared from 10 
mg of tissue used in the assay. 50 pi enzyme homogenate was chosen for subsequent 
assays. This was chosen as the optimum volume since the extent of reaction had just 
reached the plateau. Beyond this the amount of enzyme would no longer be rate- 
limiting. The rate at which the nitrogen was blown on the MOME in the initial stages 
of the emulsion preparation was found to affect the assay blank. This effect is 
displayed in figure 3.3 and shows that the final Dpm for the blank, which was very 
variable, increased with increasing N2 flow rate. A gentle flow was chosen to give a
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low blank value for subsequent assays, since the results were found to be very 
variable when higher flow rates were used.
HSL activity measurements taken from normal male individuals (n=7) in the fasting 
state were 2.38 ± 0.75 nmol oleate released per minute at 37°C (figure 3.4).
£
SJj
I
- 3
<
Subjects
Figure 3.4 Adipose tissue HSL activity in normal fasted individuals. 
Values are mean +/- SEM.
3.3.1.6. Discussion
The MOME substrate (Tomqvist et al, 1978), which is used for the measurement of 
HSL activity has several advantages for both sensitivity and specificity of the assay. 
The high sensitivity of this assay is partly explained by the fact that diacylglycerol is 
the preferred substrate for HSL and is hydrolysed at least 10 times more rapidly than 
TAG (Fredrikson and Belfrage, 1983). In addition, specificity is conferred by the fact 
that MOME is not a substrate for monoacylglycerol lipase, another intracellular
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lipase, and that under the assay conditions (pH 7.0, without apo Oil) no LPL activity 
is measured (Plee-Gautier et <3/.,1996; Reynisdottir et al., 1997a).
The high values for the blank Dpm with increasing N2 flow indicates changes in the 
composition of the lipid droplets as no active enzymes were present at this stage. 
Since the assay measures the release of oleate, either this compound or another 
tritiated breakdown product must have been formed from TAG when the N2 flow 
was increased. Further study of the cause of this effect was not thought to be needed 
for this thesis.
The HSL activity assay represents the total potential HSL activity. The substrate does 
not discriminate between phosphoiylated and dephosphorylated HSL, therefore, 
measuring HSL activity with this substrate may be considered as a mass 
determination assay for enzymatically active HSL (Frayn et al, 1993). The results of 
previous studies on HSL activity are shown in (table 3.2). Although their units are 
not comparable to each other or to my units there are major discrepancies between 
these earlier studies (Large et a l, 1997 & 1999; Reynisdottir et a l, 1997) and those 
reported in this thesis. The previous workers did not report differences between the 
adipose tissue HSL activity of males and females. Reynisdottir et al. (1997) did find 
a 2-fold difference between adipose tissue taken from different sites, i.e. omental and 
subcutaneous adipose tissue. Large et al. (1997 & 1999) did find 8-fold differences 
between their low lipolytic rate subjects and their non-obese group. However, the 
results in this thesis show a ~50-fold difference between males and females in 
adipose tissue HSL activity. There were important differences between my two 
studies; the male subjects were older (53 - 61 years) than the pre-menopausal females 
(33 -  38 years), and the adipose tissue was obtained from the gluteal fat depot of 
males but abdominal subcutaneous samples were collected from females. In view of 
the published work these differences are unlikely to account for a 50-fold difference 
between the sexes. Another difference was that the samples from males were 
collected using a local anaesthetic whilst general anaesthesia was used with the 
females. However, Large et al. (1997), compared the effect of these two types of 
anaesthesia on lipolysis in vitro did not find a significant
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Table 3.2 Previous studies along with the present study showing the HSL 
activity in human adipose tissue using MOME as a substrate emulsion.
Author Subjects Amount of 
adipose tissue 
used
HSL activity 
mean value 
+/- SEM
Unit used
The present
study
(using
optimised
conditions)
Pre-
menopausal,
females
non-obese
(n=T0)
10 mg 47.0 +/-12.5 pmol oleate 
released per 
minute per 
gram of tissue 
at 37°C
The present 
study
(from figure 
4.3)
Males, aged 53 
to 61 years 
(n=7)
10 mg 2.38 +/- 0.75 nmol oleate 
released per 
minute per 
gram of tissue 
at 37°C
Large et al. 
(1999)
Male or female
non-obese
(n=14)
300 mg 10.1+/-2.6 mU*/mg total 
protein
Large et al. 
(1999)
Male or female
Obese
(n=34)
300 mg 5.8 +/- 0.7 mU*/mg total 
protein
Large et al. 
(1997)
Low lipolytic 
rate subjects 
males and 
females 
(n=8)
300 mg 1.26 +/-0.22 mU*/mg total 
protein
Large et al. 
(1997)
High lipolytic 
rate subjects 
males and 
females 
(n=8)
300 mg 2.35 +/-0.42 mU*/mg total 
protein
Reynisdottir 
et al. (1997)
Males (n=9), 
females (n=12) 
Omental 
adipose tissue
100 mg 14.4 +/- 3.5 mU*/10' cells
Reynisdottir 
et al. (1997)
Males (n=9), 
females (n=12) 
subcutaneous 
adipose tissue
100 mg 27.5+/-4.2 mU*/10z cells
*One unit of enzyme activity (U) is defined as 1 pmol of oleic acid released per
min at 37°C.
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difference between them. The most important difference was that the studies on 
female HSL activity used the optimised conditions established in this chapter using a 
large sample of adipose tissue from a young female. These conditions were also 
used for the HSL activity measurements for the male subjects. Since their activity 
was much greater, in these assays the values would have been on the plateau of 
figure 3.2, this means that enzyme activity was no longer rate limiting in the assay 
and comparisons are not valid. However, this suggests that the activity of the males 
was even greater than reported here. Unfortunately there was insufficient sample to 
repeat the HSL activity measurements.
3.3.I.7. Conclusion
There are several advantages of the present method for the determination of HSL 
activity compared to existing methods. The main one is that it allows the 
measurement of HSL activity in only 10 mg of subcutaneous human adipose tissue. 
This amount can be obtained by biopsy of normal individuals with minimal 
discomfort. It also makes it possible to perform multiple biopsies that are needed to 
assess the regulation of HSL activity in dietary and metabolic studies. However, the 
optimised conditions for HSL activity need to be re-checked.
3.3.2. Competitive RT-PCR method development for the analysis of 
HSL gene expression
The levels of gene transcription within a cell change in response to a wide variety of 
pathological states. These changes in transcriptional levels in turn cause variations in 
the steady-state levels of individual mRNAs. Thus analysis of selected mKNA levels 
could provide vital information on the regulation of the expression of corresponding 
genes. Therefore a specific quantitative technique for the measurement of HSL- 
mRNA, was developed using the same multi-specific internal standard that was used 
for the LPL gene expression and the housekeeping gene (Vmicroglobulin (Laville et
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al, 1996). Using the primers described by Laville et a l, 1996 (as shown in the table 
3.3) resulted in a non-specific band of product of 300 bp in length.
Table 3:3 Properties of Laville’s HSL primers.
Primer Sequence
(5'-3')
Length 
of primer 
(bp)
Expected
size of
target
mRNA
product
(bp)
Expected size of 
mimic 
product 
(bp)
NRiHSL TCT TCT 20 252 306
-sense GCA
GCC
AC
CCA
ACA
NRiHSL AGA TGG 20
-antisense TCT
GGA
GC
GCA
ATG
A series of experiments which consumed six months work, including using different 
settings of annealing temperature, increasing the reverse transcription reaction 
incubation temperature, the use of detergents such as betaine (Daniel et a l, 1996), 
formamide (Sarkar et a l, 1990) and DMSO (Varadaraj & Skinner, 1994), setting a 
hot-start RT-PCR (D'Aquila et al, 1991) and finally using touchdown PCR; (Don et 
al, 1991), were performed to try to increase the specificity of the RT-PCR reaction. 
Unfortunately there was no improvement. However, during the investigation into the 
HSL sequence, using gene bank with accession number (LI 1706), it was observed 
that the primers described by Laville et al (1996) were missing three base-pairs in the 
sense primer as shown in red colour below: -
NRiHSL (Laville’s 1996 ) TCT TCT GCA CCA GCC ACA AC
NR2HSL (from gene bank) TCT TCT TCC GCA CCA GCC ACA AC
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Therefore the primers used to develop this assay described in the following section 
were designed based on the HSL sequence from the gene bank (computer 
programme) with accession number (LI 1706) which were 100% homologous to the 
human HSL genomic DNA.
3.3.2.1. Properties of the primers
The primers were designed firstly, to exactly match the expected c-DNA sequences 
derived from the target mRNAs, this allowed the annealing temperature to be as high 
as possible, thus minimising the possibility of non-specific hybridisation. Secondly, 
the band sizes of both the mimic and target transcripts should be relatively close to 
allow for easy comparison between the intensity of the control and test bands during 
competitive RT-PCR. Finally, the primer is often planned to span an intron to stop 
genomic DNA contamination being amplified. The properties of the primers used in 
this technique are given in table 3.4.
Table 3.4 Properties of the RT-PCR primers used
Primer Sequence
(5'-3')
Location in 
the
gene (bp)
Length
primers
(bp)
of Expected 
size of 
target 
mRNA 
product 
(bp)
Expected 
size of 
mimic 
product 
(bp)
NR2HSL
-sense
TCT TCT 
TCC GCA 
CCA GCC 
ACA AC
929-951 23 252 306
NRiHSL
-antisense
AGA TGG 
TCT GCA 
GGA ATG 
GC
1164-1183 20
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3.3.2.2. RT-PCR optimisation
A series of experiments were done using total RNA which had been extracted from 
human adipose tissue as described in Chapter 2, section (2.2.8.1) which included 
alteration of the primer concentration, MgS0 4  concentration, annealing temperature, 
and cycle number. These established the optimal conditions for the primer and are 
summarised in table 3.5.
3.3.2.3. RT-PCR assay protocol
The RT-PCR assay protocol for HSL and ^-microglobulin were carried out in the 
same way as for LPL and p2-microglobulin as described in Chapter 2, table 2.3.
Table 3.5 Optimisation of RT-PCR conditions for amplification of HSL gene 
using Access RT-PCR system.
Parameters Ranges tested Optimum parameters chosen
HSL
Primer concentration 25-50 pmolar 50 pmolar
MgS04 0.5-2.5 mM 1 mM
Tfl DNA polymerase 0.1 u/pl 0.1 u/pl
AMV-RT 0.1 u/pl 0.1 u/pl
Number of cycles 25-35 28
Annealing temperature (°C) 55-68 65
Denaturing temperature (°C) 94 94
Extension temperature (°C) 65-72 68
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3.3.3. Confirmation of the amplified product
3.3.3.1. Cloning of HSL-cDNA product
The PCR product of the c-DNA generated from the human adipose tissue total RNA 
samples were cloned into the TOPO TA Cloning vector supplied by Invitrogen. This 
cloning provides a rapid (5 minutes) and highly efficient, one step cloning strategy to 
add a single deoxyadenosine (A) to the 3 -end of the PCR product, the TA vector has 
a single, overhanging 3 -deoxythymidine (T) residue. This allows PCR inserts to 
ligate using the activity of the ligase enzyme (Topoisomerase I), which is supplied 
with the kit, as illustrated in figure 3.5. The cloning was carried out as following, 2 
pi of 20 ng/pl of HSL RT-PCR product, 1 pi of the TOPO vector and 2 pi of 
nuclease free water, were mixed gently and incubated for 5 minutes at room 
temperature. Then 1 pi of the 6 X TOPO cloning stop solution was added and mixed 
for 10 seconds at room temperature, the product was kept on ice for the 
transformation step.
3.3.3.2. Transformation reaction
A 2 pi aliquot of the TOPO Cloning reaction was added to a vial of One Shot cells 
(competent cells which are an E.coli strain) that were supplied with the TOPO 
Cloning kit by Invitrogen and mixed gently. The vial was then incubated for 30 
minutes on ice. The mixture was placed in a water bath at 42°C for 30 seconds 
without shaking, and then it was immediately cooled on ice. A 250 pi aliquot of SOC 
medium (supplied with the TOPO kit) was added and the tube was capped tightly 
and shaken horizontally at 37°C for one hour. 50 pi of the mixture was spread on a 
kanamycin agar plate and incubated at 37°C overnight.
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Activated TOPO Cloning
Vector
opoisomerase I
Vector
Amplified PCR product with 3-A  
overhangs
Polvmerase 
amplUied 
PCR-product
H H H I
Topoisomerase I
5 minutes at room
temperature
Ligation complete readyVector
Vector
Figure 3.5: Protocol for using TOPO TA Cloning Vector
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3.3.3.3. Screening for positive clones and extraction of plasmid DNA
Using a sterile wire loop ten white colonies were sampled and placed in LB medium 
containing 50 pg/ml kanamycin and incubated overnight at 37°C in a shaking 
incubator. A miniprep was carried out using a Magic miniprep kit supplied by 
Promega. The overnight culture (1.5 ml) was microcentrifuged for 1 minutes to pellet 
the cells and the supernatant was decanted. Next, 200 pi of resuspension solution 
which was supplied with the kit, was added to the cells and vortexed briefly. Cell 
lysis solution (200 pi), supplied with kit, was added and the sample mixed by 
inverting the tube until the mixture cleared. Following this the suspension was 
neutralized by addition of 200 pi of neutralization solution, which was supplied with 
the kit, and mixed by inverting the tube several times. The mixture was centrifuged 
for 5 minutes, and the supernatant was transferred to a clean tube and mixed with 1.0 
ml of DNA purification resin by inverting the tube. The resin / DNA mixture was 
pipetted into a syringe barrel, vacuum was applied to the syringe barrel to pull the 
resin / DNA into a minicolumn. Then the vacuum was broken and 2 ml of column 
wash solution was added to the syringe barrel and the vacuum was reapplied to draw 
the solution through the minicolumn. The resin was then dried by continuing to draw 
a vacuum for an additional 30 seconds. The syringe barrel was removed and the 
minicolumn was transferred to a 1.5 ml microfuge tube and centrifuged for 2 minutes 
in order to remove any residual column wash solution. The minicolumn was then 
transferred to a new microcentrifuge tube and 50 pi of nuclease free water applied 
for 1 minute to elute the DNA which was precipitated by centrifugation for 20 
seconds. Finally the plasmid DNA was ready for the next step, confirmation that the 
clone contained the insert was made by restriction mapping using EcoRI enzyme (as 
shown in figure 3.6 a, b) and by sequencing (as shown in figure 3.7 a 1 & 2; b). This 
confirmed that the amplified product was specific to the HSL-mRNA.
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3.3.3 4. Automated sequencing
Mr. Steven Dyer, (Molecular Microbiology Group, School of Biological Sciences) 
carried out the sequencing of the PCR product by employing the dye termination 
cycle sequencing procedure.
A minimum of 800 ng of purified PCR product was required. Cycle sequencing was 
carried out on two separate samples of the DNA, one containing the sense and the 
other the anti-sense primer. The sequences were identical to those employed for the 
PCR reactions.
3.3.3.5. Amplification and competition
Competitive RT-PCR was carried out using the HSL-primers described in section
3.3.2.1. A series of competitive RT-PCR reactions were set up using 2-fold dilutions 
of PCR mimic (ranging form 50 to 0.78 pg) with a constant amount of total RNA 
extracted from human adipose tissue. The amplified products were then resolved by 
agarose gel electrophoresis and visualised with sybr green dye. An example of the 
results of the competitive RT-PCR for the quantitation of HSL is shown in figure 3.8.
3.3.3.6. Quantitation of RT-PCR product yields
The relative intensities of the bands corresponding to the target and mimic PCR 
products were quantitated in the same way as for LPL and f^-microglobulin. See 
LPL calculation in chapter 2 (section 2.2.8.5 and 2.2.8.6) for explanation. The 
nucleotide ratio of HSL-mRNA target: HSL-mRNA mimic was calculated as 
follows:
HSL = 252 bp : 306 bp = 0.82.
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The concentration of the target c-DNA was calculated and expressed as the number 
of molecules of HSL-mRNA per number of molecules of p2 -microglobulin-mRNA.
The intra-assay coefficient of variation CV was 6.2% at 9.2 X 104 molecules of HSL- 
mRNA per ng of total RNA.
&oRI(284)
HSL
&oRI(557
TOPO/HSL
4163 bp
Kanamycin
Figure 3.6 (a):
Plasmid diagram of the c-DNA clone containing the HSL gene.
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3890 bo
273 bp
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Figure 3.6 (b):
The restriction digest of (a) confirming the integrity of this clone which was 
used for PCR optimisation using the HSL primers. Lane 1: Molecular size 
m arker (1 kb ladder). Lane 2 & 3: Restriction digest of TOPO/HSL vector 
confirming that the HSL gene was cloned in the vector. 3890 bp indicates the 
TOPO/HSL vector following digestion by EcoRI and 273 bp indicates the HSL 
insert gene and the region just outside it contain the EcoRI restriction digest 
sites.
Lane 4: Molecular size marker (A Hind III).
Lane 5: Molecular size marker (<j)A7 74).
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3AlGG1CT'aC^GA(TGGCC^AlGGCAGG^IGAACTGG^G0CCAGGC^CGGCCAT^AGCATCCC^ATGCAGCG^4CA1ACT^
f
C C G G G f  A ACCAGC t G G C G C T G G G M T  ANT AA ACpGGAGGfAG^CGGCGGTGAgpCCC1CG1C^pCCIC;*AN^fNANT,CCt%pGGCCGA
( .f  (-n
yAAACGCGG^GTGGGTT(^GGCAACGA^TnGGCCT^CAGCTCGG^AGGTT1Gl^GCTGGTGCC^AAAAAAAA^IIGGCGAAT^
Figure 3.7 (a)
A region of the amplified HSL-cDNA was sequenced using the protocol for 
the AB I  model 373A automated sequencer. Cycle sequencing was achieved 
using (1) sense and (2) antisense primers used in the PCR.
# — ► Indicates the beginning o f the prim ers.
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 1>
TCTTCT TCCGCACCAG CCACAACCTG GCCGAGCTGG AGGCCTACCT GGCTGCCCTC ACCCAGCTCC 
AGAAGA AGGCGTGGTC GGTGTTGGAC CGGCTCGACC TCCGGATGGA CCGACGGGAG TGGGTCGAGG
GCGCTCTGGT CTACTACGCC CAGCGCCTGC TGGTTACCAA TCGGCCGGGG GTACTCTTCT TTGAGG 
CGCGAGACCA GATGATGCGG GTCGCGGACG ACCAATGGTT AGCCGGCCCC CATGAGAAGA AACTCC
GCGA CGAGGGGCTC ACCGCCGACT TCCTCCGGGA GTATGTCACG CTGCATAAGG GATGCTTCTATG 
CGCT GCTCCCCGAG TGGCGGCTGA AGGAGGCCCT CAT AC AGTGC GACGTATTCC CT ACG AAG AT AC
GCCGCTGC CTGGGCTTCC AGTTCAGCCC TGCCATCCGG CCATTCCTGC AGACCATCT
CGGCGACG GACCCGAAGG TCAAGTCGGG ACGGT AGGCC GGTAAGGACG TCTGGTAGA
----------------------------------
1165
Figure 3.6 (b)
The region of human HSL gene (position 930 to 1165) confirmed by sequencing. 
Red color sequences indicate the primer sequence (sense and antisense), whereas 
the black sequences were confirmed by the sequencing data generated from the 
digest of TOPO/HSL vector (see figure 3.5a & b).
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Figure 3.8 An example of the results of a competitive RT-PCR reaction using 
the HSL primers. The photograph shows a 2-fold serial dilution of competitor 
RNA. Lanes 3-9 contain 2-fold serial dilutions of the HSL competitor ranging 
from 100 to 0.78 pg. Lane 2 & 11 contain the negative control. Lanes 1 & 12 
contain 1Kb DNA ladder marker. The approximate equivalence point is at 3.13 
pg in lane 8. The 306 bp on the right hand side indicates the position of the 
competitor and the target PCR fragments are at 252 bp.
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Chapter 4
Changes in lipoprotein lipase and hormone sensitive lipase 
in subjects with type 2-diabetes mellitus
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4.1. Introduction
Abnormalities in lipid and lipoprotein metabolism contribute to the increased risk of 
CHD observed in patients with type 2-DM. Diabetes mellitus is a group of metabolic 
diseases characterised by hyperglycaemia due to absolute or relative lack of insulin 
and/or insulin resistance leading to long-term complications.
The major effects of insulin on adipose tissue are, as in other tissues, anabolic: 
stimulation of glucose uptake and lipogenesis, suppression of fat mobilization, and 
increased activity of LPL, the enzyme responsible for hydrolysis of TAG to fatty 
acids for uptake by the tissue. The stimulation of glucose uptake, via the glucose 
transporter GLUT4, and the stimulation of lipogenesis, mainly via activation of 
acetyl-CoA carboxylase, are well documented effects of insulin in adipocytes in 
vitro, but their role in vivo is not clear (Frayn & Coppack, 1992).
The regulation of the HSL and LPL during feeding and fasting is important for the 
maintenance of appropriate levels of plasma TAG and NEFA.
This chapter examines the physiology and pathophysiology of both HSL and LPL, 
and some factors, including insulin, which are involved in the acute regulation of 
these enzymes, by modifying their activity and gene expression.
4.2. Aim of the study
The specific aim was to investigate the regulation of LPL and HSL in human adipose 
tissue in response to a fat-containing meal in type 2-DM and control individuals. 
This work compared the activity and gene expression for the two lipases in the 
fasting and fed states.
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4.3. Methods
4.3.1. Subject recruitment
Eight male subjects with type 2-DM aged between 55 to 63 years, with a BMI range 
of 23.0 to 32.6 kg/m2 were recruited using the GP register at 3 local GP clinics in 
Guildford. These subjects were compared with matched control male subjects aged 
53 to 61 years, with a BMI range of 22.5-29.7 kg/m2 who were recruited from the 
University of Surrey, Guildford. None of the control subjects had a family history of 
diabetes, in addition, none of them suffered from diagnosed cardiac, hepatic or renal 
problems. The control subjects were not taking any medication affecting their 
glucose or lipid control and none of the type 2-DM subjects were taking insulin. All 
the subjects maintained their normal diet whilst participating in the study and were 
asked not to undertake any form of heavy exercise during the day prior to the study. 
Written consent was given by each of the subjects after being informed of the 
purpose, risks and nature of the study. The study was approved by the South West 
Local Research Ethics Committee and University of Surrey Committee (see table 4.1 
for the study protocol).
4.3.2. Handling the samples
4.3.2.1. Blood samples
Blood samples were collected first (as described in section 2.2.1) and then adipose 
tissue biopsies were taken from the upper gluteal region from each subject (as 
described in section 2.2.7). Biopsies were taken after an over-night fasting and 4 
hours after the consumption of a high fat mixed meal on two separate occasions.
Plasma samples were analysed using automated enzymatic assays on the Cobas Mira 
Plus analyser, for glucose, TAG, NEFA, cholesterol and HDL as described in section
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2.2.6. Plasma insulin was measured as described in section 2.2.3 using the radio- 
immuno assay, as was GIF as detailed in section 2.2.5.
Table 4.1 The study protocol
Day 1 Day 2 Day 3
□ Approximately 100 
mg of subcutaneous 
adipose tissue obtained 
at fasting state.
□ Subjects were 
cannulated.
□ Blood samples were 
collected for TAG and 
glucose test at fasting 
state.
□ Consumption of the 
test meal which 
contained about 40 g 
of fat in 20 minutes.
□ After 4 hours (750 
units) of heparin were 
given intravenously.
□ 5 minutes PHL A blood 
samples were 
collected.
□ 15 minutes PHL A 
blood sample were 
collected.
□ Subjects were 
cannulated in the 
fasting state.
□ Blood sample were 
collected in the fasting 
state.
□ Consumption of the 
test meal which 
contains about 40 g of 
fat in 20 minutes.
□ Approximately 100 
mg of subcutaneous 
adipose tissue obtained 
4 hours into the post­
prandial state.
□ Blood sample were 
collected post- 
prandially at 1-2-3-4 
hourly intervals.
□ Subjects were 
cannulated in the 
fasting state.
□ Heparin (750 units) 
were given 
intravenously.
□ 5 minutes PHLA blood 
samples were 
collected.
□ 15 minutes PHLA 
blood samples were 
collected.
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4.3.2.2. Adipose tissue samples
Total RNA was extracted from the adipose tissue biopsies as detailed in section
2.2.7.1, and analysed for LPL-mRNA, fc-microglobulin-mRNA and HSL-mRNA by 
competitive RT-PCR as described in sections 2.2.8.4 and 3.2.2.4 respectively. 
Adipose tissue LPL activity was measured using the radioactive triolein technique 
detailed in section 2.2.1.6. In addition, adipose tissue HSL activity was measured 
using the radioactive MOME technique described in section 3.2.1.3.
4.3.3. Test meal
In the current study a comparison was made between the fasting and fed state after 
consumption of mixed meal containing about 40 g fat. The composition of the meal, 
which was eaten in 20 minutes, is shown in table 4.2.
4.4. Statistical analysis
Statistical analysis was performed on the data to compare and determine any 
significant differences between the fasting and post-prandial state and any 
differences in levels between the type 2-DM and the matched controls. Mean, SD 
and SEM were calculated for each measurement. Statistical analysis was carried out 
using Microsoft Excel ™ ; SPSS version 9 and one way repeated-measures ANOVA. 
Comparisons between levels in the fed and fasted state in individuals were analysed 
using a paired Student's t-test. In addition, an unpaired Student's t-test was used to 
compare differences between the two groups. Values of p < 0.05 were taken as the 
lowest level of significance.
I l l
Table 4.2 Nutritional composition of the test meal
Food Quantity 
(g or ml)
Energy 
k j  (kcal)
Fat
(g)
Protein
(g)
CH O*
(g)
Cornflakes 40 614 (147) 0.3 3.2 3.7
Milk 220 605 (145) 8.6 7 11
Croissant 80 1204 (288) 16.2 6.6 2.1
Butter 20 606(145) 16.3 0.1 0
Jam 20 223 (53) 0 0.1 13.8
Orange juice 200 306 (73) 0.2 1.0 17.8
Total 3558(850) 41.6 18.0 48.4
* carbohydrate
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4.5. Results
4.5.1. Plasma glucose
The plasma glucose concentrations are shown in figure 4.1. One way repeated- 
measures ANOVA showed significant differences between the two groups of 
subjects over all the time points (P = 0.001) for the plasma glucose response to the 
test meal.
Type 2-DM 
Controls
Glucose
concentration 10 y 
(mmol/'l)
o 4 ------------------ -------------------------------------
0  1 2  3  4
Time (hrs)
Figure 4.1 Plasma glucose concentrations in type 2-DM (n—8)and control 
subjects in response to the test meal (n=8). Values are mean +/- sem.
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4.5.2. Plasma TAG
Fasting and post-prandial plasma TAG concentrations in the two groups are shown in 
figure 4.2. One way repeated-measures ANOVA showed no significant differences 
between the two groups of subjects over all the time points (P = 0.44) for the plasma 
TAG response to the test meal.
Type 2-DM 
Controls
2.5
TAG
concentration 2 
(mmol/1)
1 4 ------
0 1 2  3 4
Time (hrs)
Figure 4.2 Plasma TAG concentrations in type 2-DM (n=8) and control subjects 
in response to the test meal (n=8). Values are mean +/- sem.
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4.5.3. Plasma NEFA
Fasting and post-prandial plasma NEFA concentrations in the two groups are shown 
in figure 4.3. The NEFA concentration decreased rapidly for both groups and 
remained low until the end of the study. One way repeated-measures ANOVA 
showed no significant differences between the two groups of subjects over all the 
time points (P = 0.73) for plasma NEFA response to the test meal.
0.7 y
0.6
0.5 T
NEFA
concentration
(mmol/1)
0.4
0.3
0.2
43210
Time (hrs)
Figure 4.3 Plasma NEFA concentrations in type 2-DIM (n-8) and control 
subjects in response to the test meal (n=8). Values are mean +/- sem.
4.5.4. Plasma total cholesterol
Fasting and post-prandial plasma total cholesterol concentrations in the two groups 
are shown in figure 4.4. The concentration of cholesterol remained almost constant 
throughout the study period and although the values for the type 2-DM appeared to 
be less than those for the controls there was no significant difference between the 
two groups of subjects over all the time points (P = 0.26) to the test meal when 
analysed using one way repeated-measures ANOVA
6 Type 2-DM
Coilrols
C holesterol
concentration
(mmol/1)
4
0 1 2  3 4
Time (hrs)
Figure 4.4 Plasma total cholesterol concentrations in type 2-DM (n=8) and 
control subjects in response to the test meal (n=8). Values are mean +/- sem.
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4.5.5. Plasma HDL-choIesteroI
Fasting plasma HDL-cholesterol concentrations in the two groups are shown in 
figure 4.5. There was no significant difference between the type 2-DM and control
subjects.
Type 2 DM Catrols
Figure 4.5 Fasting plasma HDL-Cholesterol concentrations in type 2-DM (n=8) 
and control subjects (n=8). Values are mean +/- sem.
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4.5.6. Plasma LDL-cholesterol
Fasting plasma LDL-cholesterol concentrations in the two groups are shown in figure 
4.6. There was no significant difference between the type 2-DM and control subjects.
6  -i
1
CZ)
jU
o
_co 5 4
D.
50c
t/2
CO
Type 2 DM Controls
Figure 4.6 Fasting plasma LDL-Cholesterol concentrations (mmol/1) in type 2- 
DM (n=8) and control subjects (n=8). Values are mean +/- sem.
4.5.7. Plasma insulin
Fasting and post-prandial plasma insulin concentrations in the two groups are shown 
in figure 4.7. One way repeated-measures ANOVA showed no significant 
differences between the two groups of subjects over all the time points (P = 0.7) tor 
plasma insulin in response to the test meal.
Insulin 
concentration 
(p mol/1)
450
300
150
0
2
Time (hrs)
Figure 4.7 Plasma insulin concentrations in type 2-DM (n—8) and control 
subjects (n=8) in response to the test meal. Values are mean +/- sem.
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4.5.8. Plasma GIF
Fasting and post-prandial plasma GIF concentrations in the two groups are shown in 
figure 4.8. One way repeated-measures ANOVA showed that the type 2-DM had a 
significantly decreased plasma GIF response (P= 0.0002) to the test meal.
400 Type 2-DM 
Gcntrds
300
200
Plasma
GIF
(pmol/1)
100
0 2 3 4
Time (hours)
Figure 4.8 Plasma GIP concentrations (pmol/1) in type 2-DM (n=8) and control 
subjects (n=8) in response to the test meal. Values are mean +/- sem.
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4.5.9. Plasma postheparin LPL activity
The postheparin LPL activities (PHLA) in each group are shown in table 4.3. Mean 
LPL activities were significantly higher in control subjects compared with the type 2- 
DM in both the fasting state (P< 0.0001), and in the post-prandial state at 4 hours 
(P< 0.001). There was also a significant post-prandial rise in PHLA in the type 2- 
DM subjects (P < 0.05) but no significant rise in the control subjects.
Table 4.3 Postheparin plasma LPL activity (pmol oleate released per minute at 
ST^.ml'1) in the fasting and post prandial states in control and type 2-DM 
subjects.
Control subjects Type 2-DM
(n=8) (n-8)
Fasting Post-prandial Fasting Post-prandial
(Mean +/- SEM) (Mean +/- SEM)
5 minute 64 +/- 7.9 * 56+/-8.1 (p 10+/-1.5 14.2+/-1.5Î
postheparin LPL
activity
15 minute 71+/-7.4* 57+/-7.4 tp 16+/-1.7 19.6 +/- 2.3f
postheparin LPL
activity
Symbol * indicates that the control subjects had significantly higher levels than the 
type 2-DM subjects (P<0.0001), (p indicates that in the postprandial state the control 
subjects had significantly higher levels than the type 2-DM (P<0.00J), and finally f  
indicates that the values in the postprandial state were significantly higher than in 
the fasting state for the type 2-DM subjects (P<0.05).
121
4.5.10. Adipose tissue LPL activity
Adipose tissue LPL activity results in the control and type 2-DM subjects are shown 
in table 4.4. The fasting values were significantly lower than the post-prandial values 
in type 2-DM subjects (P<0.05), and in control subjects (P<0.01). In addition, 
control subjects showed higher values than type 2-DM in both the fasting and fed 
states (P<0.01).
Table 4.4 Adipose tissue LPL activity measurements in type 2-DM and control 
subjects.
Adipose tissue LPL activity (nmol oleate released, min^.g'1)
Fasting state Postprandial state
Mean SEM Mean SEM
Control subjects (n=8) 42.7 f  * 3.0 69.8 f 7.2
Type 2-DM subjects (n=8) 26.8 * 3.1 35.3 4.1
Values are mean +/- sem. Columns with the symbol (*) indicate that the fasting 
values were significantly lower than postprandial values, (f) indicates where values 
from control subjects were significantly higher than type 2-DM subjects.
4.5.11. Adipose tissue HSL activity
Adipose tissue HSL activity levels (nmol oleate release per min per gram at 37°C), in 
both control and type 2-DM subjects are shown in table 4.5. There were no 
significant differences between the control and type 2-DM subjects nor between the 
fasting and post-prandial state.
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Table 4.5 Adipose tissue HSL activity in type 2-DM and control subjects.
Fasting
nmol oleate released per min per 
gram at 37°C
Post-prandial
nmol oleate released per min per 
gram at 37°C
Mean SEM Mean SEM
(n=8) (n=8)
Control
subjects
2.4 0.75 1.6 0.37
Type 2-
DM
subjects
1.0 0.32 0.87 0.15
4.5.12. A comparison between adipose tissue LPL & HSL activities
A comparison betweén LPL and HSL activités showed no significant correlation.
4.5.13. Total RNA concentration
The concentrations of the total RNA in the extracts from adipose tissue were 
measured prior to using samples for the analysis for the various mRNAs. In addition, 
for each individual the purity of the RNA in the extract was checked, see tables 4.6.1, 
4.6.2,4.6.3 and 4.6.4.
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Table 4.6.1 Total RNA concentration measurements in diabetic subjects after
their overnight fast.
Diabetic subjects 
(fasting state)
Total RNA
concentration
(ng/ml)
Absorbance at 
260 run
Ratio of 
absorbance at 
260:280 ran
Subject 1 41.0 1.01 2.0
Subject 2 65 1.6 2.2
Subject 3 61 1.5 1.9
Subject 4 62 1.5 1.7
Subject 5 140 2.5 2.1
Subject 6 54 1.3 2.2
Subject 7 18 0.45 1.7
Subject 8 47 1.2 2.5
Table 4.6.2 Total RNA concentration measurements in diabetic subjects in the 
post prandial state.
Diabetic subjects 
(fed state)
Total RNA
concentration
(ng/ml)
Absorbance at 
260 nm
Ratio of 
absorbance at 
260:280 nm
Subject 1 51 1.3 2.2
Subject 2 30 0.75 2.0
Subject 3 19 0.5 1.9
Subject 4 14 0.4 2.0
Subject 5 91 2.3 2.2
Subject 6 39 0.98 1.9
Subject 7 38 0.96 1.8
Subject 8 23 0.6 2.0
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Table 4.6.3 Total RNA concentration measurements in control subjects after
their overnight fast.
Control subjects 
(fasting state)
Total RNA
concentration
(ng/ml)
Absorbance at 
260 nm
Ratio of 
absorbance at 
260:280 nm
Subject 1 103 2.6 2.4
Subject 2 108 2.7 2.4
Subject 3 53 1.3 1.7
Subject 4 91 2.3 2.4
Subject 5 53 1.3 1.9
Subject 6 86 2.2 2.1
Subject 7 41 1.0 1.7
Subject 8 120 >3.00 1.8
Table 4.6.4 Total RNA concentration measurements in control subjects in the 
post prandial state.
Control subjects 
(fed state)
Total RNA
concentration
(ng/ml)
Absorbance at 
260 nm
Ratio of 
absorbance at 
260:280 nm
Subject 1 52 1.3 1.8
Subject 2 110 2.7 1.8
Subject 3 110 2.7 2.4
Subject 4 88 2.2 2.4
Subject 5 96 2.4 2.1
Subject 6 77 1.9 2.3
Subject 7 90 2.2 2.3
Subject 8 120 3.0 2.2
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4.5.14. LPL gene expression (as expressed against P2-microglobulin)
LPL-mRNA levels were expressed as a ratio to Pa-microglobulin-mRNA as shown in 
table 4.7. Type 2-DM subjects showed significantly lower LPL-mRNA levels than 
control subjects in both the fasting (P<0.002) and post-prandial (P c0.002) states. In 
addition, LPL-mRNA levels were significantly lower in the post-prandial compared 
with the fasting state for both diabetic (P<0.03) and control subjects (P<0.03).
Table 4.7 Ratio in adipose tissue of the number of molecules of LPL-mRNA: 
number of molecules of p2-microglobulin-mRNA in the fasting and post­
prandial states in control and type 2-DM subjects.
Fasting Postprandial
Mean SEM Mean SEM
(n=8) (n=8)
Control
subjects
0.46 0.03 0.40* 0.01
Type 2- 
DM 
subjects
0.28f 0.03 0.17f * 0.03
The symbol * indicates that post-prandial values were significantly lower than 
fasting values (P<0.03). In addition, the symbol f  indicates type 2-DM (n=8) values 
were significantly lower than those for control subjects (P<0.002).
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4.5.15. LPL gene expression (as expressed against total RNA)
LPL-mRNA levels were expressed as a ratio to ng of total RNA as shown in table 
4.8. Type 2-DM subjects had a significantly higher ratio than control subjects in the 
fasting state (P<0.02). In addition, the LPL-mRNA:total RNA ratio was significantly 
lower in the post-prandial compared with the fasting state for diabetic subjects 
(fcO.Ol)
Table 4.8 Ratio in adipose tissue of the number of molecules of LPL-mRNA : ng 
of total RNA X 104 in the fasting and post-prandial states in control and type 2- 
DM subjects.
Fasting Postprandial
Mean SEM Mean SEM
(n=8) (n=8)
Control
subiects
4.2 * 1.8 12 4.3
Type 2-
DM
subiects
39 *f 16 4.0 f 0.2
The symbol * indicates that type 2-DM subjects showed a significantly higher LPL- 
mRNA: Total RNA ratio than control subjects in the fasting state (P<0.02). In 
addition, the symbol f  indicates that this same ratio was significantly lower in the 
post-prandial compared with the fasting state fo r  diabetic subjects (P<0.01).
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4.5.16. HSL gene expression (as expressed against p2-microglobulin)
HSL-mRNA levels were expressed as a ratio to p2-microglobulin-mRNA as shown 
in table 4.9. Type 2-DM subjects showed significantly lower HSL-mRNA levels than 
control subjects in both fasting and post-prandial states (f<0.01). In addition, HSL- 
mRNA levels were significantly higher in the post-prandial compared with the 
fasting state for both diabetic and control subjects (P<0.01).
Table 4.9 Ratio in adipose tissue of the number of molecules of HSL-mRNA: 
number of molecules of p2-microglobulin-mRNA in both the fasting and post­
prandial states in the control and type 2-DM subjects.
Fasting Postprandial
Mean
(n=8)
SEM Mean
(n=8)
SEM
Control
subiects
0.29 0.04 1.50* 0.20
Type 2-
DM
subjects
O.lOf 0.02 0.48f* 0.07
The symbol * indicates that post-prandial values were significantly higher than the 
fasting values (P<0.01). In addition symbol f  indicates that type 2-DM values were 
significantly lower than control subjects (P<0.01).
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4.5.17. HSL gene expression (as expressed against total RNA)
HSL-mRNA levels were expressed as a ratio to ng of total RNA as shown in table 
4.10. Type 2-DM subjects had a significantly higher ratio than control subjects in the 
fasting state (P=0.03). In addition, the HSL-mRNA: Total RNA ratio was 
significantly higher in the post-prandial compared with the fasting state for both 
diabetic (PM).04) and control (P=0.01) subjects.
Table 4.10 Ratio in adipose tissue of the number of molecules of HSL-mRNA: 
ng of total RNA X 104 in the fasting and post-prandial states in control and type 
2-DM subjects.
Fasting Postprandial
Mean SEM Mean SEM
(n=8) (n=8)
Control
subjects
4.3 1.0 15f 5.4
Type 2-
DM
subjects
12* 4.3 22f 4.9
77/e symbol * indicates that type 2-DM subjects had a significantly higher HSL- 
mRNA: Total RNA ratio than control subjects in the fasting state (P=0.03). In 
addition symbol f  indicates that the same ratio was significantly higher in the post­
prandial compared with the fasting state fo r  both diabetic (P=0.04) and control 
(P=0.01) subjects.
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4.5.18. A comparison between LPL & HSL gene expression
A comparison between the ratios of LPL-mRNA and HSL-mRNA to P2 - 
microglobulin-mRNA in the two groups for both the fasting and post-prandial states 
is shown in figure 4.9. The results show that although the HSL-mRNA significantly 
increased post-prandially by about 5-fold in both groups of subjects, for the LPL- 
mRNA the change tended to be in the opposite direction. A marginally significant 
positive correlation was observed between both messages at the 4 hours post-prandial 
time point (P = 0.047, R = 0.502)
2
1.6
1.2
0.8
0.4
0
A/'
Control
subjects
f-state
Control
subjects
pp-state
____
type 2 DM 
subjects 
f-state
type 2 DM 
subjects 
pp-state
□  HSL-mRNA
□  LPLr-mRNA
Figure 4.9: A comparison between the ratio of the number of molecules of LPL- 
mRNA and HSL-mRNA to the number of molecules of p2-microglobulin-mRNA 
in the fasting (f-state) and post prandial (pp-state) states in control and type 2- 
DM subjects. Values are mean +/- sem. The column with the symbol (*) 
indicates that LPL-mRNA values in the fasting state were significantly higher 
than the HSL-mRNA values in both the control (P< 0.0001) and diabetic 
subjects (P< 0.01). In addition, symbol f  indicates that HSL-mRNA values 
during the post prandial state were significantly higher than the LPL-mRNA 
levels in both the control and diabetic subjects (P< 0.01).
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4.5.19. P2-microglobulin gene expression
P2-microglobulin-mRNA levels were expressed as a ratio to ng of total RNA as 
shown in table 4.11. Type 2-DM subjects showed significantly higher p2- 
microglobulin-mRNA levels than control subjects in both fasting (P=0.03) and post­
prandial (P=0.02) states. In addition, p2-microglobulin-mRNA levels were 
significantly higher in the fasting compared with the post-prandial state for diabetic 
subjects (P=0.03).
Table 4.11 Ratio in adipose tissue of the number of molecules of Pz- 
microglobulin -mRNA: ng of total RNA X104 in the fasting and post-prandial 
states in control and type 2-DM subjects.
Fasting Postprandial
Mean
(n=8)
SEM Mean SEM 
(n=8)
Control
subiects
8.7 4.5 4.3 1.8
Type 2-
DM
subjects
120 *f 60 26 * 13
The symbol * indicates that type 2-DM subjects had a significantly higher p2- 
microglobulin-mRNA: Total RNA ratio than control subjects in both fasting (P=0.03) 
and post-prandial (P=0.02) states. In addition symbol f  indicates this same ratio 
was significantly higher in the fasting compared with the post-prandial state fo r  
diabetic subjects (P=0.03)
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4.6. Discussion
Plasma glucose concentration
In health, the mechanisms responsible for glucose homeostasis ensure the 
maintenance of blood glucose concentrations within a narrow range, whether an 
individual is fed or fasting. Insulin plays a major role in the co-ordination of glucose 
concentration. As expected in the type 2-DM individuals, plasma glucose levels were 
markedly raised compared with the normal individuals (figure 4.1). The explanation 
for this is either insulin is secreted in amounts insufficient to prevent hyperglycaemia 
or there is insensitivity to its actions.
An elevated plasma glucose concentration leads to an increased rate of non-enzymic 
glycation of proteins. Glycation of apolipoproteins may affect the cellular handling, 
and thus the atherogenicity, of lipoprotein particles (Frayn & Coppack, 1992).
Plasma lipid concentration
Plasma TAG
The most common lipid abnormality in type 2-DM patients is elevated serum TAG 
(Garg & Grundy, 1990). High levels of serum TAG occur mainly as VLDL and can 
result from two abnormalities. Firstly, patients with type 2-DM over-produce TAG- 
rich VLDL, and this response probably results from increased serum levels of free 
fatty acids and glucose (Garg & Grundy, 1990). A secondary cause of 
hypertriacylglycerolaemia is retarded lipolysis of TAG contained in TAG-rich 
lipoproteins (VLDL and CMs), probably due to a reduction in LPL activity (Reaven 
& Chen, 1988).
The overnight fasting TAG concentrations in the type 2-DM subjects, were 
significantly higher compared with the control individuals (figure 4.2). This result is
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in agreement with many previous reports demonstrating the elevation in plasma TAG 
concentrations in type 2-DM patients (Pfeifer et ah, 1983; Garg & Grundy, 1990).
Plasma NEFA
The fasting NEFA levels in the diabetic subjects were raised (0.63 mmol/1) but not 
significantly compared with the control subjects (0.54 mmol/1). Sztalryd & Kraemer 
(1994a) suggested that the elevation of fasting plasma NEFA was consistent with an 
acceleration of lipolysis caused by the activation of HSL activity during fasting.
Plasma lipoprotein fractions
Diabetes is often considered to be a disorder characterised by a fall in plasma HDL- 
cholesterol concentration and a high LDL-cholesterol concentration (Garg & 
Grundy, 1990). Although the mean fasting plasma concentration of HDL-cholesterol 
(1.22 mmol/1) was higher in the normal individuals compared to the diabetic 
individuals (1.18 mmol/1) the difference was not statistically significant (figure 4.5). 
In addition, the mean LDL-cholesterol was slightly higher in the normal individuals 
compared with the diabetic individuals but again these differences were not 
statistically significant (figure 4.6).
Garg & Grundy (1990), suggested that patients with type 2-DM may often not have 
high LDL-cholesterol concentrations compared with nondiabetic subjects of the same 
population, but many will have increased LDL-apo B levels, as found in other 
hypertriacylglycerolaemic states. High levels of LDL-apo B, are caused by either 
overproduction of apo B-containing lipoproteins or by an increased conversion of 
VLDL to LDL.
Plasma insulin concentration
Hyperglycaemia and hyperinsulinaemia are classical presenting features of patients 
with type 2-DM (Dominiczak, 1999). The mean fasting insulin levels (100 pmol/1) 
were slightly higher in the diabetic compared to the normal subjects (70 pmol/1)
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although there was no statistically significant difference. In this situation, despite the 
presence of insulin, tissues do not efficiently utilize glucose. Insulin resistance may 
be caused by defects at several levels. Insulin-receptor binding could be 
compromised due to down-regulation of the receptors, as in obesity. Rarely, a 
mutation in the insulin receptor gene may cause extreme resistance. Resistance is 
also caused by the presence of anti-receptor antibodies. Defects in receptor signalling 
(i.e. in tyrosine kinase activity or protein phosphorylation) may also cause insulin 
resistance.
Glucose-dependent insuiinotropic polypeptide (GIF)
Glucose-dependent insuiinotropic polypeptide (GIF) is a gastrointestinal hormone 
involved in the regulation of insulin secretion (Wheeler et a l,  1999). GIF release has 
been demonstrated predominantly after the ingestion of carbohydrate and fat (Yeung 
et al.,1999). In the present study the diabetic subjects had a significantly lower GIF 
response to the meal compared with the normal individuals ( f =0.0002) (figure 4.8). 
This result is in agreement with previous studies by Nauck et a l (1993) and Vaag et 
a/. (1999).
RT-PCR measurements
The LPL-mRNA and HSL-mRNA results were initially expressed per ng total RNA. 
However, the results showed a high degree of person-to-person variation as shown 
by the large SEM values. Total RNA measurements on extracts of less than 10 mg 
adipose tissue samples are not reliable. The amount of RNA extracted which could 
be used for spectrophotometry was below the recommended limit of sensitivity for 
measurement at 260 nm. Total RNA is a crude estimate of mRNA because total RNA 
contains tRNA, rRNA and mRNA, of this mRNA only counts ~ 5%. Also total RNA 
measurements do not reflect degradation in the sample that would still be observed at 
260 nm but would not amplify during the RT-PCR procedure. In addition, total RNA
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measured spectrophotometrically would be affected by any DNA contamination. To 
ensure comparable extraction in a series of samples, endogenous standards 
(housekeeping genes) are usually quantitated in addition to the target gene 
(Zimmermann & Mannhalter, 1996). Even if the same quantity of RNA is used for 
each reaction, the final quantity of PCR product may be greatly affected by pipetting 
technique, differences in RNA integrity and the presence of inhibitors of reverse 
transcriptase (Clause & Adamovicz, 1995). Actin is the standard housekeeping gene, 
however the use of actin has been critisised since actin expression changes with 
changes in cell size. Schmittgen & Zakrajsek (2000) investigated the use of various 
housekeeping genes in starved and serum-fed fibroblasts. The mRNA for 
glyceraldehyde-3-phosphate dehydrogenase and actin increased on ‘feeding’ with 
serum as did rRNA levels whereas the level of the pz-microglobulin mRNA was 
unchanged. This work concluded that the fe-microglobulin gene was a suitable 
internal control in quantitative gene expression in fibroblasts whilst the genes for 
glyceraldehyde-3-phosphate dehydrogenase and actin were not. Another reason for 
not using the gene for glyceraldehyde-3-phosphate dehydrogenase as a housekeeping 
gene in adipose tissue, especially in our study, is that it is intimately involved in lipid 
metabolism. The internal standard obtained from Laville et al. (1996) had 
incorporated the primers for HSL, LPL and ^-microglobulin. Its use minimised the 
errors due to pipetting and avoided possible imprecision in total RNA concentration 
determination. When results were expressed as LPL or HSL against pa-microglobulin 
the person-to-person variation was much lower as indicated by the SEM values given 
in the tables (4.7; 4.8; 4.9; 4.10). Although the results have been expressed as a ratio 
to p2-microglobulin-mRNA, it has also been observed that p2-microglobulin-mRNA 
levels were significantly greater in the diabetics compared with the control subjects. 
This result was unexpected and may suggest that p2-microglobulin is not a good 
housekeeping gene for use in diabetic subjects.
In view of the doubts regarding the total RNA measurements and the confidence in 
the use of housekeeping gene measurements, as discussed above, the results will 
initially be discussed ignoring the ratios to total RNA.
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Lipoprotein lipase
Controls versus type 2-DM subjects
A consistent pattern of higher LPL activity in post-heparin plasma (table 4.3), 
adipose tissue LPL (table 4.4), and LPL-mRNA (table 4.7) in controls versus 
diabetics was observed in this study (see table 4.12 for the percentage differences).
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Table 4.12 The percentage differences between type 2-DM and control subjects 
for LPL activity and gene expression in both fasting and 4 hours post-prandial 
states (only for the significant values).
Test
Comparison between 
Diabetic and controls
Comparison between 
Fasting and post­
prandial states
15 mm PHLA 1) In the fasting state, the 
diabetic subjects values were 
23 % of the control subjects 
values.
2) During the fed state, the 
diabetic subjects values were 
35 % of the control subjects 
values.
In diabetic subjects fasting 
values were 82 % of the fed 
values.
Adipose tissue LPL 1) In the fasting state, the 
diabetic subjects values were 
63 % of the control subjects 
values.
2) In the fed state, the 
diabetic subjects values were 
51 % of the control subjects 
values
1) In diabetic subjects fasting 
values were 76 % of the fed 
values.
2) In control subjects lasting 
values were 61 % of the fed 
values.
Number o f molecules of  
LPL-mRNA:number 
o f molecules o f p2- 
microglobulin-mENA
1) In the fasting state, the 
diabetic subjects values were 
61 % of the control subjects 
values.
2) In the fed state, the 
diabetic subjects values were 
43 % of the control subjects 
values
1) In diabetic subjects fed 
values were 61 % of the fasting 
values”.
2) In control subjects fed 
values were 86 % of the fasting 
values”
Number of molecules of 
HSL-mRNA:number 
of molecules o f p2- 
microglobulin-mRNA
1) In the fasting state, the 
diabetic subjects values were 
34 % of the control subjects 
values.
2) In the fed state, the 
diabetic subjects values were 
32 % of the control subjects 
values
1) In diabetic subjects fasting 
values were 21 % of the fed 
values.
2) In control subjects fasting 
values were 19 % of the fed 
values
These results are in agreement with previous demonstrations of low PHLA in 
diabetic subjects. Nikkilâ et al. (1977) found that patients with diabetic ketosis had 
significantly lower (by 66%) PHLA compared to matched non-diabetic controls (P< 
0.001), and Pfeifer et al. (1983) found that PHLA of their diabetic subjects was only 
37% of that of their control subjects. Finally, Simosolo et al. (1992) studied PHLA 
in diabetic subjects before and after treatment with insulin. They found that pre­
137
treatment samples had 59% of the activity of post-treatment samples, and they 
suggested that improved diabetic control resulted in a significant increase of -  2-fold 
in LPL activity incomparison with pre-treatment subjects.
In addition, this study has also confirmed the differences between the diabetic and 
control subjects in their adipose tissue LPL activity. In a previous studies, Pykàlistô 
et al. (1975) found that diabetic subjects had a significantly lower (67%) adipose 
tissue LPL activity than control subjects, and Taskinen & Nikkilâ, (1979) found that 
the adipose tissue LPL activity of the diabetic patient was 34% of that of their control 
subjects when expressed on a per tissue weight basis. In addition, Pfeifer et al. 
(1983) found that the adipose tissue LPL activity of diabetic subjects was only 67% 
of that of control subjects. However, there is less information regarding the 
expression of LPL in this condition. The results presented suggest that in type 2-DM, 
the insulin insensitivity results in an inability to maintain the normal activities of the 
key enzyme involved in lipid metabolism at all levels of its production.
Fasting versus post-prandial LPL in control subjects
This study showed a significant difference in adipose tissue LPL activity (table 4.4) 
between the fasting (42.7 nmol oleate released per minute at 37°C) and fed state 
(69.8 nmol oleate released oleate released per minute at 37°C) and that adipose tissue 
LPL activity levels were higher in the post-prandial state. This result is in agreement 
with a previous study by Ong & Kern (1989) who examined the cellular mechanism 
for the of increase LPL activity, immunoreactive mass and mRNA level in lean and 
obese subjects both before and after a carbohydrate rich meal. LPL activity was -  
2.5-fold higher in the obese subjects, when compared with the lean subjects. 
However, there was no difference in LPL immunoreactive mass between the two 
groups of subjects. In response to the meal there was a 2.2-fold increase in total 
adipose tissue LPL activity in lean subjects. In addition, Doolittle et al. (1990) found 
fasting LPL activity increased 2-fold post-prandially. However, the post-prandial 
samples showed a decreased in LPL-mRNA which was only 59% of the value in the 
fasting state.
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In the present study LPL-mRNA levels were significantly lower in the post-prandial 
state compared with the fasting state. These findings are comparable with those 
obtained using rat adipose tissue where the LPL mass in the fasting state was found 
to decrease in the fed state (Bergô et a l, 1997).
Cell culture studies have shown that insulin stimulates LPL-mRNA, mass and 
activity, in a time dependent process, Ong et al. (1988). They observed that insulin 
induced a 2-fold increase in the LPL-mRNA after exposure of the primary cultures of 
rat adipocytes to insulin for as little as 60 minutes and was accompanied by only a 
10-25% increase in total protein synthesis. In addition, insulin had no effect on the 
turnover of intracellular LPL. The difficulty encountered in measurements of LPL in 
vivo is that it is impossible to monitor changes continuously and therefore, the timing 
of the biopsies in relation to the meal only give a ’snap shot1 picture of what is 
happening.
The findings of the present study indicate that at the chosen time, 4 hours after the 
consumption of a fat-containing meal, although the LPL-mRNA that had 
accumulated in the fasting state was producing potentially active LPL in the adipose 
tissue, the LPL activity on the capillary endothelium was still at similar levels to that 
in the fasting state. It could be postulated either that any additional LPL had been 
inactivated during the hydrolysis of TAG in CMs circulating earlier in the post­
prandial period or that levels had not reached their maximal activity which may 
occur later in the post-prandial period.
Fasting versus post-prandial LPL in type 2-DM
Type 2-DM subjects had reduced plasma LPL levels compared with the control 
subjects in both fasting and post-prandial states. However, in response to the fat- 
containing meal the diabetic subjects were able to respond to the meal by increasing 
PHLA although this rise still did not reach that of the control values (table 4.3). In 
addition, although there was a higher mean value for LPL tissue activity in the post­
prandial state (35.3 nmol oleate released minute"1.g"1 at 37°C) when compared with 
the fasting level (26.8 nmol oleate released minute"1.g"1 at 370C) the change was
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small. The change in the level of LPL message from the fasting (0.28 molecules of 
LPL-mRNA:molecules of p2-microglobulin) to the fed state (0.17 molecules ofLPL- 
mRNA:molecules of fo-microglobulin) was a smaller decrease in the type 2-DM 
than in the control subjects. This adds further weight to the argument that a reduction 
in the whole pathway of LPL production contributes to the slow post-prandial lipid 
clearance in type 2-DM and their increased propensity to atherosclerosis. Doolittle et 
al. (1990) observed that fasting decreased the LPL catalytic activity by 50% while 
LPL-mRNA levels increased nearly 2-fold. They suggested that LPL could be 
regulated at the level of transcription and translation. Thus, LPL can be regulated 
during feeding and fasting by a complex array of factors, such as insulin, GIP, 
glucagon, and glucocorticoid levels as well as sympathetic innervation.
Hormone sensitive lipase 
Controls versus type 2-DM subjects
No significant differences were observed in HSL activity (table 4.5) between the two 
groups which is in agreement with Reynisdottir et a l (1997b), who found that HSL 
activity was not significantly different between insulin resistant subjects compared 
with control subjects. However, the finding that type 2-DM subjects had significantly 
lower level of HSL-mRNA compared to control subjects (see table 4.12) indicates 
down regulation in response to prolonged raised plasma glucose, TAG and NEFA 
levels so that lipolysis is not impaired.
Fasting versus post-prandial state HSL in control and type 2-DM subjects
In this study we failed to detect higher HSL activities values in the fasting states in 
either control or type 2-DM subjects (table 4.5). This probably reflects the variability 
of the assay and its inability to distinguish between phosphorylated and non- 
phosphoiylated forms of HSL. In addition, the subjects may have been affected by
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stress when the adipose tissue biopsy was obtained. Stress can cause a 
catecholamine-induced increase in HSL activity which could obscure any potential 
differences between fed and fasted states. However, a significant increase in mRNA 
(table 4.8) in the post-prandial state in both groups, when one might expect lower 
activity, is perhaps unexpected. However, it is consistent with the LPL message 
results in that HSL-mRNA may be accumulated in the post-prandial state and 
utilized in the fasting state. These findings are consistent with the hypothesis of 
Frayn et al. (1995) who show co-ordinated regulation of HSL and LPL in human 
adipose tissue in vivo.
Studies in rats (Sztalyd & Kraemer, 1994a) and in pigs (Liu et a l,  1995) examined 
the regulation of HSL activity and gene expression following different periods of 
fasting. Although HSL activity and expression were relatively unchanged in normal 
periods of fasting they increased after 3-5 days of fasting by 2-fold.
The HSL activity method was developed using a large adipose tissue sample 
obtained by surgery, unfortunately the level of activity in the samples used in the 
present chapter had 50-fold higher activity than the method was optimised to 
measure. Due to lack of an approperiate sample, the optimisation of the assay could 
not be repeated and because of this limitation, although values were obtained, it may 
have reduced the likelihood of finding significant differences.
LPL-mRNA versus HSL-mRNA
The enzymes LPL and HSL apparently catalyse opposing functions in white adipose 
tissue: the former is concerned with fat storage, the latter with fat mobilisation 
(Frayn et ah, 1995). The two enzymes are regulated in a broadly reciprocal manner 
as shown in figure 4.9. Thus, although the HSL-mRNA significantly increased post- 
prandially by about 5-fold in both types of subject, for LPL-mRNA the change tends 
to be in the opposite direction.
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Consideration of changes with respect to total RNA
The finding that ^-nhcroglobnlin levels expressed as a ratio of total RNA were 
significantly increased in diabetic individuals compared to control subjects was 
unexpected and requires further investigation. This finding has not been reported in 
the literature although in a personal communication, Vidal stated that a 2-fold 
increase in p2-niicroglobulin:total RNA had been observed in adipocytes from type 
2-DM compared to controls. The direction of change between the fasting and the 
fed state in each group of subjects remained the same irrespective of whether the 
results were expressed as a ratio to p2-microglobulin or to total RNA. However, the 
differences between the subject groups were affected. The LPL-mRNA levels 
expressed as a ratio to total RNA were 6- to 7-fold higher in the diabetic subjects 
than the controls in the fasting state and ~2-fold higher in the postprandial state. 
These results were unexpected and do not reflect the reduced LPL activity levels 
widely reported in diabetic subjects compared to controls (-3 -fold higher in the 
fasting state and up to 2-fold higher in the postprandial state). Higher HSL-mRNA 
levels in diabetics could be a reflection of raised HSL activity and increased plasma 
NEFA levels that are a general feature of type 2-DM. However, in the current study 
no significant difference was found in the fasting or postprandial NEFA levels 
between the two groups of subjects.
4.7. Conclusion
I postulate, based on the findings of this study, that LPL-mRNA is accumulated in 
the fasting state and utilised in the fed state. On the other hand, HSL-mRNA is 
accumulated in the fed state and utilised in the fasted state. These new findings call 
for further studies to examine the factors that determine the level of mRNA 
production, the rate of transcription and the rate of biosynthesis of proteins and 
active enzymes in different nutritional states.
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However, the unexpected finding of a large increase in the ratio of p2-niicroglobulin 
to total RNA needs to be assessed with suitable samples.
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Chapter 5
Lipase activity and gene expression in omental and 
subcutaneous adipose tissue depots in young pre­
menopausal women
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5.1. Introduction
Adipose tissue distribution in humans is dependent on genetic and environmental 
factors; the total and regional masses of adipose tissue are dependent on the number 
of adipocytes as well as their degree of filling with depot fat (Bjorntorp, 1991). There 
is growing interest today in the regional body fat distribution, rather than in the body 
fat quantity, as a risk factor for cardiovascular disease (Zamboni el ah, 1992 a). It has 
become increasingly evident that abdominal obesity is closely associated with 
cardiovascular complications, type 2-DM and premature death (Maurèige et ah, 
1995; Zamboni et al., 1992 b). The obesity can be divided into two types based on 
waist-to-hip ratios (Guagnano et al., 1998). Android obesity is mainly found in men 
and is characterised by a central distribution of adipose tissue accumulation that is 
strongly related to a higher risk of CHD (Stewart et al., 1999; Tchernof et al., 2000). 
Gynoid obesity, that predominates in pre-menopausal women, is the tendency to 
accumulate fat in the gluteal and femoral regions and this is associated with a lower 
risk of CHD (Arner et al., 1991; Tchernof et al., 2000).
The accumulation of omental adipose tissue, is thought to increase the delivery of 
FF A to the liver via the portal system (Arner, 1995). This can lead to the metabolic 
disturbances and may in turn be a contributing factor to glucose intolerance, 
hypertriacylglycerolaemia, insulin resistance and hyperinsulinaemia, which are 
common complications associated with upper-body obesity (Arner, 1995). However, 
although widely postulated the causative link between insulin resistance and central 
adiposity lacks evidence from studies in vivo reviewed by Frayn. (2000).
5.1.1. Subcutaneous depots
In subcutaneous depots, the fat size and estimated fat cell number have been 
examined in several studies in central (epigastric and hypogastric) and peripheral 
(femoral and gluteal) regions. These studies might be summarised as comparing
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different regions within the same group; between sexes; and changes with age and 
obesity. Sjôstrôm et a l (1972) suggested that young men have little subcutaneous fat 
and do not show a characteristic central-peripheral difference. For example, fat cell 
size is similar in all examined regions, whereas young women have more 
subcutaneous fat. This was due to an increased local fat cell number in all regions 
except gluteal where the increased adipose tissue thickness was mainly due to larger 
fat cells. Krotkiewski et a l (1975) did a comparison between the sexes at different 
degrees of obesity. They suggested that with increasing severity of obesity adipose 
tissue thickness was markedly higher in the central regions in men, while the 
peripheral regions were significantly larger in women. These differences are 
explained mainly by an increase of fat cell number of central regions in men, but in 
women at ages mainly before menopause, the larger peripheral depots are due to both 
supernumerous and enlarged fat cells.
5.1.2. Omental depots
In contrast to subcutaneous adipose regions the information on omental fat is rather 
limited in human subjects, because of the difficulties of sampling intra-abdominal 
fat, plus the difficulties of measuring the mass of these tissues (Bjorntorp, 1991). The 
first study by Salans et a l (1973), suggested that the mean fat cell mass in omental 
regions was 0.81 pg which is a similar weight to adipocytes from subcutaneous sites 
in obese subjects (0.88 pg). In addition, the same study showed that in non-obese 
subjects the cell sizes from omental and subcutaneous sites were similar (0.44 and 
0.39 pg respectively). Another study by Rebuffé-Scrive et a l  (1989) examined 
groups of non-obese men (mean age 54 years) and pre- and post-menopausal women 
(mean age 38 and 60 years respectively). This study showed that the men, who were 
older than the pre-menopausal women, had omental fat cells which were almost 
double the weight of the fat cells from the both groups of women, while pre- and 
post-menopausal women were similar.
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5.1.3. Regulation of regional fat cell metabolism
The differential regulation of lipolysis in various adipose tissue depots could play an 
important role in the balance between inflow and outflow of TAG to and from cells. 
Catecholamines and insulin are the main hormones that acutely affect rates of 
lipolysis. The regulation of lipolysis by catecholamines involves adrenergic receptor 
(AR) stimulation of adenylate cyclase via the (3-AR family of receptors ((31-, (32-, (33- 
AR) and inhibition by cc2-AR (Reynisdottir et ai., 1997 b). As observed recently by 
Berman et al. (1998) the lipolytic action of catecholamines is higher in vitro in 
abdominal adipocytes versus gluteal adipocytes in obese, post-menopausal women. 
In addition, Arner (1995) reviewed that the lipolytic activity was greater in omental 
adipose tissue than in subcutaneous adipocytes. The mechanism behind this 
difference appears to be due to site variations in the activity of the major hormones 
regulating lipolysis and parahormones. Catecholamine-induced lipolysis is increased 
in omental fat cells, which is due to increased expression of (31 and (32-AR, whereas 
the antilipolytic action of insulin is decreased in omental fat cells owing to a 
combination of decreased insulin receptor affinity and impaired postreceptor 
inhibition of the lipolysis rate.
Regional differences in lipolysis have long been observed between femoral and 
abdominal tissues as well as between subcutaneous and omental fat tissues in mixed 
groups of patients (Arner, 1995; Large et al, 1999). In addition, a further study 
found that there was a difference in catecholamine-stimulated lipolysis between non- 
obese men and women. In men lipolysis was higher in both intra-abdominal fat 
tissues which drained their free fatty acids directly into the portal vein (mesentric and 
omental), while lipolysis from non-portal fat tissue (retro-peritoneal and 
subcutaneous abdominal) was higher in women (Rebuffé-Scrive et al, 1989).
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5.1.4. Sex differences in regional distribution of fat cell
Numerous studies have re-emphasised the notion that pre-menopausal women tend to 
have greater adipose tissue thickness and larger subcutaneous fat cells in the gluteal 
and femoral regions whereas, men are generally characterised by a high relative 
accumulation of abdominal adipose tissue (Sjôstrôm et al, 1972; Fried & Krai, 1987; 
Fried et al, 1993; Mauriège et al., 1999). In both sexes, omental adipose tissue is 
known to contain smaller fat cells than subcutaneous sites (Fried & Krai, 1987; Fried 
et a l, 1993). Differences in fat cell size among sites are accompanied by metabolic 
differences: Subcutaneous abdominal fat cells are more responsive to nutritional 
interventions, lipolytic stimuli and the anti-lipolytic effect of insulin than fat cells 
from the femoral region, whereas, smaller omental fat cells are more responsive to 
catecholamines and less to the anti-lipolytic effect of insulin than abdominal fat cells 
(Fried & Krai, 1987)
5.2. Aim of the study
The specific aim of this chapter was to investigate the regulation of LPL and HSL 
lipase activity and gene expression in omental and subcutaneous adipose tissue 
depots from young pre-menopausal women.
5.3. Methods
5.3.1. Subject recruitment
10 pre-menopausal non-obese women (overnight fasting) with a mean age of 35 
years (range 33-38 years), with a mean BMI of 23 kg/m2 (range 21-25 kg/m2) who 
were awaiting tubal surgery were recruited. The subjects did not have a personal or 
family history of diabetes, CHD, hypertension or any other chronic disease. Only 
healthy women able to provide medical information of their parents’ present or past
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cardiac history were studied. These women agreed to fat biopsies could be taken 
during surgery. The study was approved by the Research Ethical Committee of the 
Hammersmith Hospital NHS Trust.
5.3.2. Adipose tissue biopsies
Fat biopsies 1-5 g were obtained using a scalpel and without cauterisation, 
subcutaneous fat was taken from the mid-point of the laparotomy incision and the 
omental sample from the tip of the omentum. The sample was divided and frozen 
immediately in liquid nitrogen for subsequent measurement of lipase gene expression 
and activity.
5.3.3. LPL and HSL activity and gene expression
Total RNA was extracted from the adipose tissue biopsies as detailed in section 
2.2.8.1, and analysed for LPL-mRNA, ^-microglobulin-mRNA by competitive RT- 
PCR as described in sections 2.2.9.4. Adipose tissue LPL activity was measured 
using the radioactive triolein technique detailed in section 2.2.2. In addition, adipose 
tissue HSL activity was measured using a radioactive MOME technique detailed in 
section 3.3.1.
Note: due to the lack of time and resources HSL-mRNA was not measured in the 
samples.
5.3.4. Fasting biochemical data
Plasma overnight fasting glucose, cholesterol, HDL-cholesterol, LDL-cholesterol 
and TAG were analysed by standard colorimetric techniques (Boehringer) and 
plasma insulin by radioimmunoassay (Albano et al., 1972). These assays were 
carried out by Dr Gary Frost from the Hammersmith Hospital.
149
5.3.5. Cell size
Cells were counted manually in a 1 in 100 dilution of the cell concentrate using a 
haemocytometer (with a 200 |im gap) and cell size, diameter and surface area was 
measured on 50 cells using a Cue 2 cell counter (Olympus Ltd, UK). These assays 
were carried out by Dr Gary Frost from the Hammersmith Hospital.
5.4. Statistical analysis
Statistical analysis was performed to compare and determine any significant 
differences between the subcutaneous and omental adipose tissue in every individual. 
Mean, SD and SEM were calculated for each measurement. Statistical analysis was 
carried out using Microsoft Excel ™. Comparisons between the subcutaneous and 
omental adipose tissue in individuals were analysed using a paired Student's t-test. In 
addition, an unpaired Student's t-test was used to compare differences between the 
two groups. Values of/? < 0.05 were taken as the lowest level of significance.
5.5. Results
5.5.1. Lipoprotein lipase activity
The omental and subcutaneous adipose tissue LPL activity (nmol oleate released per 
min) results are shown in table 5.1. There were no significant differences between 
the omental and the subcutaneous adipose tissue LPL activity.
150
Table 5.1 Pre-menopausal women omental and subcutaneous depots LPL 
activity
Omental depots 
(nmol oleate released per 
minute per g at 37°C)
Subcutaneous depots 
(nmol oleate released per 
minute per g at 37°C)
Mean SEM Mean SEM
Pre-menopausal women 
(n = 10)
14.9 1.3 17.1 2.2
5.5.2. Lipoprotein lipase m-RNA
The omental and subcutaneous adipose tissue LPL-mRNA (number of molecules of 
LPL-mRNA/number of molecules of p2-microglobulin-mRNA) results are shown in 
table 5.2. There was no significant difference between the omental and subcutaneous 
adipocyte samples.
Table 5.2 Pre-menopausal women omental and subcutaneous depot LPL m- 
RNA (number of molecules of LPL-mRNA/number of molecules of 
P2-microglobulin-mRNA).
Omental depots Subcutaneous depots
Mean SEM Mean SEM
Pre-menopausal women 
(n = 10)
0.48 0.15 0.29 0.07
151
5.5.3. Hormone sensitive lipase activity
The omental and the subcutaneous adipose tissue HSL activity (pmol oleate released 
per min per gram) results are shown in table 5.3. There was no significant difference 
between the omental and subcutaneous adipocyte sites.
Table 5.3 Pre-menopausal women omental and subcutaneous depot HSL 
activity
Omental depots 
(pmol oleate released per 
minute per g at 37°C)
Subcutaneous depots 
(pmol oleate released per 
minute per g at 37°C)
Mean SEM Mean SEM
Pre-menopausal women 
(n = 10)
44.1 9.3 47.0 12.5
5.5.4. Biochemical results
Overnight fasting plasma biochemical results are shown in table 5.4. Results are 
expressed as means ± SD.
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Table 5.4. Biochemical data
Mean
(n=10)
SD Range
Fasting insulin (pmol/1) 34.1 17.0 10.0-60.0
Fasting glucose (mmol/1) 5.0 0.6 4.0-6.0
Fasting cholesterol (mmol/1) 5.2 0.5 4.S-6.5
Fasting TAG (mmol/1) 1.0 0.3 0.7-1.8
Fasting NEFA (mmol/1) 0.6 0.3 0.3-1.2
These analysis were carried out by Dr Gary Frost from Hammersmith hospital 
5.5.5. Cell size
A comparison between the adipocyte cell size from omental and subcutaneous 
adipose tissue depots is shown in table 5.5. The diameter of the subcutaneous cells 
was 75% greater than that of the omental cells, implying that their volume is 5 times 
greater.
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Table 5.5. A comparison between the cellular size of omental and subcutaneous 
adipose tissue
Subcutaneous Omental
Mean SD Mean SD
(n=10) (n=10)
Cell diameter (pm) 112.4* 23.2 64.2* 36.7
The symbol * indicates the cell diameters o f the subcutaneous adipocytes were 
significantly larger than the omental adipocytes (P= 0.007).
5.6. Discussion
The present study was conducted to examine regional differences in the LPL and 
HSL activity and gene expression in adipose tissue biopsies from pre-menopausal 
non-obese women.
LPL and HSL activity
In this study, there were no differences in the fasting activity of LPL and HSL 
derived from subcutaneous and omental adipose tissue. This finding is in agreement 
with a previous study by Rebuffé-Scrive et al. (1990) who studied groups of severely 
obese men and pre-menopausal women with an abdominal type of fat distribution. 
Their work compared fat cell size, LPL activity and also lipolysis which was 
stimulated by noradrenaline or inhibited by insulin in omental and mesenteric 
samples (which drain into the portal vein) compared with subcutaneous abdominal 
and retroperitoneal (non-portal tissues). In agreement with our results, they showed
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no significant differences in LPL activity per cell (as shown in table 5.6) and larger 
subcutaneous abdominal fat cells, those in retroperitoneal (retroperitoneal is 60% of 
subcutaneous) and omental depots (omental depots is 73% of the subcutaneous). 
There was increased lipolysis in portal tissues in obese women compared with lean 
women, and the opposite picture in obese men who had increased lipolysis in non­
portal tissues. However, there were no significant differences between the sexes. 
Taken together, they suggested that obese men and abdominally obese women have a 
greater potential to release FFA from intra-abdominal depots.
Table 5.6 LPL in different adipose tissue regions in men and women (Rebuffé- 
Scrive et aL, 1990).
LPL activity (mU/jim2.104 cells)
Site Males values Females values
Abdominal 11.3 ±3.4 17.1±4.2
Retroperitoneal 15.5 ±1.3 13.0 ±2.6
Mesenteric 12.8 ±1.7 13.9 ±3.7
Omental 14.3 ±2.7 18.1± 4.5
All the values were taken from the original article. Values are mean ± SEM.
Results are expressed as activity o f LPL per cell surface area where 1 m il = the 
release o f 1 nmole o f oleate per min.
Fried & Krai (1987) looked at adipose tissue metabolism in four subcutaneous 
regions (femoral, gluteal, abdominal and epigastric) and two internal beds 
(mesenteric, omental) in obese men and pre-menopausal, obese women. They 
observed that the LPL activity in samples from pre-menopausal women were little 
different between the subcutaneous and internal sites. Moreover, there was no 
difference in the LPL activity between all six sites in the obese men on a per cell 
basis (table 5.7). When averaged over all 6 sites females had significantly higher 
LPL activity than males.
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Table 5.7 LPL in different adipose tissue regions in men and women (Fried & 
Krai, 1987).
LPL activity (U/l 0 cells)
Adipose tissue origin Females values Males values
(mean) (mean)
Femoral 2.2 1.0
Gluteal 1.48 0.75
Abdominal 1.48 0.85
Epigastric 0.51 0.51
Mesenteric 1.48 0.75
Omental 0.5 0.51
All the values are estimated (from figure 2) from the original article (Fried & Krai,
1987). One unit o f LPL activity, U, represents the release o f 1 pmole o f oleate per 
min.
In contrast to our study which studied regional differences in adipose tissue LPL 
activity from lean subjects, Yost & Eckel (1992) studied regional differences in 
adipose tissue LPL activity in a group of seven normal weight pre-menopausal young 
women compared with ten obese pre-menopausal women. Their results showed 
increased adipose tissue LPL activity in gluteal and abdominal regions in obese 
women when compared to the lean subjects. Although they found that the LPL 
activity in the gluteal region of pre-menopausal was significantly greater than that in 
their abdominal region, no such difference was found for the obese group (table 5.8).
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Table 5.8 Adipose tissue LPL activity in obese and non-obese pre-menopausal 
young women (from Yost & Eckel, 1992).
pre-menopausal young 
women (n=7)
obese pre-menopausal 
women (n=10)
Fasting gluteal adipose 
tissue LPL activity#
1.48 ±0.34 *, 8.09 ± 1.66'1'
Fasting abdominal adipose 
tissue LPL activity #
0.74 ± 0.19 * 6.28 ± 1.45t
# LPL activity expressed as 'nmol oleate released per minute at 3 7°C by 106 cells. ’
* indicates P< 0.02 for gluteal versus abdominal adipose tissue and 
^ indicates P< 0.0 for obese versus pre-menopausal women.
Values are means ± SEM.
Mauriège et al. (1995) examined LPL and lipolytic activities in isolated human 
adipocytes obtained from two intra-abdominal depots (round ligament samples 
surrounding the liver and omental) and from subcutaneous abdominal regions from 
nine severely obese pre-menopausal women. They found that LPL activity in round 
ligament adipose cells was 2-fold higher {P< 0.05) than subcutaneous abdominal or 
omental adipocytes. The LPL activity was expressed per unit of adipocyte surface 
area. Moreover, there was a trend for both fat cell weight and LPL activity to be 
lower in omental than in subcutaneous abdominal adipose cells (the omental was 
45% of the subcutaneous) but the difference did not reach statistical significance. In 
contrast to the results of the present study, basal lipolysis was significantly higher in 
subcutaneous abdominal than omental adipocytes {P < 0.05). They suggested that 
these differences between regions might be explained by site variations in the 
functions of insulin and catecholamines.
157
Amer (1995) reviewed the mechanism behind the differences in lipolysis between 
human subcutaneous and omental adipose tissues. Insulin and catecholamines have 
marked acute effects on lipolysis in fat cells in adult man. Insulin inhibits lipolysis 
whereas, catecholamines have dual effects on lipolysis; stimulation through |3-AR 
subtypes and inhibition through a2-AR (Bolinder et al, 1983). In 1991, Mauriège et 
a l proposed that the resistance of abdominal subcutaneous fat cells of obese males to 
lipolysis in the presence of increased catecholamine was due to an increased a2-AR 
On the other hand, in obese women such resistance was due to decreased adipocyte 
P2-AR expression and a reduced ability of c-AMP to produce active HSL. In 
contrast, increased catecholamine-induced lipolysis has been observed in omental fat 
cells of subjects with upper-body obesity as a result of increased function of the P3- 
AR and, to some extent, also to decreased function of a2-AR.
In contrast to our study which studied regional differences in adipose tissue HSL 
activity from lean subjects, Large et a l (1999) compared HSL activity and HSL- 
protein levels in subcutaneous adipose tissue from obese and non-obese male and 
female subjects, they found that obese subjects had much lower HSL enzymatic 
activity and protein levels than the non-obese subjects. This suggested that the defect 
in HSL protein expression of adipocytes could be involved in the aetiology of obesity 
(table 5.9).
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Table 5.9 HSL activity, protein, and mRNA expression in fat cells of obese and 
non-obese subjects (Large et aL, 1999).
Fat cell lipolysis capacity
Non-obese Obese P  values
HSL activity 
(mU/mg total 
protein)
10.1 ±2.6 (n= 14) 5.8 ± 0.7 (n = 34) <0.001
HSL protein 
(OD/mm2 / 200 jig 
total protein)
5.3 ±1.6 (m= 10) 2.8 ± 0.5 (n= 29) <0.05
HSL protein 
(OD/mm2 / 0.5 mU 
HSL)
0.8 ±0.3 (n= 8) 0.7 ± 0.3 (n= 20) NS
mRNA ratio HSL / 
y actin)
9.7 ± 1.0 (n= 10) 7.0 ± 0.7 (n= 21) <0.05
Values are mean ±SEM. They are statistically compared by Student’s t-test; NS, not 
significant (Large et al, 1999).
LPL gene expression
No significant differences were observed in the levels of fasting LPL-mRNA 
between omental and subcutaneous adipose tissue. This finding is in agreement with 
Montague et al. (1998) who examined the LPL and HSL gene expression using the 
RT-PCR technique in a group of 19 women aged 48 ± 11 years and 12 men aged 60 
±11.  Their results showed that no transcript was specific to any depot. Fried et al. 
(1993) also studied LPL regulation in subcutaneous and omental adipose tissue that 
was obtained from obese men and pre-menopausal women. The adipose tissue
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samples were placed in organ culture for 7 days with varying concentrations of 
insulin and dexamethasone. They found that LPL-mRNA levels were ~ 2-fold higher 
in subcutaneous depots under the effect of insulin in women, whereas a 3-4 fold 
higher LPL-mRNA levels were observed in omental depots under the effect of 
dexamethasone particularly in men. Another study by Amer et a l  (1991) compared 
fasting LPL expression in abdominal and gluteal regions of subcutaneous adipose 
tissue from non-obese men and pre-menopausal women. They found that LPL- 
mRNA levels were 40-80% higher in females compared with male adipocytes from 
both regions. In addition, they found that in both sexes LPL-mRNA levels were three 
times higher in the abdominal compared with the gluteal region.
Adipocyte cell size
Our data show that subcutaneous cells were ~ 2-fold larger compared with the 
omental adipocytes. This result contrasts with a previous study (Salans et a l,  1973) 
which estimated the variations in adipocyte cell size on the basis of distribution of 
total fat between the subcutaneous and deep fat depots. They found quite similar cell 
masses in three subcutaneous regions (gluteal, abdominal and triceps) in obese and 
non-obese men and women, while the three deep fat depots (pre-peritoneal which 
was described as just lateral to the umbilicus, mesentery and omentum) cell sizes 
differed not only from the subcutaneous but also between the groups of subjects. 
They indicate that the site-to-site order of cell size within each patient group was 
gluteal > preperitoneal > abdominal > mesentery > triceps > omentum (table 5.10). 
These findings, however, are in contrast to the work done by Mauriège et al. (1995) 
in massively obese subjects. They found that subcutaneous abdominal (0.7 (ig 
lipid/cell) and omental adipose cells (0.6 pg lipid/cell) did not differ in size despite a 
slight tendency for a lower fat cell weight in deep compared to in subcutaneous 
adipocytes (P = 0.06; data estimated from graph given in the original article).
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Table 5.10 Mean values of lipid per adipose tissue cell (Salans et al.91973).
Patient
group
Subcutaneous adipose 
(pg lipid/cell)
Deep adipose 
(pg lipid/cell)
Mean 
(pg lipid/cell)
Glut Abd Trie Pre-p Mesn Omen Subcut Deep
Non-
obese
0.49 0.45 0.37 0.48 0.4 0.3 0.44 0.39
Obese 0.93 0.89 0.83 0.9 0.8 0.73 0.88 0.81
Glut: gluteal; Abd: abdominal; Trie: triceps; Pre-p: pre-peritoneal; Mesn: 
mesentery; Omen: omentum; Subcut: subcutaneous.
5.7. Conclusion
In conclusion, it is likely that the similar levels of fasting LPL and HSL activity and 
LPL gene expression in omental and subcutaneous adipose tissue found in the 
present study was due to the subjects being young and non-obese and differences 
may have been found in samples from older and obese subjects.
161
Chapter 6 
General discussion
Atherosclerosis, the underlying cause of heart attacks, strokes and peripheral 
vascular disease, is directly responsible for over 50% of all deaths in the USA, 
Europe and some parts of Asia (Mead et a l, 1999). The disease develops slowly over 
many years in the intima, the innermost, luminal part of the artery, with the lesions 
(plaques) characterised by a proliferation of smooth muscle cells, extensive 
accumulation of connective tissue matrix and lipid deposition. A number of risk 
factors are known to predispose an individual to CHD (Frayn & Coppack, 1992). 
Among the most important of these are the levels of lipids in the blood. A high level 
of LDL-cholesterol, a low level of HDL-cholesterol and a high level of TAG and 
KEF A are among the factors associated with a high risk. Appropriate regulation of 
the enzymes LPL and HSL is thought to be important for the maintenance of low 
plasma TAG and fatty acid levels, because they hydrolyse extracellular TAG in 
lipoproteins and intracellular TAG in adipocytes respectively (Reynisdottir et a l, 
1997 b). The first theory implicating LPL in atherosclerosis was proposed by 
Zilversmit in 1973 when he postulated that high local concentrations of cholesterol- 
rich remnants, produced by the action of LPL on VLDL and CM at the vascular 
endothelium, would be taken up into the arterial wall and thus lead to the deposition 
of cholesterol. In humans LPL deficiency is a common genetic cause of 
chylomicronaemia syndrome, which is characterised by accumulation of lipoproteins 
to massive levels in plasma (Zilversmit, 1973).
Type 2-DM is found to be another risk factor for the development of atherosclerosis 
and its clinical manifestations including CHD, stroke, and peripheral vascular disease 
(Mead et a l, 1999). The feature of insulin resistance may be the result of an inability 
of insulin to maintain normal activities of the key enzymes involved in carbohydrate 
and lipid metabolism, and this may contribute to the development of 
hypertriacylglycerolaemia (Taylor et a l, 1979). Several theories have been 
expounded for the atherogenic effects of diabetes. In vitro data suggest that 
hyperinsulinaemia increases the growth of cells, including macrophages and smooth 
muscle cells, which are components of the atherosclerotic plaque (Mead et a l,  1999). 
In addition, regional adiposity is recognised as another risk factor for CHD (Chen & 
Garg, 1999). Nakajima et a l (1989) suggested that the upper-body fat distribution
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represents an accumulation of intra-abdominal fat, and that insulin resistance is 
associated with this type of fat distribution in particular. This is because, firstly, the 
intra-abdominal tissue appears to have a high sensitivity to lipolytic agents compared 
with other depots and a resistance to suppression of lipolysis by insulin. Secondly, 
the delivery of fatty acids, directly into the portal vein and thus to the liver, may 
contribute both to stimulation of VLDL-TAG synthesis and secretion, and to a 
reduction in insulin extraction, and thus hyperinsulinaemia.
Chapters 2 and 3 described the modification and development of a new technique of 
RT-PCR that allows the rapid determination and quantitation of the mRNAs for both 
LPL and HSL without the need for a radioactive compound or time-consuming 
blotting and detection procedures. This sensitive method should enable us to analyse 
the expression of these two critical enzymes, which are a key enzymes in lipoprotein 
metabolism, in different nutritional states or disease states.
In Chapter 4 individuals with type 2-DM showed higher plasma TAG concentrations 
in comparison to the control subjects. Whilst, a consistent pattern of higher adipose 
tissue LPL activity, and LPL-mRNA in controls in both fasting and post-prandial 
states versus diabetic subjects was observed. These results suggest that in type 2- 
DM, the insulin insensitivity results in an inability to maintain the normal activities 
of the key enzyme involved in lipid metabolism at all levels of production. This 
contributes to the slow post-prandial lipid clearance in type 2-DM and their increased 
risk of atherosclerosis.
GIP hormone has a profound effect on stimulating insulin secretion (Morgan et ah, 
1988). In Chapter 4 it was observed that patients with type 2-DM had a decreased 
intestinal GIP secretion which may contribute to the abnormal insulin secretion and 
therefore, clearance of TAG from circulating lipoprotein particles in the plasma will 
be reduced by a lower LPL activity and gene expression. Possible explanations for a 
lower GIP secretion in type 2-DM individuals following a high fat meal; include a 
defective signal-transduction system and reduction in the number of functional 
pancreatic islet receptors due to altered expression, mutation, or degree of
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desensitization and/or internalisation. Further study is required to elucidate and to 
develop a greater understanding of the functional roles played by the different 
structural components of the GIP receptor.
The co-ordinate regulation of HSL and LPL in adipose tissue during feeding and 
fasting is critical for maintaining TAG homeostasis (Doolittle et aL, 1990). When 
studying the correlation between LPL and HSL messages during the 4 hours post- 
prandially, there was a marginal positive correlation between them (P = 0.047, R = 
0.502).
Insulin stimulates both the uptake of fatty acids into adipose tissue by the activation 
of LPL in the fed state and down-regulation of HSL thus reducing the mobilisation of 
fatty acids in the post-prandial state (Frayn & Coppack, 1992). Doolittle et al. (1990) 
suggested that the decrease in adipose tissue LPL activity is most likely to arise from 
the presence of an inactive mass of LPL protein. Coincidently, in the fasting state, 
the majority of LPL is associated with the endoplasmic reticulum, which may be 
inactive. Moreover, Ong & Kern (1989) suggested that feeding increased tissue LPL 
activity through a post-translational activation of an inactive form of LPL.
The mRNA levels have been expressed in two ways, either using p2-microglobulin as 
a housekeeping gene or versus total RNA. The finding that p2-microglobulin 
increased compared to total RNÀ was unexpected and further work is needed to see 
whether it is correct. This would require the collection of large adipose tissue 
samples from controls and type 2-DM so that reliable total RNA measurements could 
be made. As indicated in Chapter 4 the amounts of RNA available in this study were 
too small to do this. The total RNA measurements were only taken in order to 
roughly estimate the amount of sample to use for the PCR reactions to ensure that the 
levels of mRNA would be within the range required. The values are unlikely to be 
an accurate measure of the concentration of total RNA. Other reasons were given in 
Chapter 4 as to why the expression of the results against total RNA may not be a true 
reflection of the levels of specific mRNAs. Therefore the results that were mainly
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considered were those that used Pi-microglobulin as a housekeeping gene. These are 
considered further below.
The observation of higher LPL activity (table 4.3; 4.4) and mRNA (table 4.7) in 
controls versus diabetics was consistent with the original hypothesis that the elevated 
TAG levels in diabetes are in part due to reduced LPL activity (Reaven & Chen,
1988). The lower LPL-mRNA levels can be explained by lower insulin activity and 
may be attributed to two possible mechanisms; the insulin can alter the LPL gene 
transcription rate and/or the stability of LPL-mRNA. Here insulin participates in the 
transcriptional control of LPL gene expression either directly or indirectly. A direct 
mechanism would involve insulin binding to a responsive element on the LPL gene, 
which in turn stimulates LPL-mRNA synthesis; this responsive element is termed a 
promoter region or insulin regulatory element. A putative insulin regulatory element 
has not been identified in the LPL gene and could be a subject of further study. These 
hypotheses, about how insulin could influence LPL gene expression and indeed 
mRNA stability, originate from the knowledge of the action of insulin on other genes 
in the cell. For example, insulin indirectly stimulates transcription of the GLUT 4 
and hexokinase genes resulting in increases in mRNA synthesis by acting on 
identified promoter regions or insulin response sequences (Mandarino et aL, 1995).
In addition to the mechanism of altering the gene transcription rate or as a separate 
measure, insulin could act by a post-transcriptional mechanism. This could explain 
the lower LPL-mRNA levels observed in the type 2-DM subjects in that insulin 
increases the stability of LPL-mRNA leading to higher mRNA levels which in turn 
means more mRNA is available for the synthesis of LPL. In fact, at the moment, 
relatively little is known about how insulin could regulate the stability of LPL- 
mRNA, but post-transcriptional modification of LPL-mRNA stability is likely to be 
an important control step in the positive effect of insulin on LPL and is the most 
likely mechanism by which insulin increases LPL-mRNA levels. Examples whereby 
insulin increases mRNA levels by a post-transcriptional mechanism include the 
stabilisation of glycerol 3-phosphate dehydrogenase and pyruvate kinase mRNAs 
(Dani et aL, 1989; Decaux et aL, 1989). More work was done, by Raynolds et al.
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(1990), to examine the regulation by isoproterenol and insulin on LPL gene 
expression through different mechanisms. They have isolated an 868 bp rat LPL- 
cDNA clone to assess hormone-mediated changes in steady state level of LPL- 
mRNA and LPL gene transcription rates in adipocytes. The results of the northern 
blot and the nuclear run-on transcription assays showed that the adipocytes that were 
treated with isoproterenol at 15 minutes had a decreased LPL activity and steady 
state mRNA levels combined with a decrease in LPL gene transcription when 
compared to control cells. Conversely, insulin treatment did not affect LPL gene 
transcription, but caused an increase in LPL enzyme activity and steady state mRNA 
level. They concluded that the effect of insulin on LPL-mRNA is probably due to 
insulin-induced changes in mRNA stability.
The present study demonstrated unchanged HSL activity between type 2-DM and 
control subjects. This is consistent with finding of Reynisdottir et a l (1997 b), who 
studied the activities of LPL and HSL in subcutaneous adipose tissue from male 
patients with familial combined hyperlipidaemia (FCHL) and insulin resistance 
syndrome (1RS). LPL activity was 43% lower in patients with 1RS as compared with 
control subjects but HSL activity was not significantly different in the two groups. 
On the other hand, HSL activity was decreased by 45% in FCHL patients when 
compared with the control group. They concluded, that TAG metabolism in adipose 
tissue is altered in both FCHL and 1RS. However, the abnormalities observed involve 
impaired function of LPL in 1RS and impaired function of HSL in FCHL, suggesting 
separate causes for the alterations in FCHL and 1RS. In contrast to the unchanged 
HSL activity between the two groups, in our study the diabetic subjects HSL-mRNA 
was 34% of the controls at fasting state and 32% of the controls during the post­
prandial states. However, Botion & Green (1999) observed that high insulin (25 
ng/ml) and glucose (20 mmol/1) concentrations increase the rate of lipolysis by 40- 
65% in primaiy culture of adipocytes, suggesting that glucose could participate in the 
regulation of adipose tissue lipolysis by modulation of HSL gene expression. The 
lower HSL-mRNA in type 2-DM subjects in our study may indicate down regulation 
in response to prolonged raised plasma glucose, TAG and NEFA levels so that 
lipolysis is impaired. The molecular mechanisms underlying the effect of glucose on
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HSL gene expression are unknown and this could be the subject of further 
investigation.
Epidemiological studies suggest that regional body fat distribution may be a better 
predictor of cardiovascular disease than the actual degree of adiposity. Many studies 
and reviews now show an association between upper-body obesity (omental obesity) 
and insulin resistance, and the risk of developing type 2-DM and CHD (Zamboni et 
a l, 1992 a; Amer, 1995 and Maurèige et a l, 1995). However, Frayn (2000) in his 
review concludes that there is no proof at the present time of a link between omental 
fat accumulation and insulin resistance. Interestingly, he suggested the possibility of 
co-correlation with some other factor, such as subcutaneous abdominal fat 
accumulation, which usually outweighs intra-abdominal fat several-fold. In our study 
we showed that, even without obesity, the mean size of the subcutaneous adipocyte 
cell was larger than the omental adipocyte cell.
The information about depot-specific differences in LPL and HSL activity and gene 
expression in human fat cells is limited. Our results in Chapter 5, for LPL activity are 
entirely consistent with the findings of Rebuffé-Scrive et a l (1990), who also found 
no difference in the LPL activity between subcutaneous and omental adipose tissue. 
It is likely that the similar levels of LPL and HSL activity and gene expression found 
in the present study resulted from the subjects being pre-menopausal and non-obese 
whereas, other studies where differences were observed, included older and obese 
subjects or between different sexes (Yost & Eckel, 1992; Fried et a l, 1993; 
Maurèige et a l, 1995 and Large et a l, 1999)
A comparison between the results of fasting HSL activity in normal male subjects 
(from Chapter 4) with the pre-menopausal females (from Chapter 5) showed that the 
men had ~ 50-fold higher values HSL activity than the pre-menopausal females (P < 
0.00001). This may be due to many differences between the sampling and the 
subjects chosen. In Chapter 4 the male subjects were older and the samples were 
collected from the gluteal fat depot. The females studied in Chapter 5 were younger, 
pre-menopausal and the samples were collected from the abdominal subcutaneous
168
region. All or some of these factors may have contributed to the differences 
observed. Another possible relevant factor is that the adipose tissue samples were 
obtained under different anaesthesic conditions. In Chapter 4 the gluteal fat samples 
were obtained under local anaesthesia whereas in Chapter 5 samples were obtained 
from the abdominal subcutaneous region under general anaesthesia. However, Large 
et al. (1997) compared the effect of local and general anaesthesia on lipolysis in 
subcutaneous tissue. Their data showed that local and general anaesthesia were not 
statistically significantly different in their glycerol response. Their study suggested 
that the adrenergic regulation of the lipolysis is not influenced by the mode of 
sampling, at least not in subcutaneous fat cells obtained during local and general 
anaesthesia.
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